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Cd44-Mediated Collagen Remodeling Drives Wound Resolution And Pancreatic
Tumorigenesis
Abstract
Wound healing, chronic fibrosis, and epithelial tumor progression share certain
common hallmarks, including the coagulation cascade, inflammatory response,
activation of mesenchymal stromal cells, and extracellular matrix (ECM) remodeling.
Deregulation of these processes, resulting in chronic inflammation or aberrant
accumulation of ECM components, such as fibrillar collagen or hyaluronic acid (HA),
contributes to exacerbated scar formation and promotes tumorigenesis. Thus, defining
underlying mechanisms governing these processes is vital to understanding disease
progression. CD44 is a transmembrane cell-adhesion receptor that primarily binds to
HA, the predominant glycosaminoglycan found in the ECM. Owing to it ubiquitous
expression on nearly all neuroectodermal-derived cells, CD44 has been implicated in an
array of fibrotic and inflammatory processes. Altered CD44 expression or signaling is
detected in models of acute injury and epithelial tumors, but the role of CD44 in
mediating cellular functionality and matrix remodeling in cutaneous wound healing and
distinct epithelial tumors, such as pancreatic ductal adenocarcinoma (PDA), remains
poorly understood. We demonstrated that in an excisional biopsy punch cutaneous
wound healing model, CD44 mediated the kinetics of fibrotic and inflammatory
responses with ultimate implications in scar formation. During injury resolution, CD44null mice exhibited reduced collagen degradation leading to increased fibrillar collagen
accumulation and exacerbated scar formation. These data indicate a previously
unknown role of CD44 in regulating fibrillar collagen accumulation and wound healing in
response to injury. In epithelial tumors, the cross-talk between neoplastic and nonneoplastic
cells is a key determinant of tumor progression. CD44 is expressed in both
neoplastic and non-neoplastic cellular compartments; however, its functionality during
pancreatic tumorigenesis is poorly understood. Using autochthonous tumor models with
tissue-specific CD44 deletion, we found a novel tumor-suppressive role of CD44 on
neoplastic cells, by regulating neoplastic cell proliferation, and tumor-protective role of

CD44 on non-neoplastic cells, by regulating fibrillar collagen accumulation. Together,
these findings demonstrate previously unknown roles of CD44 in mediating underlying
processes that fuel wound healing, fibrosis, and epithelial tumor progression.
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ABSTRACT
CD44-MEDIATED COLLAGEN REMODELING DRIVES WOUND RESOLUTION AND
PANCREATIC TUMORIGENESIS

Priya Govindaraju
Ellen Puré

Wound healing, chronic fibrosis, and epithelial tumor progression share certain
common hallmarks, including the coagulation cascade, inflammatory response,
activation of mesenchymal stromal cells, and extracellular matrix (ECM) remodeling.
Deregulation of these processes, resulting in chronic inflammation or aberrant
accumulation of ECM components, such as fibrillar collagen or hyaluronic acid (HA),
contributes to exacerbated scar formation and promotes tumorigenesis. Thus, defining
underlying mechanisms governing these processes is vital to understanding disease
progression. CD44 is a transmembrane cell-adhesion receptor that primarily binds to
HA, the predominant glycosaminoglycan found in the ECM. Owing to it ubiquitous
expression on nearly all neuroectodermal-derived cells, CD44 has been implicated in an
array of fibrotic and inflammatory processes. Altered CD44 expression or signaling is
detected in models of acute injury and epithelial tumors, but the role of CD44 in
mediating cellular functionality and matrix remodeling in cutaneous wound healing and
distinct epithelial tumors, such as pancreatic ductal adenocarcinoma (PDA), remains
poorly understood. We demonstrated that in an excisional biopsy punch cutaneous
wound healing model, CD44 mediated the kinetics of fibrotic and inflammatory
responses with ultimate implications in scar formation. During injury resolution, CD44null mice exhibited reduced collagen degradation leading to increased fibrillar collagen
v

accumulation and exacerbated scar formation. These data indicate a previously
unknown role of CD44 in regulating fibrillar collagen accumulation and wound healing in
response to injury. In epithelial tumors, the cross-talk between neoplastic and nonneoplastic cells is a key determinant of tumor progression. CD44 is expressed in both
neoplastic and non-neoplastic cellular compartments; however, its functionality during
pancreatic tumorigenesis is poorly understood. Using autochthonous tumor models with
tissue-specific CD44 deletion, we found a novel tumor-suppressive role of CD44 on
neoplastic cells, by regulating neoplastic cell proliferation, and tumor-protective role of
CD44 on non-neoplastic cells, by regulating fibrillar collagen accumulation. Together,
these findings demonstrate previously unknown roles of CD44 in mediating underlying
processes that fuel wound healing, fibrosis, and epithelial tumor progression.
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CHAPTER 1 – INTRODUCTION
Revisiting an old hypothesis – Tumors are wounds that do not heal
In 1986, Harold Dvorak postulated that tumors are wounds that do not heal
(Dvorak 1986). In a review published in New England Journal of Medicine, he
highlighted the commonalities between development and progression of epithelial
tumors and wound healing, including injured vasculature, initiation of the coagulation
cascade, evolution of a fibrin-fibronectin rich matrix to a collagen-rich matrix, and
recruitment and activation of additional cells including inflammatory/immune cells,
fibroblasts, and endothelial cells. It is now hypothesized that wound healing, chronic
fibrosis, and solid tumors share numerous cellular and molecular processes (Rybinski,
Franco-Barraza, and Cukierman 2014; Schäfer and Werner 2008). Building on the
original hypothesis, these shared processes can be very broadly categorized into three
groups: coagulation cascade, inflammatory response, and fibrotic response. These
processes and their roles in remodeling tissue are discussed in greater length in the
following chapters.
Advances in research have broadened our understanding of tumors, and various
hallmarks of cancers have been postulated. These include sustaining proliferative
signaling, evading growth suppressors, activating invasion and metastasis, enabling
replicative immortality, inducing angiogenesis, and resting cell death (D Hanahan and
Weinberg 2000; Douglas Hanahan and Weinberg 2011). We have also come to
recognize that evolution of normal cells into neoplastic cells is a coordinated multicellular
event that encompasses crosstalk between epithelial cells, surrounding non-epithelial
cells (including fibroblasts, immune cells, and endothelial cells), and extracellular matrix
(ECM).
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Cell-cell and cell-ECM interactions partly mediate the multicellular processes in
remodeling tissue. Adhesion receptors play a fundamental role in regulating these
interactions and can, therefore, mediate numerous cellular and molecular events that
take place during wound healing, fibrosis or cancer. Thus, they are potentially attractive
therapeutic targets and warrant further investigation.
One such cell adhesion receptor that has been implicated in an array of
pathological conditions is CD44. The overall interest in CD44 stems from multiple
reasons, including its broad spectrum expression on all neuroectodermal-derived cells,
posited ability to interact with a host of matrix components, and evidence supporting
upregulation of CD44 expression in remodeling tissue. The role of CD44 has been
evaluated in various contexts including cancer, atherosclerosis, pulmonary fibrosis, renal
fibrosis, arthritis, and bacterial infections to name a few. However, given its ubiquitous
expression and the multitude of roles it plays, data pertaining to the role of CD44 in
modulating the fibroinflammatory response in pathological conditions are often
conflicting.
A critical biological model in which the role of CD44 has not been investigated is
wound healing. The wound repair process, initiated upon injury, occurs synonymously in
virtually all tissues. For example, processes leading to scar formation in response to a
burn share many parallels to the myocardial scar formed after myocardial infarction
(Gurtner et al. 2008). Scar tissue comprises of a dense acellular accumulation of matrix,
rendering that patch of tissue non-functional. In the aforementioned example, the size
and shape of the myocardial scar can negatively impact both the systolic and diastolic
functions of the heart (Richardson, Clarke, and Holmes 2016). The dysfunction caused
by scar tissue can be observed in virtually all adult tissues; thus scars and fibrosis pose
a significant clinical and economic burden.
2

Analogously, numerous studies have attempted, but have not been able to
identify the mechanistic role of CD44 in pancreatic ductal adenocarcinoma (PDA). PDA
is the fourth leading cause of cancer-related deaths with a median survival rate of six
months after detection. Extensive accumulation of ECM components and deregulated
inflammatory processes are postulated hallmarks of PDA driving tumor aggressiveness.
For instance, robust accumulation of hyaluronic acid, the primary ligand for CD44,
creates a protective physical barrier for pancreatic tumors. Studies have demonstrated
that enzymatic depletion of HA restores functional vasculature and enhances the
penetrance of chemotherapeutic agents in models of PDA (Provenzano et al. 2012).
There is evidence supporting the upregulation of CD44 in pancreatic tumors compared
to normal tissue (Rall and Rustgi 1995; Sleeman et al. 1996; Gotoda et al. 1998).
However, the role of CD44 in either mediating HA accumulation or other fibrotic and
inflammatory processes in PDA remains unclear.
Given the sparse mechanistic knowledge of CD44 in wound healing and PDA,
we studied the impact of genetic CD44 deletion in these contexts. We utilized a fullthickness excisional wound healing model to determine the role of CD44 in mediating
the injury response. The role of CD44 in PDA was elucidated using autochthonous tumor
models and genetic tissue-specific CD44 deletion. Thus data highlighted in this
dissertation will demonstrate previously unknown roles of CD44 in mediating the
fibroinflammatory response in the contexts of cutaneous wound healing and PDA.

Overview of CD44 Structure
CD44 is a type I transmembrane glycoprotein encoded on chromosome 11 in
humans and chromosome 2 in mice (Goodfellow et al. 1981). Its primary ligand is
hyaluronic acid (HA), a predominant glycosaminoglycan found in the ECM. Murine CD44
3

is encoded by 20 exons, 10 of which (exons 1 – 5 and 16 – 20) are non-variable, and 10
(exons 6 – 15) are variable and regulated by alternative splicing (Screaton et al. 1992;
Tölg et al. 1993). The shortest version of CD44, standard CD44 (CD44s), only
comprises of the non-variable exons and is expressed on most leukocytes, fibroblasts,
keratinocytes, and epithelial cells. Although the predicted molecular weight for CD44s is
37 kDa, the observed molecular weight ranges from 80 – 100 kDa due to posttranslational modifications, such as N- and O-linked glycosylation, within the extracellular
domain (ECD) (ST Jalkanen et al. 1986).
CD44-ECD contains the amino terminus that consists of 270 amino acids and is
encoded by non-variable exons 1 – 5. It folds into a globular tertiary structure by the
formation of disulfide bonds between three pairs of cysteine residues. The HA-binding
domain, known as the link domain, is located in the amino terminus and allows for CD44
binding to various GAGs (Kohda et al. 1996). The affinity of CD44 binding to GAGs is
regulated by post-translational modifications, such as glycosylation, and varies based on
cell type and activation state of specific cell types. The membrane-proximal region of the
amino terminus is encoded by exons 16 and 17. The membrane-proximal region, which
is less well conserved (~30% homology), contains putative proteolytic cleavage sites
and sites for insertion of alternatively spliced exons, resulting in the production of various
CD44 variant isoforms (CD44v). Expression pattern of CD44v compared to CD44s is of
great interest in numerous pathological conditions and will be discussed in subsequent
chapters. Murine CD44 amino terminus consists of five potential sites for N-linked
glycosylation and ten sites for O-linked glycosylation. Furthermore, three serine-glycine
motifs in the membrane-proximal region can be heavily modified by carbohydrates, such
as heparin sulfate and chondroitin sulfate (Naor, Sionov, and Ish-Shalom 1997). As
suggested earlier, these post-translational modifications are of biological interest as they
4

can alter CD44-HA binding in a cell- and tissue-specific manner. For instance, using
affinity capillary electrophoresis, four distinct N- and O-linked glycosylation residues
displayed augmented HA binding to CD44 by enhancing affinity for HA (Skelton et al.
1998; English, Lesley, and Hyman 1998).
The transmembrane domain of CD44, encoded by exon 18, consists of 23
amino acids and has been implicated in regulating CD44 association with lipid rafts. The
72 amino acid C-terminus intracellular domain (ICD) is encoded by exons 19 and 20 and
has the capacity to interact with the cytoskeleton. The cytoplasmic tail of CD44 interacts
with various binding partners, thus regulating HA binding to the extracellular domain,
mediating CD44 association with the cytoskeleton, and transducing signals from the
extracellular milieu (Isacke 1994). Ankyrin, ezrin, radixin, and moesin (ERM), and merlin
are some of the most well-characterized intracellular binding partners.
In addition to existing in a membrane-bound form CD44 can also exist in a
soluble form (sCD44) upon shedding from the cell surface by metalloproteinases,
including membrane type 1 and 3 metalloproteinases, and serine proteases (Cichy et al.
2002). sCD44 can compete with membrane-bound CD44 for ligand binding and alter
cell-cell and cell-matrix interactions. Additionally, CD44 can undergo presenilin-1
dependent gamma-secretase mediated proteolysis within two hydrophobic sites of the
transmembrane domain close to the cytoplasmic border leading to the release of the
CD44-intracellular domain (ICD) and CD44β peptide (Lammich et al. 2002). CD44-ICD
can translocate to the nucleus and promote transcription of various genes including
CD44 itself (Okamoto et al. 2001). Given its widespread expression on multiple cell
types and upregulation in diseased states, CD44 has been the focus of many studies in
a range of normal and pathological conditions.

5

CD44 Interaction with Hyaluronic Acid and Other Ligands
CD44 plays a vital role in translating cues from the extracellular environment
using various molecular mechanisms (Figure 1). One of the most well-characterized
functions of CD44 is through its HA binding ability. CD44 plays a critical role in the
retention of HA on the cell surface and also mediates HA endocytosis (Rahmanian and
Heldin 2002; Hong Jiang et al. 2002).
With respect to HA binding, CD44 can exist in three states: inactive low-affinity
state, which can transition to a high-affinity state based on stimuli, constitutively activate
high-affinity state, and an inactive state in which activation cannot be induced (Jayne
Lesley and Hyman 1992). CD44 expressed on most hematopoietic cells do not
constitutively bind HA; instead, they exist in a low-affinity inducible state. In vitro and in
vivo studies have demonstrated that transition to a high-affinity state can occur upon
stimulation by various experimental and physiological factors. One of the earliest studies
to illustrate this phenotype overexpressed CD44s in Jurkat T cells and treated them with
phorbol 12-myristate 13-acetate (PMA), which not only increased CD44s expression but
also increased HA binding ability (Liao et al. 1993). Since then numerous physiological
stimuli with the potential to activate CD44 have been identified. Exposure to cytokines
and chemokines such as interleukin 2 (IL-2), tumor necrosis factor-α (TNF-α), IL-1α, IL1β, IL-3, granulocyte–macrophage colony stimulating factor (GM–CSF), interferon γ
(IFN-γ), lipopolysaccharide (LPS), macrophage inflammatory protein 1 β (MIP-1β), IL-8,
and RANTES stimulate the transition to a high-affinity HA binding state (Underhill et al.
1993; J Lesley et al. 1992; Maiti, Maki, and Johnson 1998). CD44-HA binding is also
regulated on a molecular level by CD44 expression and clustering, N- and O-linked
glycosylation, intracellular domain phosphorylation, sulfation, and inclusion of variant
6

exons (Sleeman et al. 1996; Katoh et al. 1995; Hong Jiang et al. 2002; Puré et al. 1995;
J Lesley et al. 2000, 1992; Maiti, Maki, and Johnson 1998). Although the exact
mechanism by which cytokines and chemokines induce activation is cell-type
dependent, there is some evidence suggesting that cytokines and chemokines trigger
post-translational modifications in CD44 that result in activation. Treatment of peripheral
blood mononuclear cells (PBMCs) with TNF-α, for 72 hours, increased CD44 expression
and HA binding capacity. However, they found that after the initial 72-hour exposure to
TNF-α an additional 72-hour exposure to IL-4 reduced HA binding capacity. Treatment
with cycloheximide, a protein synthesis inhibitor, tunicamycin, an N-glycosylation
inhibitor, or β-D-xyloside, a chondroitin sulfation inhibitor, reversed the inhibitory effects
of IL-4 on HA binding capacity (Levesque and Haynes 1999). Thus suggesting that in
addition to modulating levels of CD44 expression, different cytokines and chemokines
also impact post-translational modifications, which in turn regulate the HA binding
capacity of CD44.
These data support the hypothesis that the physiological role of CD44 cannot be
minimized to levels of expression. It is a complex protein with diverse functions that are
induced or inhibited based on stimuli; therefore, the context in which CD44 is
investigated can lead to varying results, a concept which will be elaborated throughout
this dissertation. Determining mechanisms that govern CD44 activation is physiologically
critical. CD44-HA-dependent signaling (which is discussed in depth later) has been
implicated in an array of cellular processes including proliferation, migration, adhesion,
and cytoskeleton remodeling. Additionally, CD44-HA interactions regulate leukocyte
homing, rolling and activation. Fundamental experiments that established the role of
CD44 in lymphocyte rolling were conducted using a parallel-plate fluid flow-chamber
7

system, which faithfully recapitulates physiological hemodynamics. These studies
demonstrated murine T cell rolling on HA-coated plates and primary endothelial cells
was inhibited when treated with CD44-HA blocking antibody or upon treatment with
hyaluronidase (H C DeGrendele et al. 1997; Heather C. DeGrendele, Estess, and
Siegelman 1997). Using genetic deletion of CD44, antibody blocking experiments, or
hyaluronidase treatment, subsequent experiments have reiterated the crucial role of
CD44 in leukocyte recruitment in an array of pathological conditions as discussed later.
In addition to HA, other hypothesized CD44 ligands include osteopontin (OPN), a
negatively charged protein found in the ECM, and serglycin, a proteoglycan secreted by
hematopoietic and endothelial cells. OPN has been shown to interact with CD44v6 and
CD44v7 (Katagiri et al. 1999), and CD44-OPN signaling has been implicated in
chemotaxis, adhesion, and cytoskeleton reorganization (Zohar et al. 2000; Wai and Kuo
2008). CD44-serglycin interactions have been implicated in hematopoietic and myeloma
cell adhesion (Purushothaman and Toole 2014; Noriko Toyama-Sorimachi et al. 1997; N
Toyama-Sorimachi et al. 1995). However, contrary to CD44-HA interactions, CD44OPN/serglycin binding has only been evaluated in a handful of studies using in vitro
model systems. Therefore, additional experiments need to validate these findings.
Furthermore, in vitro studies have also demonstrated an association of CD44 with other
ECM ligands such as collagen, fibronectin, and laminin (Sirpa Jalkanen and Jalkanen
1992; Faassen et al. 1992). Migration of melanoma cells on type I collagen gels was
inhibited in the presence of a chondroitin sulfation inhibitor, β-D-xyloside. Based on this
initial finding, a subsequent study extracted proteoglycans from melanoma cells and
recognized a chondroitin core protein with an apparent molecular weight of 110 kDa,
which was identified as CD44 (Faassen et al. 1992). This study suggested that CD44,
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with chondroitin sulfate modifications, might mediate adhesion to type I collagen. Similar
in vitro experiments using a human colorectal cell line showed adhesion to laminin and
type IV collagen was abrogated in the presence of Hermes-1, a CD44 antibody that
blocks HA binding (Ishii et al. 1993). These data provide supporting evidence for
interactions of CD44 with additional ECM ligands. However, these findings are in a
nascent state and further characterization and in vivo replication of data need to be
conducted. Furthermore, the presumable role of CD44 in mediating matrix architecture
and remodeling, either by direct interactions with ECM ligands or other binding partners,
is poorly understood.

The Function of CD44 as a docking platform and co-receptor
In addition to associating with ECM components, CD44 can also function as a
co-receptor. One of the earliest studies supporting this hypothesis demonstrated an
involvement of CD44v3, expressed on keratinocytes, in presenting heparin sulfate
binding proteins (fibroblast growth factor (FGF) and heparin binding-epidermal growth
factor (HB-EGF)) in inflamed skin (Bennett et al. 1995). Subsequently, CD44 has been
associated with various growth factor-mediated signaling pathways including hepatocyte
growth factor (HGF), fibroblast growth factor (FGF), epidermal growth factor (EGF),
platelet-derived growth factor (PDGF), and transforming growth factor (TGF).
The proto-oncogene cMet, a receptor tyrosine kinase, is the primary receptor for
HGF. Upon HGF binding, cMet undergoes activation, characterized by phosphorylation
of tyrosine residues, and initiates downstream signaling pathways, including Akt,
ERK/MAPK, and FAK to name a few. CD44v6 is required for HGF-mediated cMet
activation and signaling in various cell types, including keratinocytes, liver cells, and
endothelial cells (Hasenauer et al. 2013; Orian-rousseau et al. 2002). Furthermore,
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studies have implicated association of CD44-ICD with ERM in mediating cMet signaling
(Orian-rousseau et al. 2002; Orian-Rousseau et al. 2007). A knockdown of ezrin, a
dominant negative version of ezrin, and CD44 fusion protein lacking ezrin-binding
domain inhibited ERK activation without impacting phosphorylation of tyrosine residues
on cMet (Orian-Rousseau et al. 2007). These data demonstrate the crucial function of
CD44v6 in regulating HGF-mediated cMet signaling in specific cell types.
CD44v6 can also co-precipitate with vascular endothelial growth factor receptor 2
(VEGFR2) (Tremmel et al. 2009). CD44v6 ECD regulates VEGFR2 activation in primary
endothelial cells, and CD44-ICD association with ERM provides the platform for
downstream signaling. Treatment of endothelial cells with CD44v6 blocking antibody
suppressed VEGFR2 activation, endothelial cell migration, sprouting, and tube formation
(Tremmel et al. 2009). Thus these data demonstrate a crucial role of CD44v6 in
regulating VEGFR2 signaling in endothelial cells.
During limb development, CD44v3, consisting of heparin sulfate modifications, is
required to present FGF to fibroblast growth factor receptor (FGFR) on mesenchymal
cells (Sherm et al. 1998). Treatment with CD44v3 blocking antibody or heparitinase
inhibited limb growth, thus demonstrating the crucial role of CD44v3 mediated FGF
signaling in limb development. CD44v3 also recruits matrix metalloproteinase 7 (MMP7)
and pro-HB-EGF to the cell surface, which subsequently leads to the processing of HBEGF and activation of its receptor ERBB4 in transformed and non-transformed cells (W.
Yu et al. 2002). Similarly, CD44-mediated docking of MMP9 on the cell surface is
required for the processing of latent pro-TGFβ to active TGFβ (Acharya et al. 2008; Q.
Yu and Stamenkovic 2000). CD44-dependent MMP9 localization and TGFβ activation
mediates fibroblast migration and tumor angiogenesis. These studies demonstrate the
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crucial role of CD44-mediated growth factor signaling in regulating an array of biological
process.

CD44-mediated signal transduction
CD44-mediated signal transduction occurs through the intracellular complexes
formed on its cytoplasmic tail. As previously mentioned, ERM, merlin, and ankyrin are
the most well-characterized CD44 intracellular binding partners. ERM and merlin belong
to the band 4.1 superfamily of proteins, and their N-terminus, but not the C-terminus,
shares a high degree of homology. Based on extracellular signals, tyrosine or serine
phosphorylation of ERM proteins regulates binding to CD44. The c-terminus domain of
ERM binds to filamentous actin (f-actin), thereby linking the plasma membrane to the
actin cytoskeleton (Pearson et al. 2000; Bretscher 1999). CD44-ERM interactions have
been implicated in signaling via Rho family GTPases. Direct interaction of CD44-bound
phosphorylated ERM with Rho GDP dissociation inhibitor (Rho GDI) results in enhanced
Rho activity (Kazuo Takahashi et al. 1997).
Merlin interaction with CD44-ICD is also modulated by phosphorylation, but
unlike ERM, dephosphorylated merlin binds to CD44. Alterations in the extracellular
environment, such as high cell density or presence of high molecular weight hyaluronic
acid (HMW-HA) can activate phosphatases (Puré and Assoian 2009). Activation of
phosphatases results in dephosphorylation and inactivation of ERM, and subsequent
replacement of dephosphorylated ERM, from the cytoplasmic tail of CD44, with
dephosphorylated merlin. The c-terminus of merlin does not contain an actin-binding site
and therefore cannot link the plasma membrane to the cytoskeleton (Okada, You, and
Giancotti 2007). CD44-merlin interactions inhibit Ras-dependent ERK activation and
GTP-loading of Rac, and are therefore growth inhibitory (Puré and Assoian 2009).
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CD44 association with RhoA can mediate ankyrin binding to the cytoplasmic
domain of CD44, in a phosphorylation-dependent manner. CD44-ankyrin interactions
mediate cell migration and anchorage-independent growth. Studies suggest that in
addition to the phosphorylation state of the binding partner, phosphorylation of the
cytoplasmic tail of CD44 also regulates association with binding partners (J Lesley et al.
2000). For instance, a protein kinase C (PKC)-mediated switch in the phosphorylation of
the cytoplasmic tail of CD44, from serine325 to serine291, resulted in disassociation of
ERM (Legg et al. 2002). Thus the highly regulated CD44-mediated signaling can alter
various cellular functions, including proliferation, migration, and actin-cytoskeleton
remodeling.

Alterations in CD44 expression in normal and pathological conditions
CD44s was originally identified on hematopoietic cells but is now acknowledged
to be widely expressed on nearly all cell types in fetal and adult tissues. On the contrary,
the expression pattern of CD44v is tightly regulated and is hypothesized to have distinct
and sometimes opposing functions compared to CD44s. Keratinocytes, lymphocytes,
macrophages and some epithelial cells express CD44v isoforms in a tissue-specific
manner. Notably, the expression of CD44s is upregulated in numerous inflammatory and
fibrotic settings. In contrast, the expression of CD44v isoforms varies based on the
pathological condition.
Previous studies have examined the expression of CD44 in diverse pathological
conditions by conducting PCR, western blot, flow cytometry or immunohistochemistry
(IHC). CD44 expression is upregulated on hematopoietic and parenchymal cells in
numerous inflammatory conditions. IHC analysis of synovial tissue from patients with
rheumatoid arthritis (RA) and osteoarthritis (OA) revealed upregulation of CD44 in
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macrophages and fibroblasts in RA and OA patients compared to normal synovial tissue
(Johnson et al. 1993). Upregulation of CD44 in astrocytes, microglia, oligodendrocyte
progenitors and neurons has been reported in response to ischemia and traumatic brain
and spinal cord injuries (Lipponen et al. 2016; Moon et al. 2004). Increased expression
of CD44 was also reported in patients with non-alcoholic steatohepatitis (NASH) and
non-alcoholic fatty liver disease (NAFLD) compared to healthy livers (Patouraux et al.
2017). In patients with single-vessel coronary artery disease, upregulation of monocytic
CD44 expression was reported in cases of impaired collateral artery formation compared
to patients with good collateralization (van Royen et al. 2004). Compared to healthy
normal subject, CD44 was downregulated in neutrophils and monocytes in patients with
systemic lupus erythematosus (Cairns et al. 2001).
CD44 has also been evaluated in a myriad of tumor types. Upregulation of CD44
has been reported in gastric cancer, colorectal cancer, hepatocellular carcinoma, clear
cell renal cell carcinoma, pancreatic ductal adenocarcinoma and glimoa (Montgomery et
al. 2004; Cao et al. 2014; Ishii et al. 1993; Todaro et al. 2014; Ryu et al. 2011; Tovuu et
al. 2013; Chou et al. 2014; Henriques da Costa et al. 2012; X. Li et al. 2015; Tsuneyasu
Yoshida et al. 2012; Rall and Rustgi 1995; S. Zhao et al. 2016). On the other hand, in
neuroblastomas, prostate cancer, and cervical cancer loss of CD44 correlates with poor
prognosis (Favrot, Combaret, and Lasset 1993; A. C. Gao et al. 1997; Woerner et al.
1995; Saegusa et al. 1999; Lou et al. 1999; Verkaik et al. 1999). CD44 was not detected
in small cell lung cancer (SCLC) (Penno et al. 1994; Ariza et al. 1995). Comparatively,
the expression of CD44 in non-small cell lung cancer (NSCLC), breast cancer, ovarian
cancer, and esophageal cancer is poorly understood due to conflicting reports. A metaanalysis of 10 studies that have evaluated CD44 expression in NSCLC revealed no
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significant correlation between the upregulation of CD44s and CD44v6 found in NSCLC
patients and overall survival (Hao Jiang, Zhao, and Shao 2014). Based on IHC analysis
of 84 ovarian carcinoma patients, one study reported reduced CD44s expression in
ovarian carcinoma patients correlated with higher tumor grade, and reduced overall
survival (Ross et al. 2001). On the contrary, IHC analysis of 26 ovarian cancer patients
reported a positive correlation between high CD44 expression and recurrence (Y. Gao et
al. 2015). Correlative analyses of human samples and in vivo consistent have reported
inconsistent findings pertaining to the role of CD44 in promoting or inhibiting metastasis
(Louderbough et al. 2011; W. Li et al. 2017; Foekens et al. 1999; Lopez et al. 2005;
Brown et al. 2011; Huang et al. 2008)
These data demonstrate altered expression of CD44 in pathological conditions
compared to normal tissue. However, a generalized statement regarding up- or
downregulation of CD44 cannot be made, as the expression is contextually and
pathologically regulated. Nonetheless, the aberrant expression pattern in a multitude of
pathological conditions raises interest in further investigation of the mechanistic role of
CD44 in remodeling tissue.

Genetic and pharmacological tools utilized to study CD44 in vivo
Distinct genetic and pharmacological approaches have been utilized to assess
the function of CD44 in homeostatic and pathological conditions in vivo. Genetic
approaches include the generation of CD44-null mice, which were generated by
replacing the 3’ end of exon 2 and the entire exon 3 with a pMC1-Neomycin cassette
(Schmits et al. 1997). Insertion of the neomycin cassette in an antisense orientation
resulted in the formation of several stop codons in the reading frame. Deletion of CD44
was confirmed using southern blot analysis and flow cytometry. Similarly, another group
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also generated CD44-null mice by inserting a β-galactosidase/neomycin cassette into
exon 1 (Protin et al. 1999). Deletion of CD44 was confirmed using northern blot analysis
and flow cytometry. Both groups reported that all mice were born at expected mendelian
ratios, and CD44-null mice developed normally with few phenotypic abnormalities,
including myeloid-progenitor migration, bone-marrow colonization and homing of
lymphocytes to lymph nodes or the thymus under normal physiological conditions
(Schmits et al. 1997; Protin et al. 1999). These data indicate that global deletion of CD44
does not impair development. Interestingly enough, although CD44 is involved in various
cellular and molecular processes, genetic global CD44 deletion did not significantly
impair normal physiological function. Thus suggesting that CD44 is dispensable under
unchallenged physiological conditions, either due to compensatory mechanisms that are
invoked in the absence of CD44 or due to redundancy in the system such that
alternative processes suffice in the absence of CD44. However, when CD44 deletion is
coupled with an inflammatory challenge or other genetic mutations various striking
phenotypes have been observed. Thus the generation of CD44-null mice provided an
essential tool in understanding the role of CD44 expression in normal and pathological
conditions
In addition to the genetic approaches used to target CD44, monoclonal
antibodies, which recognize different epitopes on CD44, have also been generated and
characterized. These antibodies can be broadly categorized into three groups, based on
their ability to enhance, inhibit, or not alter HA binding to CD44 (Zheng et al. 1995).
Thus, treatment with different types of monoclonal antibodies provided a vital tool in
dissecting the role of CD44-HA interactions. However, these antibodies can modulate
CD44 function using multiple mechanisms, such as competitive or non-competitive
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inhibition; therefore, the mechanism of action must be considered when interpreting
data. A potential drawback of CD44 monoclonal antibodies is the limited understanding
of their impact on modulating HA-independent functions of CD44, such an interactions
with other ECM ligand, enzymes, and growth factors. Additionally, CD44-variant
isoforms specific antibodies have also been generated (Weiss et al. 1997). These
antibodies allowed for the characterization of CD44s compared to CD44v functions.

Role of CD44 in fibrotic and inflammatory diseases
The role of CD44 has been evaluated in various pathological settings including
renal fibrosis, numerous models of lung injury, asthma, atherosclerosis, myocardial
infarction, rheumatoid arthritis, bacterial infections, and numerous models of carcinomas.
The role of CD44 in inflammation and fibrosis is complicated to summarize as it involves
multiple cell types, ligands, and pathways leading to some contradictory results (Puré
and Cuff 2001; Ponta, Sherman, and Herrlich 2003).
Several injury models have demonstrated the importance of CD44 in mediating
recruitment of neutrophils and macrophages to sites of tissue injury (Q. Wang et al.
2002; Hollingsworth et al. 2007; Hasan et al. 2011; Cuff et al. 2001; Van Der Windt et al.
2010). In an endotoxic shock-induced acute kidney injury model, CD44 deletion impaired
early pro-inflammatory cytokine response to LPS treatment, migration of leukocytes,
endothelial cell activation and therefore delayed the induction of acute kidney injury
(Rampanelli et al. 2013). In a cecal ligation and puncture model of abdominal sepsis,
treatment with mAb IM7 attenuated neutrophil accumulation, lung damage, and edema
compared to isotype control, suggesting that CD44 exacerbates polymicrobial sepsisinduced lung injury (Hasan et al. 2011). In response to aerosolized LPS or
mycobacterium tuberculosis, CD44-deficient mice demonstrated reduced neutrophil and
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macrophage recruitment (Hollingsworth et al. 2007; Leemans et al. 2003). These data
show the role of CD44 in mediating the early inflammatory response to acute kidney
injury, abdominal sepsis, and specific models of lung injury.
In comparison, a few studies have demonstrated either no change or an
increased inflammatory response in CD44-deficient mice compared to WT upon various
pathological stimuli. In an E coli induced urinary tract infection model, genetic CD44
deletion decreased bacterial load despite a comparable accumulation of neutrophils,
MIP-2 and IL-1β compared to WT mice (Rouschop et al. 2006). On the contrary, other
studies have reported increased neutrophil and chemokine accumulation in the
bronchoalveolar lavage fluid in CD44-deficient mice compared to WT mice upon
intratracheal E coli treatment. (Q. Wang et al. 2002; Van Der Windt et al. 2010). These
data indicate that the role of CD44 in mediating the early inflammatory response is
contextually dependent. Targeting CD44 can suppress or promote early inflammatory
responses depending on the site of inflammation.
In an apolipoprotein E (apoE)-deficient mouse model of atherosclerosis, genetic
deletion of CD44 reduced atherosclerosis compared to CD44-wildtype controls (Cuff et
al. 2001). CD44 expression on both resident vascular cells as well as recruited
inflammatory cells was found to be critical for lesion development, as shown by
decreased macrophage homing to lesions and down-regulation of vascular smooth
muscle cell (VSMC) proliferation in the absence of CD44 (Cuff et al. 2001; L. Zhao et al.
2007). Bone marrow transplant experiments, showing a clear role for CD44 expression
on both bone marrow-derived and non-bone marrow-derived cells in atherogenesis,
further supported these findings (L. Zhao et al. 2008). Comparatively, in an alternate
mouse model of atherosclerosis (low-density lipoprotein receptor-null mice on a high17

cholesterol diet) bone marrow transplantation from CD44-null mice showed no significant
changes in lesion burden compared to bone marrow transplantation from WT mice.
(Sjöberg et al. 2009). The discrepant findings are most likely due to the difference in
diets used in the two models (regular chow versus high cholesterol diet) and subsequent
diet-induced differences in levels of circulating plasma lipids and cholesterol (Krolikoski
et al. 2018). Thus, further research needs to be conducted to delineate the role of cellspecific CD44 expression in different models of atherosclerosis.
In models of rheumatoid arthritis, the role of CD44 has been evaluated using
IM7, KM81, KM201 or IRAWB14 mAb treatment (Mikecz et al. 1995, 1999; Nedvetzki et
al. 1999). Arthritis was induced in BALB/c mice using an intraperitoneal injection of
aggrecan emulsified in Freund’s adjuvant (Mikecz et al. 1999). Following aggrecan
treatment, mice were treated with 100 µg of IM7, KM201, IRAWB14 or rat IgG control
daily for five days. Treatment with IM7, an antibody that modulates CD44 from the cell
surface, demonstrated reduced joint thickness, inflammation (measured using Giemsa
and methyl green-thionin) serum HA, and surface-bound CD44, but increased sCD44.
Treatment with KM201, an antibody that block HA binding to CD44, resulted in an
intermediate phenotype, showing a less significant decrease in joint thickness,
inflammation, and serum HA. KM201 treatment did not alter levels of surface-bound
CD44 or sCD44 compared to rat IgG control. Interestingly, treatment with IRAWB14, an
antibody that enhances HA binding to CD44, increased joint thickness compared to rat
IgG, IM7 or KM81 treatment. However, no significant changes were observed in
inflammation, serum HA, surface-bound CD44 or sCD44 levels. Unlike KM81 or
IRAWB14, IM7 binds to an epitope outside the HA binding domain; therefore, it does not
compete with ligand binding, but it does modulate CD44 expression on the cell surface
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(Camp et al. 1993). While KM81 inhibits HA binding, IRAWB14 can induce HA binding
(Mikecz et al. 1999). Thus, these data suggest a crucial role for CD44 in murine models
of rheumatoid arthritis. Another study posed a similar question using a model of
collagen-induced arthritis in DBA/1 mice, treated every other day for 14 days with 150 µg
of IM7, KM81, or IRAWB14. Control mice were either treated with PBS or isotypematched controls. Treatment with IM7 or KM81 reduced paw swelling compared to
isotype; however, these are observations from independent experiments, and therefore
comparisons between IM7 and KM81 treatment cannot be drawn. Surprisingly, treatment
with IRAWB14 reduced paw swelling compared to PBS control; however, a caveat of
this study is the lack of an isotype control treated cohort. In summary, these data
suggest that CD44 plays an essential role in mediating the arthritic response; however,
the exact mechanism and the role of CD44-HA binding remain unknown.
In contrast to the acute rheumatoid arthritis models used above, the role of CD44
has also been investigated in a human TNF transgenic (hTNFtg) mouse model. These
mice have been reported to develop chronic inflammatory arthritis followed by joint
destruction and osteopenia (Keffer et al. 1991). CD44 deletion in hTNFtg mice resulted
in aggressive arthritis and bone loss (Hayer et al. 2005). These data are in contrast to
the findings described above demonstrating reduced arthritis upon anti-CD44 mAb
treatment. However, these differences highlight a crucial point: that CD44 may play
opposing roles in modulating the acute compared to the chronic inflammatory response.
In addition to investigating the role of CD44 in early inflammatory response,
studies have also focused on understanding the role of CD44 in mediating clearance of
immune cells from inflammatory sites. In a model of myocardial infarction, CD44 deletion
correlated with prolonged inflammation, characterized by increased neutrophil,
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macrophage, and pro-inflammatory cytokine accumulation, while reducing α-smooth
muscle actin+ (αSMA) fibroblast and collagen accumulation (Huebener et al. 2008). In a
bleomycin-induced lung injury model, CD44-deficient mice had impaired clearance of
neutrophils, persistent accumulation of HA and impaired activation of transforming
growth factor–β1 (TGF–β1) (Vandivier et al. 2002). These data demonstrate that CD44
plays a vital role in the resolution of the inflammatory response. Furthermore, CD44 can
also mediate the balance between inflammation and fibrosis.
The role of CD44 in murine fibrotic models has also been investigated. In a
model of obstructive nephropathy model, CD44 deletion increased tubular injury and
TGFβ1 but decreased renal fibrosis (Rouschop et al. 2004). Another study utilized a
CD44s and CD44v3 knockout/knockin mouse model to decipher their specific roles in
mediating the response to obstructive nephropathy. CD44s knockin mice demonstrated
increased tubular damage, apoptosis, and renal fibrosis; however, CD44v3 knockin mice
had decreased tubular damage, apoptosis and renal fibrosis (Rampanelli et al. 2014).
These data support the paradigm that CD44s and CD44v isoforms can exert opposing
roles in pathological conditions. In an obesity-induced hepatic steatosis model, CD44null mice on a high-fat diet (HFD) had reduced susceptibility to hepatic steatosis,
macrophages, T cells, fibrogenic gene markers (measured using microarray analysis),
and increased insulin sensitivity and glucose tolerance (Kang et al. 2013). These sparse
findings suggest that CD44 deficiency correlates with reduced fibrotic response.
However, multiple caveats need to be considered. These models quantified fibrosis
based on total collagen accumulation at a single time point. Therefore the role of CD44
in mediating the accumulation of specific types of collagen and the overall progression,
evolution, and resolution of fibrosis remains unknown.
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In summary, the role of CD44 has been evaluated in numerous inflammatory and
fibrotic models. Firstly, the role of CD44 is contextually dependent; therefore, findings
from one pathological condition or murine model cannot be generalized to other models
of fibrosis or inflammation. Secondly, CD44 can play differing roles during the evolution
of a pathological condition and thus must be analyzed during various stages of disease
progression. Given that only select studies have investigated the role of CD44 in fibrotic
models, a glaring gap in the literature is the role of CD44 in mediating fibrosis. Thus the
data presented in this dissertation was aimed at bridging this gap in knowledge.

Dissertation Goals
As previously described, CD44 is a transmembrane receptor expressed on
nearly all cell types. CD44 has a multitude of functions including binding to its primary
ligand HA, acting as a co-receptor for growth factor signaling, operating as a docking
platform for numerous proteins and enzymes involved in ECM remodeling and mediating
gene transcription. CD44 has been studied in various pathological conditions and has
been implicated in initial recruitment and clearance of immune cells from sites of tissue
injury or inflammation, accumulation and turnover of HA, and TGFβ activation. However,
the role of CD44 in wound healing and PDA has either not been evaluated or is poorly
understood. Therefore, the research described in this dissertation aimed to delineate the
role of CD44 in these contexts.
As described earlier, various approaches can be utilized to study CD44 in vivo.
We decided to use a genetic approach as it allowed us to determine the role of cellspecific CD44 expression in either aforementioned context. Specifically the goals of this
dissertation were to 1) determine the role of CD44 in the inflammatory and fibrotic
response during wound healing 2) elucidate the role of CD44 in wound resolution 3)
21

delineate the role of neoplastic cell-specific CD44 expression on pancreatic
tumorigenesis and 4) delineate the role of non-neoplastic cell-specific CD44 expression
on pancreatic tumorigenesis.
The work described herein has identified a previously unknown role of CD44 in
fibrillar collagen accumulation in remodeling tissue, challenged the hypothesis that CD44
is merely a cancer stem cell marker, and identified functionally distinct roles of CD44
expression on malignant vs. non-malignant cells in PDA.
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Figure 1. Schematic Representation of the roles of CD44 as an Adhesion Molecule
and Signaling Regulator
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Transmembrane receptor CD44 has diverse biological functions that can be summarized into
three broad molecular mechanisms. (Left) CD44 binding to HA can induce intracellular
signaling, based on HA molecular weight and phosphorylation of intracellular binding partners
such as ERM and merlin. (Middle) CD44 can also function as a co-receptor for various growth
factors and mediate signaling by receptor tyrosine kinases. (Right) MMP14 mediated cleavage
of the extracellular domain results in the production of soluble CD44 (sCD44), which can bind
to extracellular matrix components including HA and compete with transmembrane CD44-HA
interaction. Presenilin-1 dependent gamma-secretase mediated cleavage of CD44 triggers
intracellular domain (ICD) nuclear localization and gene transcription.

•
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CHAPTER 2 - CD44-DEPENDENT INFLAMMATION, FIBROGENESIS, AND
COLLAGENOLYSIS REGULATES EXTRACELLULAR MATRIX REMODELING
AND TENSILE STRENGTH DURING CUTANEOUS WOUND HEALING
Introduction
Wound Healing: A co-ordinated set of events
Wound healing is a dynamic multi-cellular process that is initiated upon tissue
injury. Broadly speaking, wound healing can be divided into four overlapping phases:
coagulation, inflammation, re-epithelialization, and remodeling (Flanagan 2000; Singer
and Clark 1999; Gurtner et al. 2008).
One of the earliest events in response to injury is the recruitment of platelets.
Platelets are recruited to the wound site in response to newly exposed prothrombotic
extracellular matrix (ECM) proteins such as collagen (Golebiewska and Poole 2015).
The release of platelet agonists such as ADP and thrombin by damaged cells leads to
platelet activation and aggregation thus triggering the coagulation cascade. The final
product of the coagulation cascade is the conversion of fibrinogen to fibrin, which then
undergoes crosslinking resulting in a fibrin clot. Fibrin clots, composed of cross-linked
fibrin, plasma fibronectin, vitronectin, and thrombospondin, act as a scaffold for
circulating cells, primarily leukocytes, migrating to the injury site (Clark et al. 1982;
Chester and Brown 2017). As the wound transitions from the coagulation to the
inflammatory phase of wound healing, fibrinolysis, degradation and clearance of the
fibrin clot, is initiated. Similar to the coagulation cascade, fibrinolysis is a tightly regulated
process. Serine proteases, urokinase-type plasminogen activator (uPa) and tissue
plasminogen activator (tPa), convert plasminogen to plasmin (the primary fibrinolysin).
Serine protease inhibitor, plasminogen activator inhibitor-1 (PAI-1) regulates uPa and
tPa protease activity.
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Previous studies have elucidated the role of various components of the
coagulation cascade and fibrinolysis in wound healing. In an excisional wound healing
model, fibrinogen-deficient mice exhibited altered keratinocyte migration and reduced
tensile strength of early granulation tissue. However, ultimately fibrinogen-deficient mice
had comparable rates of wound closure compared to wild-type mice (Drew et al. 2001).
The role of fibrinolysis in wound healing has been delineated using plasminogen or PAI1 deficient mouse models. Plasminogen deficient mice exhibited increased fibrin and
neutrophil accumulation, delayed keratinocyte migration and wound closure, and
sustained inflammation post wound closure (Sulniute et al. 2016); however, these
phenotypes were rescued in a fibrinogen and plasminogen double knockout mouse
model (Bugge et al. 1996). Analogously, PAI-1 mice demonstrated accelerated wound
closure compared to wild-type mice (Chan et al. 2001). These studies show that
alterations in clearance of early fibrin-rich matrix change the rate of wound closure and
migration of additional cells required for wound healing.
In addition to playing a vital role in the coagulation cascade, platelets have also
been implicated in the secretion of chemoattractants, such as PDGF and TGF-β,
required for the recruitment of leukocytes and mesenchymal cells from circulation to the
injury site. During the early inflammatory phase of wound healing, neutrophils, which
play an essential role in engulfing dead cells and tissue debris, represent a majority of
the leukocytes recruited from circulation. (Eming, Krieg, and Davidson 2007; Rosique,
Rosique, and Farina Junior 2015; Martin and Leibovich 2005). Soon after, monocytes
are recruited to the injury site and differentiated into macrophages, which along with
neutrophils further clear up debris and fibrin-rich matrix. Macrophages also secrete
chemokines and cytokines to enable the recruitment of vascular and stromal cells
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(Delavary et al. 2011; Lucas et al. 2010; Koh and DiPietro 2013). The late inflammatory
response primarily composed of macrophages, mast cells, and lymphocytes influence
wound resolution and repair by secreting various growth factors and cytokines that
initiate the angiogenic and fibro-proliferative response (Ng 2010; Wulff and Wilgus 2013;
Schäffer and Barbul 1998; Efron et al. 1990). Sequential and timely termination of the
inflammatory response is vital for injury resolution, as chronic inflammation is
characteristic of pathological wound healing.
Various studies have focused on evaluating the role of immune modulation on
the final outcome of wound healing. Neutrophil depletion accelerated wound healing by
~50% in wild-type and diabetic mice but ultimately showed no difference in collagen
accumulation or tensile strength of wounds (Dovi, J. V. He, Li-Ke, and DiPietro 2003).
Matricellular protein, CCN1, whose name is derived from three members of its protein
family,
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growth
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Nephroblastoma overexpressed) is hypothesized to regulate neutrophil efferocytosis.
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knockout
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inflammation, and delayed wound closure (Jun, Kim, and Lau 2015). These studies
suggest that neutrophils play a vital role in debridement, and control the rate of wound
healing. Neutrophil depletion accelerates wound healing and thus has been posited as a
therapeutic option for non-healing wounds such as diabetic wounds.
Comparatively, various studies have shown that macrophage depletion is
detrimental to wound healing. One of the earliest studies was conducted using an antimacrophage serum and hydrocortisone treatment to induce monocytopenia in adult
guinea pigs in a linear incision wound healing model (Leibovich and Ross 1975).
Macrophage depletion led to impaired debridement, delayed re-epithelialization, and
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reduced fibroblast and collagen accumulation. Similarly, macrophage deletion,
accomplished using diphtheria toxin administration in mice expressing a human
diphtheria toxin receptor until the control of a CD11b promoter, resulted in delayed reepithelialization, reduced collagen deposition, impaired angiogenesis, increased
production of TNF-α, and attenuated production of VEGF and TGF-β1 (Mirza, DiPietro,
and Koh 2009). Mast cells have also been implicated in collagen deposition and
remodeling. In an excisional wound healing model, mast cell-deficient mice
demonstrated reduced vascular permeability, neutrophil recruitment, and scar formation
(Shiota et al. 2009; Wulff et al. 2012). Elevated number of mast cells have been detected
in human and animal models of hypertrophic scars and keloids (Kischer, Bunce, and
Shetlah 1978; J. Wang et al. 2011). On the contrary, the role of lymphocytes in wound
healing is subtype-dependent and poorly understood. Global T cell depletion using antimouse Thy1.2 monoclonal antibody impaired wound healing as revealed by a decrease
in mechanical strength and collagen accumulation (Efron et al. 1990). On the contrary,
depletion of CD8+ T cells, but not CD4+ T cells, increased collagen deposition and
mechanical strength (Barbul et al. 1989). Depletion of natural killer (NK) T cells
accelerated wound closure and modified the compositions of chemokines present during
wound healing, but did not alter the infiltration of additional inflammatory/immune cells
(Schneider et al. 2011). Thus, the inflammatory/immune response is activated soon after
tissue injury but regulates various processes impacting the rate of healing, and injury
resolution.
The release of cytokines including IL-1, IL-6, TNF-α, and growth factors such as
EGF, FGF, and TGF-β by cells recruited to the granulation tissue, promotes the
activation, migration, and proliferation of keratinocytes, which are required for re27

epithelialization (Werner, Krieg, and Smola 2007; Pastar et al. 2014; Barrientos et al.
2008). Matrix metalloproteinases (MMPs) play a vital role in the remodeling phase of
wound healing by digesting the latent form of growth factors to an active form and
releasing growth factors from the matrix (Rohani and Parks 2015). Increase in
accumulation of growth factors such as VEGF and FGF stimulate the fibroproliferative
and angiogenic responses (Barrientos et al. 2008; Behm et al. 2012; Werner, Grose, and
Rosenthal 2008). The existing capillaries at the wound edge become dilated with
increased permeability thus allowing the extravasation and migration of bone marrowderived endothelial progenitor cells into the wound. Proliferation of endothelial cells
leads to the formation of new capillaries. The ultimate goal of angiogenesis is to restore
normoxia and replenish damaged tissue with required nutrients (Tonnesen, Feng, and
Clark 2000; Risau 1997). Soluble factors also promote the recruitment of fibroblasts from
neighboring tissue or bone marrow (Werner, Krieg, and Smola 2007; Greiling and Clark
1997).
Recruitment of fibroblasts allows for the deposition of a provisional matrix, which
is predominantly composed of fibronectin, glycosaminoglycans, and type III collagen
(Chester and Brown 2017; Greiling and Clark 1997; Clark et al. 1982; Welch, Odland,
and Clark 1990). The provisional matrix plays an essential role in setting the stage for
further recruitment of fibroblasts. Fibronectin is hypothesized to be required for collagen
fibril stabilization prior to cross-linking (Sottile and Hocking 2002). In vitro studies have
also shown that fibronectin is required for fibroblast migration and adhesion to a
collagen-rich matrix (Greiling and Clark 1997; Clark et al. 1982). Glycosaminoglycans,
including hyaluronic acid and heparin sulfate, have high water retention properties,
leading to increased viscoelasticity and realignment of fibrin and fibronectin in the
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granulation tissue. Thus presence of glycosaminoglycans increases the porosity of the
provisional matrix, which facilitates the migration of additional fibroblasts into the
provisional matrix (Weigel, Fuller, and LeBoeuf 1986; Chester and Brown 2017).
Although local tissue is the primary source of fibroblasts, mesenchymal stem cells and
fibrocytes can also differentiate into activated fibroblasts (Bucala et al. 1994; Bellini and
Mattoli 2007; Fu et al. 2006).
Fibroblasts are a heterogeneous population of cells that play a critical role in
ECM production and remodeling (Avery et al. 2017; Sorrell and Caplan 2009). In the
granulation tissue, activation of fibroblasts can occur in response to mechanical stress,
growth factors, cytokines, and cell-ECM interaction (Gurtner et al. 2008; Darby et al.
2014) α-smooth muscle actin (α-SMA), is the canonical marker for myofibroblasts with
contractile properties. α-SMA+ myofibroblasts have been implicated in wound closure
due to their capacity to produce strong contractile forces (Darby et al. 2016). The
increased accumulation of fibroblasts promotes the transition from a FN and type III
collagen-rich to a type I collagen-rich matrix. Even after wound closure, continued
synthesis and turnover of collagen, predominantly type I collagen, is characteristic of the
remodeling phase of wound healing.
As described above, wound healing encompasses a cascade of inter- and intracellular events initiated upon injury to restore tissue homeostasis and normal function.
Broadly speaking, wound healing responses can be categorized as regenerative,
reparative, or aberrant. Deregulated repair and/or chronic insult can result in abnormal or
chronic wound healing characterized by persistence of the inflammatory response, and
excessive accumulation and realignment of ECM, which ultimately leads to a loss of
tissue function. Defining mechanisms that govern ECM synthesis, remodeling, and
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turnover is vital to understanding normal versus pathological hypertrophic scarring and
developing therapeutic approaches to minimize scarring
Clinical Relevance of Abnormal Wound Healing
Regenerative wound healing reflects the body’s ability to terminate the
aforementioned processes in a sequential and regulated manner, therefore, aiding in the
restoration of original tissue architecture and function. In humans, fetal tissues are
capable of regenerative wound healing; however, this ability is lost in adults.
Reprogramming of fibrotic and inflammatory responses are postulated to play a role in
the transition from regenerative to reparative wound healing in adulthood leading to the
replacement of normal tissue with scar tissue. Scars are generated by the controlled
accumulation of connective tissue that retains neither the mechanical properties nor the
function of healthy tissue. Aberrant wound healing is associated with uncontrolled
accumulation of ECM with a distinct structure and composition relative to normal tissue,
resulting in a hypertrophic scar. Hypertrophic scars have densely aligned collagen
accumulation, prolonged inflammation, and impaired neovascularization. Hypertrophic
scars in human dermis have been characterized as thickened but weaker skin. Although
various biochemical and biomechanical processes have been hypothesized to play a
role in wound healing, there is still a significant gap in understanding regulators of
normal versus aberrant cutaneous wound healing and in understanding the relationship
between collagen density, alignment, mechanical stress and tensile strength of scar
tissue
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CD44 Expression in Normal vs. Pathological Skin Conditions
In the dermal layer of normal skin, keratinocytes, hair follicular, eccrine, and
dendritic cells express CD44 (Yasaka, Fume, and Tamaki 1995; Penneys 1993). While
CD44s is expressed in both the epidermis and dermis, CD44v is only expressed in the
epidermis and is spatially regulated (Seelentag et al. 1996; Teye et al. 2016). CD44v
isoforms were not found in stratum granulosum and corneum, while weaker staining was
detected in the stratum basale and the upper two-thirds of the stratum granulosum. The
most robust CD44v staining was observed in the lower third of the stratum spinosum.
The mechanism mediating the spatial distribution of CD44 and its impact on the
epidermis remains unknown. Altered CD44 expression is observed in cutaneous fibrotic
and inflammatory conditions. In models of cutaneous inflammation including lupus
erythematosus, lichen planus, and lichen schelosus, CD44 was downregulated in
keratinocytes and was not detected in lymphocytes (Kaya et al. 2000; Harris et al. 1997).
Fibroblasts isolated from hypertrophic scar tissue exhibited elevated expression
of CD44 compared to normal skin fibroblasts (Messadi and Bertolami 1993). In vitro
treatment with exogenous HA further attenuated CD44 expression in normal skin
fibroblasts, but not hypertrophic skin fibroblasts. Interestingly, one study demonstrated
that the pattern of HA accumulation, in normal versus hypertrophic scar tissue, was the
antithesis of CD44 expression. Normal skin contained high levels of HA in the papillary
dermis; however, in hypertrophic scar tissue HA accumulation was attenuated but still
present in the papillary dermis (Bertheim and Hellström 1994). Given the inverse
relationship between levels of CD44 and HA in scar tissue, it would be interesting to test
if inhibition of CD44 expression or activity impact HA accumulation in scar tissue. This is
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of particular interest especially considering the hypothesis that high HA accumulation in
fetal tissue is responsible for scarless healing.
Role of CD44 in mediating cutaneous injury response
The role of keratinocyte cell-specific CD44 expression was tested in a fullthickness excisional cutaneous wound healing using a keratinocyte-specific promoter
driven cre crossed to CD44flox/flox mice. Keratinocyte-specific CD44 deletion resulted in
decreased HA accumulation, delayed wound healing, morphological alterations in
keratinocytes, reduced keratinocyte proliferation, and reduced epidermal stiffening
(Shatirishvili et al. 2016; Kaya et al. 1997). These studies provide evidence for the vital
role of keratinocyte-specific CD44 expression in cellular response, matrix accumulation
and injury resolution. In acute models of irritant and allergenic contact dermatitis, WT
and CD44-null mice demonstrated no difference in inflammatory response (Man et al.
2009). However, following repeated hapten challenge increased inflammatory response
and epidermal hyperplasia was observed in CDD44-null mice compared to WT mice.
These data demonstrate the role of CD44 in mediating inflammatory responses in a
distinct model of injury challenge. Given the crucial role of timely recruitment and
clearance of inflammatory/immune cells in mediating cutaneous wound healing,
delineating the potential role of CD44 in modulating inflammation during cutaneous
wound healing is of interest.
CD44 has also been implicated in regulating substratum- and stiffnessdependent fibroblast migration in vitro. In response to a scratch wound assay, CD44-null
fibroblasts had increased velocity but decreased directionality, which was overcome by
the addition of exogenous TGF-β (Acharya et al. 2008). Primary lung fibroblasts were
also isolated from patients with adult respiratory distress syndrome. Cell adhesion and
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invasion into fibrin, fibronectin, and HA were compared between untreated and antiCD44 blocking antibody treated samples (Svee et al. 1996). Blocking CD44 attenuated
fibroblast adhesion and invasion into the aforementioned substrata, demonstrating the
potential importance of mesenchymal CD44 expression in an early wound response.
Additionally CD44-null dermal fibroblasts exhibited impaired stiffness-dependent motility
on polyacrylamide FN-coated hydrogels. However, other cellular processes such as cell
spreading, stress fiber formation, focal adhesion maturation, and intracellular stiffening
were not affected (Razinia et al. 2017). Given the evolution of the granulation tissue from
a soft FN-rich granulation tissue to a stiff ECM dense tissue, these data hint towards a
potential role of CD44 in mediating fibroblast migration during wound resolution.
In summary, CD44 has been implicated in regulating the various processes
involved

during

wound

healing,

including

recruitment

and

clearance

of

inflammatory/immune cells, HA synthesis and turnover, recruitment and activation of
keratinocytes, motility/migration of fibroblasts, and TGFβ activation. However, the role of
CD44 in cutaneous wound healing remains unknown.

Material and Methods
Animals
WT BALB/c mice were purchased from Charles River Laboratory Inc. CD44-null mice
(Schmits et al. 1997) were backcrossed 12 generations onto a BALB/c background. Mice
were used between 10 – 16 weeks of age. All mice were housed in University of
Pennsylvania facilities, and all research was overseen by University Laboratory Animal
Resources (ULAR). Experimental protocols were approved by the Institutional Animal
Care and Use Committee and were in compliance with the Guideline for the Care and
Use of Animals.
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Generation of full-thickness excisional wounds
Mice were anesthetized using isoflurane (Henry Schein) and two equidistant 6-mm full
thickness excisional wounds were generated using biopsy punches (Miltex) in the dorsal
skin 4 mm below the shoulder blades. The wounds were covered using curad dressing
(Medline) and tegaderm adhesive tape (Medline). Wound closure was determined by
taking digital pictures every other day. Mice were sacrificed 5, 7, 11, or 63 days after
wounding using CO2.
Immunohistochemistry (IHC) and immunofluorescence (IF) analysis
Skin samples were collected, fixed in prefer (Anatech Ltd.), and paraffin-embedded. Skin
samples were laterally bisected through the midline and 5-µm sections were mounted
onto positively charged glass slides. Hematoxylin and eosin staining was conducted by
the Penn Vet comparative pathology core. Masson’s Trichrome Staining Kit (SigmaAldrich) was used to analyze total collagen accumulation as per manufacturers’
instructions. Picrosirius Red staining was conducted using 0.1% Direct Red 80 (SigmaAldrich). For all other stains, tissue sections were wax-cleared, rehydrated then
subjected to antigen retrieval (Table 1). For IHC, sections were blocked with avidin/biotin
blocking kit (Vector Labs), 3% H2O2 (Sigma-Aldrich), and 10% goat serum prior to
incubation with overnight primary antibody incubation in 10% goat serum in 1%
BSA/PBS

(Table 1). Sections were then incubated with secondary antibody in 1%

BSA/PBS (Table 1), ABC Elite Reagent (Vector Labs), and DAB (Dako). For IF, sections
were blocked with 10% goat/donkey serum prior to primary antibody incubation (Table
2). Sections were then incubated with anti-FITC/TRITC (Table 2). To reduce tissue autofluorescence sections were treated with 0.1% sudan black (in 70% ethanol) prior to
counter staining with DAPI. For all staining, 10x (IHC) or 20x (IF) images were acquired
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using a Nikon Eclipse Ti-E inverted microscope. The motorized stage was utilized to
obtain multichannel stitched-images of the entire skin section (including normal skin and
granulation tissue). IHC and IF stain quantification was conducted using NIH Image J
analysis software and NIS-elements analysis software.
Two-Photon Second-Harmonic Generation (2P-SHG)
Fibrillar collagen images were obtained using a Leica SP5 confocal/multiphoton (5-µm
paraffin embedded sections day 7, 11, and decellularized FDMs) or a Leica SP8
confocal/multiphoton microscope (5-µm paraffin embedded sections day 5 and 63). 2PSHG signal was obtained by tuning coherent chameleon Vision II Ti:Sapphire laser to
800 nm and an external non-descanned detector (HyD) configured to capture
wavelengths <495 nm. Tissue autofluorescence signal was obtained by tuning two
additional non-descanned detectors to 495 to 560 nm and 560 to 620 nm wavelengths.
Fibrillar collagen images were obtained by subtracting autofluorescnce signal from the
original SHG image. For wound healing samples, a motorized stage was utilized to
obtain multichannel stitched-images of the entire skin section (including normal skin and
granulation tissue). For decellularized matrices, 5 SHG images were acquired per
matrix, and each experiment was conducted in triplicate.
Curvelet Transform Fiber Extraction Analysis (CT Fire Analysis)
Quantitative evaluation of collagen fibers were conducted as previously described
(Bredfeldt et al. 2014). A binary image was formed based on manually selected
threshold parameters using the FIRE algorithm to detect fibers and eliminate potential
background pixels. A preprocessed algorithm was then utilized to quantify fiber angle,
length, width, and straightness.
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In-situ Zymography
MMP activity was measured using in-situ zymography as previously described (George
and Johnson 2010). 5-µm paraffin embedded sections were wax-cleared and
rehydrated. As per manufacturers instructions, skin sections were incubated with DQ
Gelatin or DQ Collagen 1:200 (Thermofisher) in reaction buffer (50 mM Tris, 150 mM
NaCl, 5 mM CaCl2, 0.2 mM NaN3) for 2 hours. Control sections were treated with
reaction buffer alone (no DQ Gelatin or DQ Collagen). Sections were then treated with
sudan black, counterstained with DAPI and mounted with slowfade gold (Thermofisher).
Using a motorized stage, 20x fluorescence images of the entire skin section were
acquired using a Nikon Eclipse Ti-E inverted microscope.
Isolation of primary dermal fibroblasts
Primary dermal fibroblasts were isolated from naïve unwounded 10 – 16 weeks old WT
and CD44-null BALB/c mice. Dorsal and ventral skin sections were finely minced and
digested using 1 mg/ml collagenase type II (Worthington) and hyaluronidase (SigmaAldrich) in DMEM (Corning Inc.) at 37°C for 1.5 hours. Digestion was quenched using
equal volume of 10% fetal calf serum (FCS) DMEM, strained through a 70 µm cell
strainer (Corning Inc.), and pelleted by centrifugation at 1200 rpm for 5 minutes at 4°C.
Cell pellets were washed with PBS (Corning Inc.) and resuspended in 10% FCS-DMEM
containing 0.02 M HEPES, 1mM L-Glutamine, 10 units penicillin and 10 µg
streptomyocin, 0.05 mg gentamicin, and 0.25 µg amphothericin B and plated on tissue
culture-treated plastic (polystyrene). Cells were maintained at 37 °C with 5% CO2 in a
humidified incubator. The following day, cell monolayers were thoroughly washed with
PBS and supplemented with fresh media. Cells were maintained in 10% FCS DMEM on

36

tissue culture-treated plastic for one passage. First passage fibroblasts were used for all
experiments.
Fibroblast-Derived Matrices (FDMs)
FDMs were generated as previously described (Beacham, Amatangelo, and Cukierman
2007). 5.0x105 first passage dermal fibroblasts were plated onto 0.2% cross-linked
gelatin (Fisher Scientific) coated 35-mm plates. The next day, fibroblasts were
supplemented with 75 µg/ml of ascorbic acid (Fisher Scientific), which was replenished
every 48 hours for 8 days. Matrices were decellularized for matrix analysis using
detergent treatment with 0.5% Triton X-100, 20 mM NH4OH in PBS for 5 minutes at
37°C (H. O. Lee et al. 2011).
Calcein AM
Cell viability was analyzed using a calcein AM cell permanent dye as per manufacturer’s
instructions. On 8th day of matrix production, FDMs were washed twice with PBS and
then incubated with 1 µm calcein AM for 30 minutes at room temperature. Fluorescence
excitation was measured at 485 nm. Data was represented as raw fluorescence units
(RFU).
Quantitative Real-Time PCR
A 4 mm biopsy punch was used to extract wounds at closure (day 11 post-wounding).
Samples were flash frozen using liquid nitrogen and crushed with a mortar and pestle on
dry ice. RNA isolation was conducted using TriZol (Invitrogen) as per manufacturer’s
instructions. Gel electrophoresis was conducted to ensure RNA quality. 1 µg RNA was
utilized for cDNA synthesis using TaqMan Reverse Transcription kit (Applied
Biosystem). Transcript levels were quantified using StepOnePlus Real-Time PCR
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System (Applied Biosystems) and SYBR Green (Invitrogen). All samples were run in
triplicate and averaged. mRNA levels for each gene of interest were normalized to Hprt.
Primer

Sequences:

ggtccttttcaccagcaagct;

Hprt1-F,
Mmp2-F,

5’-tgacactggtaaaacaatgca;
5’-

cccatgaagccttgtttacca;

Hprt1-R,
Mmp2

-R,

5’5’-

tggaagcggaacgggaact; Mmp14-F, 5’- ccgaccgcgctctagga; Mmp14-R, 5’- cgcgccgcctctctt;
Mmp8-F, 5’- aaaagggaagctcagtctgtatactc; Mmp8-R, 5’- agagggctgcagagttagttacca;
Mmp9-F, 5’- tatttttgtgtggcgtctgagaa; Mmp9-R, 5’- gaggtggtttagccggtgaa; Lox-F, 5’ –
gggagtggcacagctgtca; Lox-R, 5’ – tcctctgtgtgttggcatcaag.
Immunoblot
A 6 mm biopsy punch was used to extract wounds days 5 and 7 post-wounding.
Samples were flash frozen using liquid nitrogen and crushed with a mortar and pestle on
dry ice. Protein lysates were obtained using RIPA lysis buffer (Thermofisher) and were
supplemented with complete protease inhibitor tablets (Sigma-Aldrich), sodium
orthovanadate, and sodium fluoride. Protein concentration was measured using a BCA
protein assay kit (Thermofisher). 10 µg of protein was loaded onto a 4 – 12% Bis/Tris
Mini Gel (Thermofisher), transferred onto PVDF membrane, and probed with antibodies
to anti-MRC2 (Endo180, abcam), β-Actin (Cell Signaling), followed by HRP-conjugated
goat anti-rabbit secondary antibody (Sigma-Aldrich).
ELISA
Analysis of IL-4 (eBioscience), IL-1β (eBioscience), IL-10 (eBioscience), and TNF-α
(eBioscience) in wound samples were conducted using above mentioned protein lysates
as per manufacturer’s instructions.
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Flow Cytometry
Dorsal and ventral skin samples were extracted from 10 – 16 week old WT and CD44null mice and digested using 10 ml of 1 mg/ml collagenase type II and hyaluronidase in
DMEM for 2 hours at 37°C. Tissue lysates were then filtered through 70- and 40-µm cell
strainer (Corning Inc.). For FDM experiments, cells depositing matrices were treated with
2 ml of 500 µg/ml of collagenase type I (Worthington) in DMEM for 30 minutes followed
by 5 minutes trypsinization 37°C and filtration through a 70-µm cell strainer. The
obtained single-cell suspension was stained for viability using aqua live/dead fixable cell
stain kit (Molecular Probes). Extracellular stromal cell analysis was conducted using
antibodies listed Table 3. Prior to intracellular staining with anti-αSMA FITC 1:540
(Sigma Aldrich), cell suspension was fixed and permeabilized using cytofix/cytoperm
fixation permeabilization kit (BD Bioscience). Unstained, LIVE/DEAD only, and single
stains were used as controls. Single cells were gated on using forward and side scatter
width and height event characteristics. The specificity of the FAP antibody was verified
using FAP-null fibroblasts. Flow cytometric analyses were performed on a LSR-Fortessa
using FACSDiva software (BD Bioscience) and data were analyzed using FlowJo (Tree
Star).
Hydroxyproline Assay
Hydroxyproline assay was conducted as previously described (Santos et al. 2009). 4
mm normal and wounded skin biopsies were weighed, cut and digested overnight at
110°C in 1 ml of 6N HCl. After neutralization with equal volume 6N NaOH, the pH was
adjusted (6.0<pH<10.0). FDMs were treated with 100 µl 6N NaOH, collected using a
cell scraper, and digested at 110°C for 20 minutes. Samples (100 µl) were mixed with 1
ml chloramine T solution for 20 minutes at room temperature, followed by 1 ml erlich’s
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solution (Sigma Aldrich) and incubated at 65°C for 15 minutes. 200 µl aliquots were
transferred to 96-well plates, and absorbance was measured at 570 nm. Collagen
content was calculated by comparison with a standard curve generated with cis-4
hydroxy-L-proline (0.01–110 µg/ ml; Sigma-Aldrich), using the conversion factor of 1 µg
hydroxyproline, corresponding to 6.94 µg collagen. Total collagen was expressed as µg
collagen normalized to mg of tissue weight or raw fluorescence unit corresponding to
calcein AM signal.
HA Purification and ELISA
4 mm biopsy punches were conducted to obtain normal skin samples. HA purification
was conducted by digesting skin samples in 10 mg/ml proteinase K in ammonium
acetate at 60°C for 4 hours. 4 volumes of pre-chilled 200 proof ethanol was added and
samples were incubated at -20°C overnight. Samples were then pelleted by
centrifugation at 14,000 g for 10 minutes at room temperature followed by 4 volumes of
pre-chilled 75% ethanol and re-pelleted by centrifugation at 14,000 g for 10 minutes.
Pellets were air-dried and resuspended in 100 µl 100 mM ammonium acetate. A second
ethanol precipitation was conducted by repeating aforementioned protocol and samples
were resuspended in 20 ul of 100 mM ammonium acetate. Total amount of HA was
quantified using Hyaluronan DuoSet ELISA Kit (R&D) as per manufacturer’s instructions.
Tensile Strength Analysis
Wound samples were extracted using a standardized method via the use of a dog-bone
punch resulting in a gauge length of 10mm and width of 2.5mm at the smallest crosssection. The cross-sectional area of the samples was measured at 5 locations via a
custom laser-based measuring device (Favata et al. 2006). The final area was
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determined as the average of these five readings. Sample termini were sandwiched
between sandpaper (grit = 400) using cyanoacrylate glue. The dog-bone skin samples
were then placed in metal clamps and tested in an Instron 5542 materials testing
machine (Instron Inc.). The mechanical testing protocol consisted of a preload to 0.25N
followed by a 60 second hold to collect gauge length images. This was followed by a
ramp to failure at a ramp rate of 0.24mm/sec till failure of the sample occurred.
Parameters collected were: maximum load (N), maximum strain (mm/mm), stiffness
(N/mm, slope of the linear region from the load-displacement curve), maximum stress
(N/mm2, maximum load divided by the cross-sectional area), and Young’s modulus
(MPa, slope of the linear region from the stress-strain curve).
Statistical Analysis
All results are expressed as mean ± SEM. Statistical analysis was performed using 2tailed student’s t test (GraphPad Prism 7.0). Asterisks denote statistical significance: ****
p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05.

Results
CD44 deficiency alters the kinetics of fibrillar collagen accumulation during
cutaneous wound healing
Cutaneous wound healing occurs in three main stages: inflammatory, reepithelialization, and tissue remodeling (Gurtner et al. 2008). During early stages of
wound healing, the granulation tissue is comprised of a provisional matrix, including high
levels of fibronectin (FN), HA, and type III collagen, which is vital for cellular adhesion
and migration to the granulation tissue (Greiling and Clark 1997; Gurtner et al. 2008;
Xue and Jackson 2015; Fronza et al. 2014). During the tissue remodeling phase, there is
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an increase in type I collagen accumulation, which is crucial for regaining tissue elasticity
and strength. Aberrant ECM accumulation and architecture is indicative of pathological
wound healing with excess scar formation.
At baseline, CD44-null mice demonstrated normal skin histology, collagen
content (measured by quantification of masson’s trichrome and picrosirius red staining
visualized under circular polarized light), HA (measured by ELISA) and stromal cell
content (based on quantification of percent positive cells and levels of expression of
CD90+, fibroblast activation protein (FAP+) and/or alpha-smooth muscle actin (αSMA+)
cells quantified by flow cytometry) compared to WT mice (Fig. 2 A - I).
We investigated the impact of CD44 on wound healing by comparing the
response to full thickness excisional wounds (6 mm in diameter) generated 4 mm below
the shoulder blades on the dorsal side of the skin using biopsy punches, in WT and
CD44-null mice. Wounds were kept hydrated using tegaderm (bandages) and curad
(tape) to minimize scab formation (Dunn et al. 2013) (Fig. 3A). The rate of wound
closure was measured by quantification of digital images captured on days 1, 3, 5, 7, 9,
and 11 post-wounding. The kinetics of wound closure were comparable in WT and
CD44-null mice (Fig. 3B) with both genotypes exhibiting complete re-epithelialization and
wound closure by day 11. Morphometric analysis of sections revealed no significant
differences in total cellularity days 5, 7 and 11 post-wounding, measured using DAPI
nuclear stain, and area of granulation tissue visualized by H&E staining at wound
closure (Fig. 4 A-B).
The role of CD44 in matrix accumulation and remodeling during cutaneous
wound healing was investigated by comparing ECM composition, organization and
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architecture in WT and CD44-null mice at days 5, 7 and 11 post-wounding. During early
phases of wound healing (days 5 and 7), wounds from CD44-null mice had reduced type
I collagen (measured using immunofluorescence), and fibrillar collagen (measured using
two-photon second harmonic generation imaging - 2P-SHG) compared to WT mice (Fig.
3 C - D). However, at wound closure (day 11) CD44-null mice exhibited greater
accumulation of type I collagen and fibrillar collagen compared to WT mice (Fig. 3 C D). CD44-null mice did not show any significant differences in accumulation of HA (Fig.
5A) or FN at any time point during the wound healing response when compared to WT
mice (Fig. 5B). These results indicate that in response to injury, CD44 plays a role in
matrix remodeling by regulating fibrillar collagen accumulation.
CD44 deficiency enhances leukocyte but attenuates FAP+ fibroblast accumulation
during early phases of wound healing
Wound healing is the result of a coordinated multistep cascade of events
involving inflammatory cells, endothelial cells, keratinocytes and fibroblasts. The
inflammatory response initiated upon tissue injury plays a vital role in the release of
cytokines and growth factors involved in fibroblast recruitment, activation, and
consequent ECM deposition (Eming, Krieg, and Davidson 2007; Ogawa 2017; Mack
2017). In several models of tissue injury CD44 was shown to be required for leukocyte
recruitment, adhesion, and clearance. In contrast however, in a lung injury model CD44
deletion enhanced neutrophil recruitment suggesting that CD44 can limit recruitment of
neutrophils in particular settings (Maiti, Maki, and Johnson 1998; Schmits et al. 1997;
Vandivier et al. 2002; Q. Wang et al. 2002). Given this cell-type and context-dependent
role of CD44 in regulating the inflammatory/immune response, we next investigated the
impact of CD44 deletion on the inflammatory/immune response during cutaneous wound
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repair. We analyzed infiltration by total leukocyte, neutrophils, T cells, M1 and M2
macrophages days 5, 7 and 11 post-wounding. During early phases of wound healing
(days 5 and 7), perhaps surprisingly, we found that CD44-null wounds had increased
numbers of total leukocytes as measured using the pan-leukocyte marker CD45+ (Fig.
6A). Further analysis revealed that no specific immune cell population was altered
including

neutrophils

(CD11b+

Ly6G+),

M1

macrophages

(F4/80+ iNOS+),

M2

macrophages (F4/80+CD206+), and T cells (CD3+) in CD44-null wounds (Fig. 6 B - E)
that collectively accounted for the overall increase in CD45+ leukocytes. To determine
the impact of increased leukocytes on the inflammatory milieu during early phases of
wound healing, levels of cytokines implicated in wound healing including IL-1β, IL-4,
TNF-α, and IL-10 were analyzed using ELISAs (Barrientos et al. 2008; Coussens and
Werb 2002; Elliott et al. 2015; Ono et al. 2018). Consistent with the observed increase
in leukocytes during early phases of wound healing, we found increased levels of IL-1β
and IL-4 day 5 post-wounding in CD44-null wounds compared to WT wounds (Fig. 7 A B). These increases were selective in that CD44-null wounds showed no significant
differences in TNF-α, and IL-10 levels day 5 post-wounding (Fig. 7 C - D). Additionally,
despite a significant increase in number of leukocytes, no significant differences in
expression levels of cytokines were found in WT and CD44-null wounds day 7 postwounding (Fig. 7 A - D). These data suggest that at day 7 post-wounding, the increase in
leukocytes in CD44-null wounds is not sufficient to alter cytokine levels or that additional
cell types, including fibroblasts, may compensate for the increase in leukocytes in CD44null wounds compared to WT wounds.
The initial inflammatory phase of wound repair is followed by recruitment,
proliferation, and activation of fibroblasts Singer and Clark 1999; Flanagan 2000;
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Gurtner et al. 2008). Fibroblasts are a heterogeneous cell population responsible for
matrix production and remodeling (Sorrell and Caplan 2009; Avery et al. 2017). α-SMA is
a canonical marker of myofibroblasts that are involved in wound contraction, as well as
tissue fibrosis. In epithelial tumors, pulmonary fibrosis, liver cirrhosis and myocardial
infarction, fibroblast activation protein (FAP) identifies distinct, yet to varying degrees,
overlapping subsets of activated fibroblasts (Acharya et al. 2006; Levy et al. 1999;
Tillmanns et al. 2015; Lo et al. 2015; Öhlund et al. 2017; Tchou et al. 2013). We recently
demonstrated that FAP+ and α-SMA+ fibroblasts exhibit distinct gene expression patterns
and divergent functions in vitro (Avery et al. 2017). Based on these findings, we
conducted immunohistochemistry (IHC) on serial sections of wounds days 5, 7 and 11
post-wounding for vimentin (mesenchymal cell marker), FAP, and α-SMA to analyze the
spatial and temporal distribution of total mesenchymal cells as well as these distinct
activated fibroblast subsets over the course of wound healing. Interestingly, we found
that in WT wounds, vimentin+ and α-SMA+ fibroblasts gradually increased over the
course of wound closure, whereas FAP+ fibroblasts were prevalent early and remained
relatively constant (Fig. 8). These data provide key evidence for temporal regulation of
different mesenchymal cell subsets during cutaneous wound healing. Compared to WT
wounds, CD44-null wounds showed no significant differences in the temporal profile of
vimentin+ and α-SMA+ fibroblasts (Fig. 8 A-C), but exhibited a marked delay in the
kinetics of FAP+ fibroblasts accumulation. Specifically, during early phases of wound
healing (days 5 and 7) CD44-null wounds had a significant reduction in FAP+ fibroblasts
compared to WT wounds (Fig. 8A, 8D), which was overcome by the time of wound
closure, providing evidence for CD44-dependent temporal regulation of FAP+ fibroblasts.
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These mesenchymal cells also exhibited interesting differences in their spatial
distributions.

At day 5 post-wounding, vimentin+, FAP+, and α-SMA+ cells were all

concentrated at the wound edge and proximal to the hypodermis region in both WT and
CD44-null wounds (Fig. 8A; top panel). By day 7 post-wounding, vimentin+ fibroblasts
were found dispersed throughout the granulation tissue while the α-SMA+ cells remained
mainly at the wound edge in both genotypes. Interestingly, we distribution of FAP+ cells
diverged in wounds in WT vs CD44-null mice by day 7. Specifically, in WT wounds,
FAP+ fibroblasts showed a similar distribution pattern to vimentin+ fibroblasts throughout
the granulation tissue but in wounds in CD44-null mice FAP+ cells were primarily present
proximal to the hypodermis region (Fig. 8A; middle panel). At wound closure (day 11),
vimentin+ fibroblasts remained dispersed throughout the granulation tissue in both
genotypes. While FAP+ cells were mainly concentrated proximal to the hypodermis
region, α-SMA+ cells were present throughout the granulation tissue and proximal to the
epidermis (Fig. 8A; lower panel) in both WT and CD44-null wounds. This indicated that
CD44 regulates both spatial and temporal distribution of FAP+ reactive fibroblasts during
early phases of wound healing.
CD44 deficiency reduces collagenolysis activity during cutaneous wound healing
Fibrillar collagen biosynthesis involves synthesis of pro-α chains, hydroxylation of
proline and lysine residues, inter- and intra-molecular crosslinking, and assembly into
fibrils (Prockop et al. 1979a, 1979b). Following incorporation into the extracellular matrix,
collagen metabolism occurs by extracellular proteolysis (by collagenases and
gelatinases) followed by cellular uptake and lysosomal degradation (McKleroy, Lee, and
Atabai 2013).
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To identify the role of CD44 in collagen metabolism resulting in increased
accumulation at wound closure, a biochemical analysis of collagen was conducted day
11 post-wounding. CD44-null wounds showed no difference in content of hydroxylated
proline residues or in mRNA levels for lysl oxidase (lox), an enzyme involved in collagen
crosslinking, compared to WT wounds (Fig. 9 A – B). CD44-null wounds also showed no
significant differences in protein levels for Endo180, a receptor involved in cellular
uptake/lysosomal degradation of collagen, when compared to WT wounds (Fig. 9 C –
D). In situ zymography however demonstrated reduced collagenase activity during early
phases of wound healing and at wound closure, days 7 and 11, in CD44-null compared
to WT wounds (Fig. 10A). CD44-null wounds also had reduced gelatinase activity during
early phases of wound healing but not at wound closure (Fig. 10B).
Fibroblast CD44-dependent collagenolysis regulates fibrillar collagen
accumulation in vitro
To determine the mechanism by which CD44 regulates fibrillar collagen
accumulation, we utilized a fibroblast-derived matrix (FDM) approach (Beacham,
Amatangelo, and Cukierman 2007). WT and CD44-null dermal fibroblasts from naïve
unwounded skin were cultured for 8 days on cross-linked gelatin coated plates in the
presence of 75 µg/ml of ascorbic acid - an essential cofactor of collagen lysl and prolyl
hydroxylation and facilitates the formation of the collagen triple helix (Schwarz,
Kleinman, and Owens 1987). CD44-null fibroblasts showed no difference in cell viability
(Fig. 11A), measured by calcein AM, total and activated fibroblast markers (Fig. 11B),
based on flow cytometric analysis for CD90, FAP, and α-SMA, and lox mRNA levels
(Fig. 11D) compared to WT fibroblasts in vitro.
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Analogous to day 11 wounds, analysis of collagen from WT and CD44-null FDMs
showed no differences in hydroxylated proline residues (Fig. 11C). On the 8th day of
matrix production, a detergent treatment was used to decellularize matrices, which were
then analyzed using 2P-SHG for fibrillar collagen accumulation. Analogous to day 11
wounds, FDMs derived from CD44-null fibroblasts contained greater fibrillar collagen
accumulation compared to WT fibroblasts (Fig. 12A).
Quantification of MMP mRNA levels using qPCR, revealed no significant
differences in MMP levels between WT and CD44-null fibroblasts depositing FDMs (Fig.
12B). To identify if CD44 plays a role in MMP activity, WT and CD44-null fibroblasts
depositing matrices were supplemented 20 µg/ml of DQ collagen 24 hours prior to
decellularization. DQ collagen is a collagen analog with excessive fluorescein labeling in
close proximity resulting in a quenched fluorescence signal. Enzyme-driven hydrolysis of
the substrate, by collagenases and gelatinases, results in the separation of the dye
molecules and the generation of a fluorescence signal. The increase in fluorescence is
proportional to the proteolytic activity. When incubated with DQ collagen, but not DQ
gelatin, CD44-null FDMs had reduced fluorescence signal compared to WT FDMs,
indicating that CD44-null fibroblasts had reduced collagenase (Fig. 12C) but not
gelatinase activity (Fig. 11E).
CD44 deficiency increases fibrogenic response and reduces tensile strength of
scar tissue
Excess accumulation of fibrillar collagen is a hallmark of scar tissue formation
and aberrant wound healing (Wulandari et al. 2016; Takeo, Lee, and Ito 2015; Andrews
et al. 2016). To determine if the increase in fibrillar collagen accumulation observed at
wound closure at day 11 persists after wound closure, WT and CD44-null wounds were
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harvested 9 weeks (ie. day 63), post-wounding. CD44-null scars showed an increase in
fibrillar collagen accumulation, using 2P-SHG (Fig. 13A), no significant difference in type
I collagen accumulation, using IF (Fig. 13B), and reduced collagenase activity compared
to WT scar tissue (Fig. 13C). WT and CD44-null scars showed no significant differences
in HA or CD45+ leukocytes (Fig. 14 A – B). Furthermore, CD44 deficiency had no
significant impact on fibrillar collagen length, width, or angle analyzed using CTfire (Fig.
14 C – E). CD44-null scar tissue revealed an increase in FN accumulation and total
mesenchymal fibroblasts (vimentin+ area) but no significant changes in subsets of
activated fibroblasts (FAP+ or α-SMA+ area) compared to WT (Fig. 13 D, E, Fig. 14F, G).
These results indicate that CD44-deficient scars had an overall increase in the
fibroproliferative response.
Scar tissue has compromised biomechanics compared to normal skin. Due to
alterations in amount and architecture of fibrillar collagen present, scars can potentially
regain a maximum of 80% tensile strength compared to normal skin (Brenda et al. 1999;
Eleswarapu, Responte, and Athanasiou 2011). To examine whether the increased
fibrotic response we observed in scars in CD44-null mice impacted biomechanical
properties of the scar tissue, the tensile strength of WT and CD44-null wounds were
analyzed day 63 post-wounding. WT and CD44-null scars were extracted using a stamp
to obtain samples of comparable size and shape. Samples were subjected to a ramp to
failure test and tensile strength (Megapascal - MPa) was calculated using the slope (of
the linear region) of a stress-strain curve. Using ramp to failure test, CD44-null scar
tissue had reduced tensile strength compared to WT scars (Fig. 13F). Taken together,
these data indicate that the increased accumulation of fibrillar collagen in CD44-null
scars correlated to compromised tissue biomechanics.
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Discussion
In summary, we show that loss of CD44 impacts inflammation, fibrogenesis and
matrix remodeling during various stages of cutaneous wound healing (Fig. 15).
Specifically, during early stages of wound healing, loss of CD44 enhanced the kinetics of
leukocyte infiltration while delaying the accumulation and altering the spatial distribution
of FAP+ fibroblasts. The effect of FAP+ fibroblasts was selective in that loss of CD44 had
no impact on the kinetics or spatial distribution of total mesenchymal cells or α-SMA+
myofibroblasts. Finally, loss of CD44 reduced collagen early – consistent with FAP+
fibroblasts being a major source of collagen (Avery et al. 2017; Lo et al. 2015). However,
by day 11 loss of CD44 was associated with an increased accumulation of collagen, due
at least in part to a reduction in collagenolysis, which persisted in late scar tissue (day
63) and was associated with reduced tensile strength of scar tissue.
Increased HA accumulation has been reported to contribute to scarless healing
in fetal wounds compared to adult wounds (Balaji et al. 2017). Given the role of CD44 in
mediating HA endocytosis (Hong Jiang et al. 2002; Rahmanian and Heldin 2002), one
posited mechanism by which HA contributes to scarless healing in fetal wounds is
through its predominant receptor, CD44. As suggested by previous studies, here we
have shown that HA accumulation begins at early stages of wound healing and is
prevalent throughout the wound response; however, we found that genetic deletion of
CD44 did not alter the total amounts of HA accumulation. This suggests that a
compensatory mechanism may offset for CD44 deletion with regards to HA
accumulation in our cutaneous wound healing model. In addition to CD44, HA can bind
to other receptors such as receptor for HA-mediated motility (RHAMM) and intracellular
adhesion molecule-1 (ICAM-1). These findings indicate that CD44 deletion is not
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sufficient to increase HA accumulation post-wounding, and further studies need to be
conducted to understand the regulation of HA synthesis, signaling via other receptors,
and interaction with additional CD44 ligands such as fibronectin and collagen during
cutaneous wound healing.
Fibroblasts are a heterogeneous population of cells that play a critical role in the
dynamics of ECM composition and architecture (Avery et al. 2017; Sorrell and Caplan
2009). In an in vitro wound healing model, CD44 was required for directional migration of
fibroblasts (Acharya et al. 2008). Similarly, CD44-null fibroblasts isolated after acute lung
injury showed reduced invasion into a fibrin gel and adhesion to provisional matrix
components such as fibrin, fibrinogen, fibronectin, and HA (Svee et al. 1996). However,
we found that in an in vivo cutaneous wound healing model, CD44-deficiency did not
alter total fibroblast accumulation based on quantification of vimentin+ area, in the
granulation tissue. These data suggest that CD44 is either dispensable for fibroblast
accumulation in this setting or that compensatory mechanisms such as upregulation of
other adhesion molecules implicated in adhesion and migration, including integrins
(Greiling and Clark 1997), may overcome the lack of CD44. Evaluation of integrin
expression in WT and CD44-null wounds and loss of function experiments in future
studies will help understand the cross-talk between CD44 and integrins in regulating
fibroblast migration in response to cutaneous wound healing.
Traditionally, α-SMA was considered the primary marker for activated fibroblasts
during cutaneous wound healing. Our data shows that similar to models of fibrosis and
solid tumors, during cutaneous wound healing FAP and α-SMA identify distinct, and
sometimes to varying degrees, overlapping cell populations (Acharya et al. 2006; Levy et
al. 1999; Tillmanns et al. 2015; Lo et al. 2015; Öhlund et al. 2017; Tchou et al. 2013). α51

SMA, is the canonical marker for myofibroblasts with contractile properties (Hinz et al.
2001). Using a mouse model with genetic deletion of α-SMA, multiple papers have
reported that α-SMA facilitates but is not necessary for wound contraction and closure
(Tomasek et al. 2013; Ibrahim, Mohamed et al. 2015). These data also suggest that αSMA is significant but not the only fibroblast protein involved in wound healing.
Extrapolating from this hypothesized role in wound contraction, using IHC we found that
α-SMA+ cells are concentrated at the wound edge and close to the epidermis during
early stages of wound healing, suggesting that α-SMA aides in the contraction of the
wound edge. α-SMA+ cells peaked at wound closure (day 11) and were dispersed
throughout the granulation tissue, but were primarily concentrated near the epidermis.
We found that WT and CD44-null mice had no significant differences in α-SMA+ cells,
which was consistent with comparable rates of wound closure observed.
Importantly, in WT wounds, we found that FAP+ cells, but not α-SMA+ cells,
account of the bulk of total fibroblasts in the granulation tissue during early phases of
wound healing, when the ratio of FN to collagen is much higher in the granulation tissue.
Furthermore, we found that during early phases of wound healing (day 5), FAP+ cells are
concentrated proximal to the hypodermis. The hypodermis lies between the dermis and
underlying muscle and contains loose connective tissue and adipose tissue. Using an
indentation test, the elastic modulus of human hypodermis is approximated to be 2 kPa
(Pailler-Mattei, Bec, and Zahouani 2008). This is in line with recent data from our lab that
showed selective differentiation of fibroblasts to a FAPhi phenotype on soft (2 kPa) rather
than stiff (20 kPa) FN-coated hydrogels (Avery et al. 2017) and evidence in the field
highlighting the importance of the mechanical properties of provisional matrix on cellular
migration and behavior (Chester and Brown 2017). Additionally, we found that CD44
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deficiency reduced the number of FAP+ cells in the granulation tissue during early
phases of wound healing. Taken together, these data suggest that CD44 may play a
critical role in the recruitment and/or generation of FAP+ fibroblasts in response to tissue
injury.
Gene expression profiling of FAPhi fibroblasts revealed higher levels of various
ECM components (including collagens) compared to α-SMAhi fibroblasts (Avery et al.
2017). Similarly, depletion of FAP+ cells has been shown to reduce the desmoplastic
response in tumors (Lo et al. 2015). Analogously, our data reveled that reduced FAP+
fibroblasts in CD44-null wounds during early phases of wound healing correlated with
reduced fibrillar collagen accumulation. These data suggest a potential role of FAP+ cells
in mediating the deposition of the early provisional matrix during cutaneous wound
healing.
A potential mechanism for recruitment or activation of FAP+ fibroblasts is the
cross talk between inflammatory/immune cells and mesenchymal cells. One of the
earliest events following tissue injury is activation of the innate immune response
followed by monocytes, macrophages and lymphocytes (Gurtner et al. 2008; Eming,
Krieg, and Davidson 2007). Each cell type plays a vital role in the repair process;
however, genetic studies have shown that no particular cell type is essential for overall
healing (Martin and Leibovich 2005). There is evidence supporting the hypothesis that
prolonged acute inflammation can delay early tissue restoration and fibrotic processes
including keratinocyte proliferation, and recruitment of pro-fibrotic macrophages (M2
macrophages) (Koh and DiPietro 2013; Landén, Li, and Ståhle 2016). We found that at
day 5 post-wounding, CD44 deficiency increased the number of leukocytes and proinflammatory cytokines, including IL-4 and IL-1β. This was accompanied by delayed
53

recruitment of FAP+ fibroblasts and fibrillar collagen accumulation. These data suggest
that future studies need to be conducted to delineate if resolution of early inflammation
or IL-4 and IL-1β play an essential role in recruitment of FAP+ fibroblasts and
accumulation of fibrillar collagen during early phases of wound healing. By day 7 postwounding, the increase in leukocyte accumulation found in CD44-null wounds did not
correlate to alterations in cytokine levels. These data suggest that at day 7 postwounding, either the increase in leukocytes is not sufficient to increase cytokine levels or
that an increase in additional cell types, such as mesenchymal cells, offsets the increase
in leukocyte. Further studies need to be conducted to delineate the cross-talk between
fibroblasts and inflammatory cells in regulating cytokine levels during early phases of
wound healing.
An interesting finding from our study was that CD44 deficiency increased fibrillar
collagen accumulation in closed wounds, scar tissue, and in an in vitro model of
fibroblast-derived matrices. Collagen has been a speculated CD44 ligand (Naor, Sionov,
and Ish-Shalom 1997). Soluble CD44 (sCD44), generated after cleavage from
extracellular membrane, can be integrated bind to ECM components including collagen
(Cichy et al. 2002). Immunoprecipitation studies have also demonstrated collagen XIV, a
fibril associated collagen, can directly interact with CD44 (Ehnis et al. 1996). Despite this
evidence for collagen-CD44 interactions, few studies have investigated the role that
CD44 plays in collagen accumulation or organization. In models of infarct healing and
renal fibrosis, CD44-null mice had reduced total collagen accumulation, myofibroblast
infiltration and impaired TGF-β signaling (Huebener et al. 2008; Rouschop et al. 2004).
On the other hand, in atherosclerosis CD44 deficiency had increased fibrous cap
formation (L. Zhao et al. 2008). In a bleomycin induced lung injury model, CD44-null
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mice showed no significant differences in pulmonary fibrosis (Y. Li et al. 2011).
Combined, these data indicate that the role of CD44 in collagen accumulation is tissue,
injury and context dependent. A possible hypothesis for these paradoxical roles of CD44
in collagen accumulation is the nearly ubiquitous expression of CD44 on various cell
types present in response to injury. Therefore, depending on the milieu, CD44 can play
contradictory roles. Keeping this in mind, in our current study we analyzed wounds
during early inflammatory (day 5), late inflammatory (day 7), remodeling (day 11), and
resolution (day 63) phases. During early and late inflammatory phases, we found that
CD44-null mice had reduced fibrotic response, including reduced FAP+ activated
fibroblasts and fibrillar collagen accumulation. However, during remodeling and
resolution phases we found that CD44-null mice had increased fibrillar collagen. This
data supports the hypothesis that the role of CD44 in collagen accumulation is
contextually regulated.
In order to elucidate the role of CD44 in collagen biosynthesis and turnover, day
11 wounds were biochemically analyzed. Collagen post-translational modifications
include hydroxylation of proline and lysine residues, O-glycosylation of hydroxylysine
residues, and intermolecular crosslinking. Post-translational modification of collagen is
crucial for the stability of the triple-helical conformation of fibrillar collagen (Chopra and
Ananthanarayanan 1982; Terajima et al. 2014). CD44-null wounds exhibited no
differences in the level of hydroxylated proline residues or lysl oxidase at day 11 postwounding or in vitro FDMs compared to WT controls. Collagen crosslinking and
architecture have been identified as determinants of tensile strength in scar tissue
(Eleswarapu, Responte, and Athanasiou 2011; Depalle et al. 2015; Brenda et al. 1999;
Xue and Jackson 2015). In a normal skin, fibrillar collagen is present in a “basket weave”
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orientation, but in a scar tissue fibrillar collagen is present in greater amounts, and is
accumulated in large bundles parallel to the length of the tissue. Due to the change in
collage amounts and architecture, scar tissue is more susceptible to rupture/tear when
stretched (Xue and Jackson 2015). Consistent with these observations, we found that
increased fibrillar collagen accumulation observed in CD44-null scar tissue was
associated with concomitant reduction tensile strength. We also found that majority of
collagen fibers were aligned parallel to the length of the tissue. However, we did not
observe any differences between WT and CD44-null fibrillar collagen width, length and
angle in scar tissue. These data suggest that in this setting, CD44 may not play a
significant role in collagen post-translational modification or crosslinking, although further
in-depth studies would need to be conducted to support these results. For example,
analysis of WT and CD44-null wounds for collagen crosslinking products dehydrodihydroxylysinonorleucine (DHLNL), dehydro-hydroxylysinonorleucine (HLNL), and
dehydro histidinohydroxymerodesmosine (HHMD) will further help elucidate the role of
CD44 in collagen crosslinking.
While our data did not show any differences in collagen crosslinking, we found
that CD44-null wounds had reduced collagenase activity. These data support prior
evidence implicating CD44 in cell surface MMP9 localization (Q. Yu and Stamenkovic
2000), MMP2 and MMP9 expression in tumor cells (Chang et al. 2014), and MMP
activation in tumor cells (Desai, Rogers, and Chellaiah 2007). Our results indicate that
FDMs derived from CD44-null fibroblasts and CD44-null wounds have reduced
collagenase activity and increased fibrillar collagen accumulation compared to WT
controls. These results indicate that CD44-mediated collagen proteolysis regulates
fibrillar collagen accumulation during cutaneous wound healing.
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Prior studies have demonstrated the role of CD44 in various pathophysiological
states including mouse models of cancer, atherosclerosis, pulmonary fibrosis and
bacterial infections (Cuff et al. 2001; L. Zhao et al. 2008; Vandivier et al. 2002; Q. Wang
et al. 2002; Desai, Rogers, and Chellaiah 2007; Nikitovic et al. 2013; Cichy et al. 2002;
Sague et al. 2004; Schmits et al. 1997) . The impact of CD44 in these models can at
least in part be attributed to CD44-mediated signal transduction induced by HA
engagement of the receptor and thereby regulating leukocyte trafficking, cell
proliferation,

actin-cytoskeletal

remodeling,

and

vascular

smooth

muscle

cell

differentiation. However, CD44 has also been implicated in T-lymphocyte migration
within tumors independent of the HA binding motif contained within the extracellular
domain (Mrass et al. 2008). CD44 can also function as a docking platform for various
matricellular proteins, proteases, and growth factors as well as molecular interactions
with other cell surface molecules such as c-Met (Puré and Assoian 2009). Herein, we
demonstrate a novel role for CD44 in the fibroinflammatory response to cutaneous
injury. Our data indicate that in this context CD44 acts through regulating remodeling of
the collagen-rich matrix and that CD44-dependent matrix remodeling contributes to
resolution of the response to injury. In light of these new findings, it will be interesting to
explore the mechanisms involved in the CD44-dependent collagen-rich matrix
remodeling and to assess the functional outcome of CD44-dependent matrix remodeling
in other pathophysiological settings.
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Primary Antibody

Company

Antigen
Retrieval

Working
Concentration

Incubation

Biotinylated-HABP

EMD Milipore (385911)

N/A

2 µg/ml

Overnight at 4°C

Rabbit-anti-vimentin

Cell Signaling (5741)

10mM boiling
sodium citrate

1 µg/ml

Overnight at 4°C

Rabbit-anti-FAP

abcam (ab207178)

10mM boiling
sodium citrate

2.5 µg/ml

Overnight at 4°C

Rabbit-anti-SMA

abcam (ab5694)

10mM boiling
sodium citrate

3 µg/ml

Overnight at 4°C

Rabbit-anti-CD45

abcam (ab10558)

20 µg/ml
proteinase K

4 µg/ml

Overnight at 4°C

Rabbit-anti-CD3

abcam (ab5690)

10mM boiling
sodium citrate

1 µg/ml

Overnight at 4°C

Chrompure Rabbit IgG

Jackson Immuno
Research (011-000003)

N/A

N/A

Overnight at 4°C

Secondary Antibody

Company

Antigen
Retrieval

Working
Concentration

Incubation

N/A

1 µg/ml

1 hour at room
temperature

N/A

1 µg/ml

1 hour at room
temperature

Biotinylated goat-anti- Vector Laboratory (BArabbit
1000)

Streptavidin-HRP

Jackson Immuno
Research (016-030084)

Table 1. List of antibodies used for immunohistochemical (IHC) staining on
cutaneous wound healing samples
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Primary Antibody

Company

Rabbit-anti-fibronectin Sigma Aldrich (F3648)

Antigen Retrieval

Working
Concentration

Incubation

10mM boiling sodium citrate

1 µg/ml

Overnight at 4°C

Goat-anti-Type I
Collagen

Southern Biotech
(1310-01)

10mM boiling sodium citrate

1 µg/ml

Overnight at 4°C

Rat-anti-F4/80

Biorad (MCA497R)

20 µg/ml proteinase K or 2N
HCl

4 µg/ml

Overnight at 4°C

Rabbit-anti-iNOS

Novus Biologicals
(NB300-605)

20 µg/ml proteinase K

80 µg/ml

Overnight at 4°C

Rabbit-anti-CD206

abcam (ab64693)

2N HCl

1 µg/ml

Overnight at 4°C

Rabbit-anti-CD11b

abcam (ab133357)

2N HCl

1.269 µg/ml

Overnight at 4°C

Rat-anti-Ly6G

abcam (ab25377)

2N HCl

5 µg/ml

Overnight at 4°C

Jackson Immuno
Chrompure Rabbit IgG Research (011-000003)

N/A

N/A

Overnight at 4°C

Goat IgG

Jackson Immuno
Research (005-000003)

N/A

N/A

Overnight at 4°C

Rat IgG2b

Southern Biotech
(0118-01)

N/A

N/A

Overnight at 4°C

Secondary Antibody

Company

Antigen Retrieval

Working
Concentration

Incubation

Alexa Fluor 488 Goatanti-Rabbit

Life Technologies
(A32723)

N/A

2 µg/ml

1 hour at room
temperature

Alexa Fluor 488
Donkey-anti-Goat

Life Technologies
(A11055)

N/A

2 µg/ml

1 hour at room
temperature

Alexa Fluor 568 Goatanti-Rat

Life Technologies
(A11077)

N/A

2 µg/ml

1 hour at room
temperature

Alexa Fluor 647
Donkey-anti-Rabbit

Life Technologies
(A31573)

N/A

2 µg/ml

1 hour at room
temperature

Table 2. List of antibodies used for immunofluorescence (IF) staining on
cutaneous wound healing samples
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Primary Antibody

Company

Working
Concentration

Incubation

Fc block

eBiosciences (140161-85)

2 µg/ml

15 minutes on ice

Live Dead Aqua

Molecular Probes

N/A

20 minutes on ice

anti-CD45 PeCy7

eBiosciences (250451-82)

0.4 µg/ml

30 minutes on ice

anti-CD90 PE

Biolegend (140308)

0.5 µg/ml

30 minutes on ice

anti-CD44 APC

eBiosciences (170441-81)

2 µg/ml

30 minutes on ice

Biotinylated-anti-FAP (clone
73-3)

Homemade

5 - 10 µg/ml

30 minutes on ice

anti-αSMA FITC

Sigma Aldrich
(F3777)

5 µg/ml

30 minutes on ice

Rat IgG2bκ PeCy7

Biolegend (400618)

0.4 µg/ml

30 minutes on ice

Rat IgG2bκ PE

BD Biosciences
(553989)

0.5 µg/ml

30 minutes on ice

Rat IgG2bκ APC

eBiosciences (174031-81)

2 µg/ml

30 minutes on ice

Biotinylated IgG1κ

BD Biosciences
(550615)

5 - 10 µg/ml

30 minutes on ice

IgG2a FITC

BD Biosciences
(554647)

5 µg/ml

30 minutes on ice

Secondary Antibody

Company

Working
Concentration

Incubation

Streptavidin-BV421

Biolegend (405225)

1 µg/ml

15 minutes on ice

Table 3. List of antibodies used for flow cytometry on cutaneous wound healing
samples
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Figure 2. CD44 deficiency does not alter collagen, HA or stromal cell content in
normal skin.
Representative 20x images of A) masson’s trichrome B) picrosirius red C) DQ collagen
staining of WT and CD44 KO uninjured skin. Quantification of D) masson’s trichrome,
n=6 per group E) picrosirius red, n=6 per group) F) DQ collagen, n=4 per group staining
normalized to total dermis area. G) Quantitative ELISA measurement of HA in WT and
CD44 KO uninjured skin, n=4 per group normalized to tissue weight. H) Representative
histogram plot of flow cytometric analysis of WT and CD44 KO uninjured skin, n = 3 per
group for CD90+ cells. I) Representative dot plot of flow cytometric analysis of WT and
CD44 KO uninjured skin CD90+ population for FAP and α-SMA. Scale bars = 500 µm.
Bar graphs depict mean ± SEM.
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Figure 3. CD44 deficiency alters the kinetics of fibrillar collagen accumulation
during cutaneous wound healing.
A) Representative images illustrating the generation of two 6 mm excisional biopsy
punches on the dorsal side of WT and CD44 KO BALB/c mice. B) Quantitative
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using the formula A = πr . C) Representative 20x images of type I collagen staining of
wounds extracted 5, 7, and 11 post-wounding (left), n=6-7 per group. White arrows
indicate wound edges. Quantification of type I collagen staining normalized to total area
of granulation tissue (right). Scale bars = 500µm D) Representative 20x images of twophoton second harmonic generation (2P-SHG) images to visualize fibrillar collagen
accumulation of wounds extracted 5, 7, and 11 days post-wounding (left), n = 6-7 per
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± SEM. * p < 0.05

62

A

Day 7

Day 11

# of cells

6000

CD44 KO

4000

2000

0

D5

D7

D11

Day 11

CD44 KO

WT

B

Area of Granulation Tissue (mm2)

DAPI

WT
CD44 KO

8000

WT

Day 5

1.00
0.75
0.50
0.25
0.00

WT

CD44 KO

Figure 4. CD44 deficiency does not alter cellularity or area of granulation tissue
post wounding.
A) Representative 20x images (left) and quantification (right) of DAPI nuclear staining of
wounds extracted 5, 7, and 11 days post-wounding, n=6-7 per group B) Representative
10x H&E images of WT and CD44 KO wounds extracted 11 days post-wounding (left),
n=6-7 per group. Dotted line denotes granulation tissue. Quantification of granulation
tissue area (right). Scale bars = 500 µm. Bar graphs depict mean ± SEM.

63

Day 5

Day 7

Day 11

WT
CD44 KO
50

WT

A

CD44 KO

% HA+ Area

40
30
20
10
0

B

D5

D7

D11

CD44 KO

% FN+ Area

WT

80
60
40
20
0

D5

D7

D11

Figure 5. CD44 deficiency does not alter the accumulation of HA or FN during
cutaneous wound healing.
A) Representative 10x images of HA staining of wounds extracted 5, 7, and 11 days
post-wounding (left) and quantification of HA staining normalized to total granulation
tissue area, n=6-7 per group (right). B) Representative 20x images of FN staining of
wounds extracted 5, 7, and 11 days post-wounding (left) and quantification of FN
staining normalized to total granulation tissue area, n=6-7 per group (right). Arrows used
to indicate wound edges. Scale bars = 500µm. Bar graphs depict mean ± SEM.

64

WT
CD44

Day 5

Day 7

Day 11

CD44 KO

% CD45 + cells

WT

100

60
40
20
0

C
iNOS

F4/80

Merge

CD206
% F4/80+ iNOS+ Cells

40
30
20
10
0

D5

D7

D5

D7

D11

Merge

D11

D

5

WT
CD44 KO

4
3
2
1
0

D5

D7

D11

E
WT
CD44 KO

WT

Merge
10
8
6

CD44 KO

Ly6G

% CD11b + Ly6G+ Cells

CD11b

F4/80

*

**

% F4/80+ CD206+ Cells

B

80

WT
CD44 KO

4
2
0

D5

D7

100
WT
CD44 KO

% CD3 + cells

A

80
60
40
20
0

D5

D7

D11

Figure 6. CD44 deficiency increases leukocyte accumulation during early phases
of wound healing.
A) Representative 10x images of CD45 staining (left). Quantification of CD45+ cells
normalized to total cells in the granulation tissue, n=6-7 per group (right). Black arrows
indicate wound edges. B) Representative 20x images of F4/80 (red) iNOS (green) and
DAPI (blue) staining (left). Quantification of F4/80 and iNOS+ cells normalized to total
cells (DAPI) in the granulation tissue (right), n=6-7 per group. C) Representative 20x
images of F4/80 (red) CD206 (green) and DAPI (blue) staining (left). Quantification of
F4/80 and CD206+ cells normalized to total cells (DAPI) in the granulation tissue (right),
n=6-7 per group. D) Representative 20x images of CD11b (green) Ly6G (red) and DAPI
(blue) staining (left). Quantification of CD11b+ Ly6G+ cells normalized to total cells
(DAPI) in the granulation tissue (right), n=6-7 per group. E) Representative 10x images
of CD3 staining (left). Scale bar = 100µm. Bar graphs depict mean ± SEM. ** p < 0.01, *
p <.05

65

250

A

WT
500
CD44 KO
400

B

*

IL-1β (pg/mg)

IL-4 (pg/mg)

200
150
100
50
0

D5

IL-10 (pg/mg)

TNF-α (pg/mg)

40
20

D5

100
D5

D7

25

60

0

200

0

D

WT
CD44 KO

300

D7

80

C

*

20
15
10
5
0

D7

WT
CD44 KO

D5

D7

Figure 7. CD44 deficiency increases leukocyte accumulation during early phases
of wound healing.
Quantitative ELISA measurement of A) IL-4 B) IL-1β C) TNF-α and D) IL-10 levels in day
5 and day 7 wounds normalized to protein concentration, n=5 per group. Bar graphs
depict mean ± SEM. ** p < 0.01, * p <.05

66

A

α-SMA

FAP

Day 7

C

% Vimentin + Area

50
40
30
20
10
0

D5

D7

D11

D

50
40

% FAP+ Area

B

% α-SMA+ Area

Day 11

CD44 KO

WT

CD44 KO

WT

CD44 KO

Day 5

WT

Vimentin

30
20
10
0

D5

D7

D11

20

*

WT
CD44 KO

15
10

**

5
0

D5

D7

D11

+

Figure 8. CD44 deficiency attenuates FAP fibroblast accumulation during early
phases of wound healing.
A) Representative 10x images of vimentin, α-SMA, and FAP IHC images 5 days 7 days
and 11 days post-wounding. Black arrows indicate wound edges. Quantification of B)
vimentin+ area C) α-SMA+ area and D) FAP+ area normalized to total granulation tissue
area, n=6-7 per group. Scale bars = 500µm. Bar graphs depict mean ± SEM. ** p < 0.01
and * p < 0.05
67

WT
CD44 KO

B

OH-pro/mg

2.0
1.5
1.0
0.5
0.0

0.5

Lox mRNA levels
normalized to HPRT

2.5

0.4
0.3
0.2
0.1
0.0

Normal

Wound

C

WT

CD44 KO

D
WT

Day 5

CD44 KO

WT

Day 7

1.5

CD44 KO

Endo180
β-ac-n

Integrated Density

A

WT
CD44 KO

1.0

0.5

0.0

D5

D7

Figure 9. CD44 deficiency does not alter proline hydroxylation, lysyl oxidase, or
Endo 180 levels in wounds.
A) Quantification of hydroxyproline content in normal skin and day 11 post-wounding,
n=3 per group. B) QRT-PCR for lysl oxidase (lox) mRNA levels in day 11 wound, n=3-4
per group. C) Immunoblot for endo180 (collagen internalization receptor) and β-actin
(housekeeping protein conducted at 5 and 7 days post-wounding, n=3 per group. D)
Quantification of integrated density of endo180 normalized to β-actin. Bar graphs depict
mean ± SEM.

68

A

CD44 KO
WT
CD44 KO

Day 7

% DQ Collagen+ Area

80

Day 11

DQ Collagen

Day 5

WT

60

*

*

40
20
0

D5

D7

D11

Day 7

% DQ Gelatin+ Area

80

Day 11

DQ Gelatin

Day 5

B
*

60

*

40
20
0

D5

D7

D11

Figure 10. CD44 deficiency reduces collagenolysis during cutaneous wound
healing.
A) Representative 20x images of DQ collagen staining of wounds extracted 5, 7, and 11
days post-wounding (left) and quantification of DQ collagen positive area normalized to
total granulation tissue area (right), n=6-7 per group. B) Representative 20x images of
DQ gelatin staining of wounds extracted 5, 7, and 11 days post-wounding (left) and
quantification of DQ gelatin positive area normalized to total granulation tissue area
(right), n=6-7 per group. White arrows indicate wound edges. Scale bar = 500µm. Bar
graphs depict mean ± SEM. * p < 0.05

69

105

80

RFU

% of Max

0.10

60
40

0.05

0.00

C

WT

D

1.0

0.5

CD44 KO

103

E

4
2

WT

0

33.7

7.87
103
FAP

104

32.4

CD44 KO

8.62
2

0 10

105

3

10
FAP

4

10

5

10

FAP
1.5

1.0

0.5

0.0

CD44 KO

19.3

103

DQ Gelatin
WT

39.7

102

102

105

6

0

WT

103
104
CD44-APC

8

Lox mRNA levels
normalized to HPRT

Fold Change µg/RFU

1.5

0.0

0 102

CD44 KO

105
104

0 102

0

17

104

0

20

41.3

alpha-SMA

Sample ID
Isotype
WT
CD44 KO

Fold Change

100

alpha-SMA

B

0.15

α-SMA

A

WT

CD44 KO

Figure 11. CD44 deficiency does not alter activated fibroblasts, proline
hydroxylation lysyl oxidase levels or gelatinase activity in vitro.
A) Quantification of calcein AM measurements on 8th day of matrix production, n=3
independent experiments. B) Flow cytometric analysis of CD44 (left) and α-SMA and
FAP (right) expression in WT and CD44-null dermal fibroblasts on 8th day of matrix
production. C) Quantification of hydroxyproline content in matrices derived from WT and
CD44-null dermal fibroblasts normalized to raw fluorescence units from calcein AM
measurement. Data combined from 3 independent experiments. D) QRT-PCR for Lox
expression in WT and CD44-null dermal fibroblasts on 8th day of matrix production
normalized to Hprt, n=4 independent experiments. E) Representative IF images of
decellularized matrices derived from WT and CD44-null dermal fibroblasts supplemented
with DQ gelatin 24 hours prior to decellularization. Data combined from 4 independent
experiments. Scale bars = 100 µm. Bar graphs depict mean ± SEM.

70

A

1

0

C

20
8
6
4

Fold Change

40

WT

60

CD44 KO

**

1.0

0.5

0.0

2
0

WT

1.5

CD44 KO

80

DQ Collagen

mRNA levels normalized to HPRT

B

**

2

CD44 KO

2P-SHG

Fold Change

WT

3

WT

CD44 KO

MMP 14 MMP 8 MMP 9 MMP 2

Figure 12. CD44-null fibroblast-derived matrices have increased fibrillar collagen
accumulation and reduced MMP activity compared to WT.
A) Representative 2P-SHG images of decellularized matrices derived from WT or CD44null dermal fibroblasts (left). Scale bars = 200µm. Quantification of SHG positive area.
Data combined from 5 independent experiments (right). B) QRT-PCR of Mmp 14,
Mmp8, Mmp9, and Mmp 2 mRNA levels in fibroblasts depositing matrices on 8th day of
matrix production. Data combined from 4 independent experiments. C) Representative
IF images of decellularized matrices derived from WT and CD44-null dermal fibroblasts
supplemented with DQ collagen 24 hours prior to decellularization. Data combined from
3 independent experiments. Scale bars = 100 µm. Bar graphs depict mean ± SEM. ** p
< 0.01

71

B

A

WT

20

CD44 KO

4

WT

CD44 KO

CD44 KO

***

% FN+ Area

60
40
20
0

F

***

8

0

WT

80

WT

CD44 KO

8
Linear Modulus (MPa)

WT

% Vimentin+ Area

WT

WT

20

12

CD44 KO

WT

40

FN

% DQ Collagen + Area

WT
CD44 KO

40

100

*

60

0

60

0

D

80

p = .056

80

CD44 KO

CD44 KO

0

% Type I Collagen + Area

20

CD44 KO

40

E
Vimentin

Type I Collagen

% SHG+ Area

WT
CD44 KO

SHG

*

60

C
DQ Collagen

100

80

*

6
4
2
0

WT

CD44 KO

Figure 13. CD44 deficiency increases the fibrogenic response and reduces tensile
strength in scar tissue.
A) Representative 20x 2P-SHG images of wounds 63 days post-wounding (left). Scale
bars = 200µm Quantification of SHG positive area normalized to total scar tissue area
(right), n=8 per group. B) Representative 20x type I collagen IF images of wounds 63
days post-wounding (left). Quantification of type I collagen positive area normalized to
total scar tissue area (right), n=6 (WT) and 7 (CD44 KO). C) Representative 20x DQ
collagen IF images of wounds 63 days post-wounding (left). Quantification of DQ
collagen positive area normalized to total scar tissue area (right), n=6 (WT) and 7 (CD44
KO). D) Representative 20x fibronectin IF images of wounds 63 days post-wounding
(left). Quantification of FN positive area normalized to total scar tissue area (right), n=6
(WT) and 7 (CD44 KO). E) Representative 10x vimentin IHC of wounds 63 days postwounding (left). Quantification of vimentin positive area normalized to total scar tissue
area (right), n=6 (WT) and 7 (CD44 KO). Arrows indicate wound edges. F) Quantification
of Young’s Modulus using ramp to failure test of WT and CD44-null wounds 63 days
post-wounding, n=8 (WT) and 9 (CD44 KO). Scale bar = 500 µm. Bar graphs depict
mean ± SEM. *** p < 0.001 * p < 0.05

72

A

B

40
20
WT

C

D
30
20
10

E

4

2

0

61 - 90 91 - 120 121 - 150 151 - 180
Fiber Orientation

F

20
WT

WT

CD44 KO

CD44 KO

80
60
40
20
0

WT

CD44 KO

G

1.0

CD44 KO

% FAP+ Area

1.5

0.5
0.0

0.20

WT

2.0

WT
CD44 KO

40

WT

% α-SMA+ Area

31 - 60

60

0

6

Fiber Width (Pixels)

% Fiber Distribution

40

80

CD44 KO

Fiber Length (Pixels)

0

0 - 30

% CD45 + cells

60

CD44 KO

CD44 KO

% HA + Area

80

0

100

WT

WT

100

0.15
0.10
0.05
0.00

CD44 KO

WT

CD44 KO

Figure 14. CD44 deficiency does not alter fibrillar collagen alignment, HA,
leukocyte, FAP+ or α-SMA+ fibroblast accumulation in scar tissue.
Representative 10x images and quantification of WT and CD44-null wounds 63 days
post-wounding A) HA staining B) CD45, n=6 (WT) and 7 (CD44 KO). Quantification of
CT Fire Analysis of SHG images for C) fiber angle D) fiber width E) fiber length on WT
and CD44-null wounds day 63 post wounding. Representative 10x images and
quantification of WT and CD44-null wounds day 63 post-wounding F) FAP and G) αSMA staining, n=6 (WT) and 7 (CD44 KO). Black arrows indicate wound edges. Scale
bar = 500µm. Bar graphs depict mean ± SEM.

73

Solid Lines: WT

Dotted Lines: CD44 KO

Leukocytes

Fibrillar Collagen

Vimentin+

Quantity

α-SMA+
FAP+

5

7

11

5

63

7

Collagenolysis

11

63

5

7

11

63

Days post wounding

Key Differences in CD44-null wounds compared to WT wounds
Fibroblasts

Days post
wounding:

Leukocytes

5&7

Collagenolysis

Fibrillar
Collagen

Vimentin

FAP

α-SMA

Increased

ND

Decreased

ND

Decreased

Decreased

11

ND

ND

ND

ND

Decreased

Increased

63

ND

Increased

ND

ND

Decreased

Increased

Figure 15. Schematic representation of the impact of CD44 loss on evolution of
leukocytes, fibroblasts and fibrillar collagen over the course of wound healing.
During early phases of wound healing (days 5 & 7), CD44 deletion increases the
inflammatory response while delaying the fibrotic response. During the tissue remodeling
phase of wound healing (days 11 & 63), CD44 deletion decreases collagenolysis, which
correlates with increased fibrillar collagen accumulation.

74

CHAPTER 3 – DIVERGENT ROLE OF NEOPLASTIC VS. NON-NEOPLASTIC
CELL-SPECIFIC CD44 EXPRESSION IN PANCREATIC TUMORIGENESIS
Introduction
Overview of Pancreatic Ductal Adenocarcinoma (PDA)
In 2017, pancreatic cancers accounted for approximately 3.2% of all new cancer
cases and were the fourth leading cause of cancer-related deaths. Pancreatic ductal
adenocarcinomas (PDA) arise from the exocrine cells in the pancreas and account for
94% of pancreatic cancers. PDA is most commonly diagnosed in people between the
ages of 65 to 74. The lifetime risk for developing pancreatic cancer is 1 in 63 in men and
1 in 65 in women. Various risk factors are associated with pancreatic cancer including
family history, chronic pancreatitis, smoking, alcohol, diabetes, and obesity. Select
treatment options, such as surgery, radiation therapy, and chemotherapy, are available
for PDA patients, but less than 20% of patients are candidates. One of the primary
reasons for the high lethality associated with PDA is that only 10% of cases are
diagnosed at the local stage. Most patients are diagnosed with advanced disease and
are resistant to treatment, which is one possible explanation for the median overall
survival from diagnosis of PDA being less than 1 year. Given these dismal statistics,
there is an urgent need to understand PDA biology better, identify potential biomarkers,
and develop more efficacious treatment options.
Genetic alterations found in PDA
Various genetic mutations have been implicated in PDA pathogenesis. Kras
mutations are prevalent in ~95% of advanced cases making it the most common
mutation found in PDA patients (Jones et al. 2008). Kras belongs to the Ras family of
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GTP-binding proteins and is implicated in a variety of cellular functions including
proliferation, differentiation, and survival (Campbell et al. 1998). The most common Kras
mutations in PDA are point mutations at codon 12 from GGT to GAT or GTT, which
result in an amino acid substitution from glycine to valine or aspartic acid respectively.
Kras point mutations lead to an inhibition of GTP hydrolysis resulting in constitutively
active Ras and subsequently, downstream signaling pathways including RAF/MEK/ERK
and phosphatidylinositol 3 kinase (PI3K). Loss of INK4a, caused by mutation, deletion,
or hypermethylation of the promoter, are other genetic/epigenetic variations that occur in
80 to 95% of PDA cases (Rozenblum et al. 1997). The 9q31 locus INK4a encodes for
the tumor suppressor p16 and p19. While p16 inhibits CDK4/6 mediated phosphorylation
of Rb, thereby blocking entry into the S phase of the cell cycle, p19 stabilizes p53 by
inhibiting MDM2-dependent proteolysis (Bardeesy et al. 2006). A missense mutation in
the tumor suppressor gene p53 is also found in 70 to 80% of PDA cases (Rozenblum et
al. 1997; Scarpa et al. 1993). Under normal conditions, the p53 pathway is involved in
cell cycle arrest, apoptosis, DNA damage repair, and cellular metabolism (Beckerman
and Prives 1995). Loss or mutation of p53 is thought to be a late-occurring event during
PDA pathogenesis, possibly caused by the accumulation of other genetic mutations,
telomere erosion, and reactive oxygen species (ROS) (Hezel et al. 2006).
In addition to these well-characterized mutations, recent advances in wholegenome sequencing have helped identify various other mutations in PDA, including
components of the TGFβ, hedgehog, and WNT/Notch signaling pathways (Jones et al.
2008). Use of genome sequencing coupled with genetically engineered mouse models
(GEMMs) now allows us to further elucidate the role of various signaling pathways and
genetic mutations in PDA pathogenesis.
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Biology of PDA
Historically, based on histological evidence, PDA was hypothesized to originate
from ductal cells (Warshaw and Castillo 1992). More recently, a growing body of work
suggests that acinar cells can undergo metaplasia and form duct-like structures (acinarto-ductal metaplasia – ADM), which can then develop into precursor lesions and
subsequently PDA (Murtaugh and Leach 2007). There is also some evidence supporting
the hypothesis that PDA originates from endocrine cells (T Yoshida and Hanahan 1994).
Despite the ongoing debate regarding the cell of origin for PDA, the progression from
precursor lesions to PDA is well understood.
Histopathological studies have shown that PDA can evolve from three precursor
lesions: pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous
neoplasm (IPMN), and mucinous cystic neoplasm (MCN) (Brudgge et al. 2004; Maitra,
Fukushima, and Takaori 2005). Of these, PanIN lesions, which are non-invasive, nonmucin producing, epithelial neoplasms are the most prevalent precursor lesions and are
graded from stages I to III with increasing dysplasia and architectural disruption (Hruban
et al. 2001). PanIN-1A are flat epithelial lesions composed of tall columnar cells with
basally located nuclei, which is perpendicularly oriented to the basement membrane.
PanIN-1B lesions are very similar to PanIN-1A except they have a papillary,
micropapillary, or basally pseudostratified architecture. PanIN-2 lesions are mostly
papillary with nuclear abnormalities including loss of polarity and nuclear crowding.
PanIN-3 lesions are papillary with clusters of epithelial cells budding off into the lumen.
The nuclear abnormalities in PanIN-3 lesions are more pronounced than PanIN-2 and
often resemble those found in PDA; however, invasion through the basement membrane
is absent in PanIN-3 lesions. MCNs and IPMNs are mucin-producing epithelial lesions.
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Further research needs to be conducted to identify the cellular, and molecular events
that drive these precursor lesions, as defining these precursor lesions will help identify
common underlying processes that contribute to the onset of PDA.
Genetically Engineered Mouse Models (GEMMs) to study PDA
As mentioned above, PDA is a highly lethal cancer with very few available
therapeutic options. Even during early invasive stages of PDA, surgical resection does
not seem to enhance long-term survival markedly. These dismal statistics emphasized
the importance of understanding risk factors and the pathogenesis of PDA from early
precursor lesions to advanced stage carcinoma. Historically, injections of murine or
human tumor cell lines were conducted into syngeneic or immunodeficient mice, either in
the flank or orthotopic region, to evaluate tumor growth. However, this approach
supersedes the events leading to initiation and progression into PDA. Recently greater
efforts have been made to generate transgenic mouse models with oncogenic and tumor
suppressor gene mutations that more faithfully recapitulate the various stages of
spontaneous human PDA development. This was made possible by identifying
transcription factors involved in cellular fate decisions during development.
PDX-1 and P48, expressed around embryonic day 8.5 and 9.5 respectively, are
transcription factors whose double expression gives rise to all mature cells in the
pancreas. In adult mice, islets express PDX-1 while P48 expression is restricted to
acinar cells (Obata et al. 2001; Offield et al. 1996). Given the high prevalence of
constitutively active Kras mutations in human PDA, an autochthonous pancreatic tumor
model was generated using the cre lox recombination system. An activating Kras
mutation was generated by engineering a GàA mutation in codon 12, which resulted in
a glycine to aspartic acid amino acid substitution. A Lox-STOP-Lox (LSL) construct was
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inserted upstream of exon 1. Breeding with mice containing pancreatic specific
promoters, either PDX-1- or P48-cre, resulted in excision of the stop cassette and
thereby expression of oncogenic Kras in the pancreas. These mice, known as LSLKrasG12D/+; Pdx-1-/p48-cre (KC) mice, display Stage I to III precursor lesions and,
although with prolonged latency, eventually develop PDA (Hingorani et al. 2003). Mice
expressing of Trp53R172H/+ along with KrasG12D/+ under the control of the Pdx-1-cre or
p48-cre promoter, known as LSL-KrasG12D/+; p53R172H/+; Pdx-1/p48-cre (KPC) mice,
demonstrate accelerated pancreatic tumorigenesis, metastasis to the lung, liver,
mesentery, and lymph nodes, and develop cachexia and abdominal distension, which is
reminiscent of clinical symptoms found in human PDA patients (Hingorani et al. 2005).
These GEMMs that recapitulate the development, histological features and hallmarks of
human PDA have greatly facilitated in vivo studies to delineate mechanisms regulating
the aggressiveness of PDA, and the development of potential new therapeutic targets.
Hallmarks of PDA
The tumor microenvironment comprises of mesenchymal cells, endothelial cells,
inflammatory/immune cells, adipocytes, and ECM. One of the most striking features of
PDA is the pronounced desmoplastic response, characterized by increased HA,
collagen, fibronectin, and activated mesenchymal cell accumulation. The dense stromal
accumulation results in elevated stiffness, hypoxia, and hydrostatic fluid pressure, and is
hypothesized to contribute to tumor aggressiveness, chemotherapeutic inefficacy,
immune
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exclusion,
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suppression
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anti-tumor

immunity.

Therefore,

understanding mechanisms that govern desmoplasia is vital to understanding PDA
pathogenesis.
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First isolated in 1998, pancreatic stellate cells (PSCs) are resident cells that
comprise 4–7% of the pancreas and are primarily located in the periacinar, periductal
and perivascular spaces of the pancreas (Apte et al. 1998; Omary et al. 2007). Under
normal physiological conditions, PSCs exist in a quiescent state and contain lipid
droplets. Two primary markers for quiescent PSCs are desmin and glial fibrillary acidic
protein (GFAP). PSCs are the predominant cell type responsible for ECM production and
remodeling in the pancreas (Apte et al. 2004). In response to pancreatic injury or insult,
including pancreatitis and neoplasia, PSCs undergo activation, which is accompanied by
a loss of lipid droplets and increase in activated fibroblast markers including α-SMA and
FAP (Öhlund et al. 2017; Apte et al. 1998). Activated PSCs exhibit increased
proliferation, migration, ECM synthesis, and secretion of growth factors and cytokines. In
PDA, increased accumulation of activated stellate cells (also known as cancerassociated stellate cells or CASCs) is one of the predominant cellular responses
characteristic of the robust desmoplasia. Historically speaking, α-SMA, the canonical
myofibroblast marker, was used as an activated stellate cell marker, and depletion of αSMA+ cells was hypothesized to diminish tumor stroma and therefore tumor growth.
However, recent studies have questioned this dogma.
Current approaches used to target the stromagenic response in PDA
Similar to models of lung adenocarcinoma, fibrosis and wound healing, CASCs
are a heterogeneous population of cells, and therefore depletion of specific
subpopulations can have opposing effects (Lo et al. 2017; Öhlund et al. 2017). Multiple
approaches have been utilized to target the desmoplasia in PDA, but they can be
broadly divided into three categories: 1. Inhibition of signaling pathways involved in
driving the stromal responses 2. Depletion of CASCs using genetic, pharmacological, or
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immune-based approaches or 3. Enzymatic depletion of matrix components. When
interpreting results from these studies, it is prudent to recognize that they utilize different
mechanisms to target the stromal response. Therefore, unexpected or contradictory
results need to be assessed in the context of the approach used.
Studies have attempted to target various signaling pathways implicated in driving
the stromal response. The hedgehog signaling pathway is upregulated in response to
inflammation or neoplasia. Pharmacological inhibition of the ligand sonic hedgehog
(Shh) in Capan-2 pancreatic tumor cells correlated with reduced accumulation of αSMA+ cells, type I collagen and fibronectin in an orthotopic injection model (Bailey et al.
2008). This data suggested that expression of Shh on malignant epithelial cells
promotes desmoplasia thus serving as an attractive target for anti-stromal therapy. To
determine if targeting Shh-mediated desmoplastic response in PDA is a promising
approach, a transgenic mouse model, KrasLSL-G12D/+; p53flox/+; Rosa26LSL-YFP/+; Pdx1-cre
crossed to Shhflox/flox, was generated. This approach resulted in the deletion of Shh from
pancreatic epithelial cells. As seen in the orthotopic injection model, deletion of Shh
resulted in reduced α-SMA+, CD45+, and F4/80+ cells. Surprisingly, loss of Shh
accelerated tumor progression, reduced survival, and increased metastasis. This
resulted in more invasive, undifferentiated tumors, with increased vascularity and
heightened proliferation (Rhim et al. 2014). These data suggest that specific
components of the tumor stroma play a protective role in PDA; however, further
investigation needs to be conducted to determine these components and their
underlying mechanisms.
The vitamin D receptor (VDR), expressed on PSCs, is another potential target
that can be used to disrupt the tumor stroma. Treatment of CASCs with calcipotriol, a
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VDR analogue, increased accumulation of lipid droplets and decreased expression of αSMA in vitro, thus indicating a transition back to quiescent PSCs. Combination therapy
of gemcitabine, a chemotherapeutic agent, plus calcipotriol reduced tumor volume and
increased survival of KPC mice (Sherman et al. 2014). This was accompanied by
reduced collagen accumulation, increased vascularity, and increased apoptosis. These
data suggest that stromal reprogramming, via VDR activation, restores PSCs to a
quiescent-like state and suppresses tumor growth.
Another approach that has been used to target the desmoplastic response in
PDA is genetic, enzymatic or immune-based depletion of CASCs. As previously
mentioned, α-SMA is a marker for the myofibroblast subset of CASCs. Genetic depletion
of α-SMA+ cells was accomplished using ganciclovir administration in transgenic mice
expressing herpes simplex 1 virus thymidine kinase under the control of Acta2 (α-SMA)
promoter (α-SMAtk mice). Administration of ganciclovir resulted in depletion of
proliferating α-SMA+ cells in α-SMAtk mice. To understand the role of myofibroblasts in
PDA, ganciclovir was administered to transgenic LSL-KrasG12D/+ Tgfbr2flox/flox Ptf1acre/+
(PKT) mice crossed with α-SMA-tk mice. Upon ganciclovir treatment, an ~ 80%
depletion of α-SMA+ cells and ~50% depletion in fibrillar collagen was observed.
Unexpectedly, depletion of α-SMA+ cells resulted in reduced survival and greater
invasive, undifferentiated tumors. This was a surprising finding given past evidence
demonstrating tumor-promoting roles of fibrillar collagen and α-SMA+ cells. Depletion of
α-SMA+ cells correlated with increased of CD4+ Foxp3+ Tregs in KPC mice. Dual
treatment of myofibroblast depletion with anti-cytotoxic T-lymphocyte associated antigen
4 (anti-CTLA-4) immunotherapy reversed the disease progression and prolonged
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survival (Özdemir et al. 2014). This study demonstrated that myofibroblasts can play a
tumor-protective role by regulating the infiltration of Tregs in PDA.
FAP and α-SMA identify distinct populations of activated fibroblasts in myriad of
epithelial tumors, wound healing, and fibrosis (Acharya et al. 2006; Levy et al. 1999;
Tillmanns et al. 2015; Lo et al. 2015; Öhlund et al. 2017; Tchou et al. 2013). Gene
expression data based on in vitro studies have also demonstrated functional
heterogeneity of these distinct populations (Avery et al. 2017). Although depletion of αSMA+ cells exacerbated tumorigenesis, the functional role of FAP+ cells in PDA
remained unknown. A number of recent studies have shown that depletion of FAP+
fibroblasts using genetic or immune-based approaches inhibited tumor growth. Some
studies have demonstrated that depletion of FAP+ fibroblasts resulted in an
enhancement of antitumor immunity (Feig et al. 2013; Roberts et al. 2013; Kraman et al.
2010; Lo et al. 2017; J. Lee et al. 2005). Additionally, chimeric antigen receptor T cells
targeting FAP+ cells (FAP-CAR T cells) demonstrated a marked disruption of tumor
stroma, including depletion of FAP+ and α-SMA+ cells, fibrillar collagen, hyaluronic acid,
fibronectin, and versican. The ablation of tumor stroma was accompanied by increased
apoptosis, and reduced proliferation and tumor burden in subcutaneous and
autochthonous PDA tumor models (Lo et al. 2015). Given that FAP and α-SMA identify
distinct populations of CASCs, an interesting finding from this study was the decreased
accumulation of α-SMA+ cells upon treatment with FAP-CAR T cells. In vitro studies
have demonstrated the selection of α-SMAhigh cells on a stiff substratum (Avery et al.
2017). Thus, future studies need to investigate if ablation of tumor stroma leads to
attenuated tissue stiffness resulting in reduced accumulation of α-SMA+ cells or if αSMA+ arise from FAP+ progenitor cells. Further investigation of such phenotypes will aid
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in characterizing the functional heterogeneity of CASCs in PDA, the relationship
between the distinct subsets, and the crosstalk between CASCs and ECM. Taken
together, in PDA these studies demonstrate the phenotypic and functional heterogeneity
of CASCs, and the potential tumor-constraining and tumor-promoting properties of αSMA+ and FAP+ cells, respectively.
As previously mentioned, HA is the predominant glycosaminoglycan found in the
ECM. It contains repeating units of D-glucuronic acid and N-acetyl-glucosamine. Under
normal physiological conditions, HA accumulation is carefully regulated by balanced
synthesis, degradation, and turnover achieved through hyaluronic acid synthases (HAS)
1 – 3, and hyaluronidases (Hyals) 1 – 4 respectively. Under homeostatic conditions, HA
is predominantly present in a high molecular weight form, >1000 kDa, and plays a vital
biophysical role in hydrating tissues and sequestering growth factors and cytokines.
Additionally, HA also plays an essential biochemical role using receptors including
CD44, LYVE, and RHAMM. Under pathological conditions, such as cancers, there is an
increase in HA accumulation and fragmentation into a low molecular weight (LMW) form.
The aberrant HA accumulation results in alterations in the biophysical role of HA and
receptor-mediated biochemical signaling. HA accumulation is 12 fold greater in PDA
compared to normal pancreas and correlates with worse prognosis (Sato et al. 2016). In
vitro and in vivo models have implicated dense HA accumulation in causing a high
interstitial

fluid

pressure

and

regulating

cell

proliferation,

migration,

invasion,

angiogenesis, and resistance to chemotherapeutic agents. Depletion of stromal HA
using pegylated hyaluronidase, PEGPH20, reduced interstitial fluid pressure and
increased the efficacy of drug delivery to the tumor site. Although treatment with
PEGPH20 alone did not impact overall survival of KPC mice, dual treatment of
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PEGHP20 with gemcitabine significantly increased survival (Provenzano et al. 2012).
Based on these promising results in preclinical models, PEGPH20 is now being tested in
clinical trials for metastatic pancreatic cancer, NSCLC, gastric cancer, and breast
cancer. Phase 3 clinical trials testing the treatment of PEGPH20 in combination with
Nab-Paclitaxel and Gemcitabine on Stage IV metastatic pancreatic cancer patients are
currently ongoing (NCT02715804). The safety and efficacy of PEGPH20 treatment in
combination with atezolizumab (Programmed death-ligand 1 or PD-L1 inhibitor) in
patients with metastatic PDA is currently in Phase Ib/II (NCT03193190). In summary, HA
degradation has emerged as a promising therapeutic approach for PDA. However, one
question remains unanswered: what is the role of HA receptors in PDA?
Expression Pattern of CD44 in PDA
Broadly speaking in PDA, two types of correlative analyses pertaining to CD44
have been conducted: 1. Expression pattern of CD44s compared to CD44v in normal
compared to neoplastic tissue 2. Correlation between levels of CD44s, CD44v, or total
CD44 expression and tumor grade, stage, or overall survival.
One of the earliest studies to analyze CD44s and CD44v expression in human
PDA reported increased CD44v6, but no difference in CD44s and CD44v8-10, in 15
primary and 6 metastatic PDA samples compared to normal pancreas (Rall and Rustgi
1995). Using PCR and IHC, another study demonstrated that CD44s, CD44v3, CD44v6,
and CD44v6-v10 were present in normal pancreatic tissue. In PDA, isoform CD44v5 was
also expressed, in addition to the previously listed standard and variant isoforms
(Gansauge et al. 1995). These data did not allow for comparison of expression levels
between normal and PDA samples; therefore, no conclusions in this regard could be
drawn. Two independent studies found increased CD44v6 expression in peripheral
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blood mononuclear cells (PBMCs) from 30 PDA samples compared to 12 healthy
individuals. They additionally found that increased CD44v6 expression correlated with
tumor size and liver metastasis (Zhou et al. 2012; Chiu et al. 2013). IHC analysis of 42
PDA samples revealed CD44v6 and CD44v2 expression correlated with decreased
overall survival (Gotoda et al. 1998). Upon analysis of 101 human PDA samples, using
qPCR, one study reported that increased CD44v6 and CD44v9 and decreased CD44s
gene expression in high-grade (stage III/IV) PDA samples compared to low-grade (Stage
I) PDA samples. RNA analysis revealed increased CD44v5, CD44v6, CD44v8 and
decreased CD44s expression (Z. Li et al. 2014). Although data in regards to changes in
specific isoforms is inconsistent, overall these data indicate that increased CD44v
expression is a potential prognostic marker for metastatic PDA.
Correlative analysis of total CD44 expression in PDA samples has also been
conducted. Studies have reported increased CD44 expression in PDA samples
compared to chronic pancreatitis and normal tissue (Immervoll et al. 2011; Durko et al.
2017). CD44 IHC on 23 PDA patients revealed decreased CD44 expression in highgrade PDA (Stage 3) compared to low-grade PDA (Stage 1 or 2) (Durko et al. 2017).
However, a meta-analysis of 9 studies with over 583 samples revealed no association
between CD44 expression and tumor size, differentiation and metastasis (Y Liu et al.
2018). These data indicate that CD44 is aberrantly expressed in PDA compared to
normal tissue; however, our current understanding of the role of CD44 in PDA is limited.
CD44: Cancer Stem Cell Marker
Cancer stem cells (CSCs) are a postulated small population of cells that display
high self-renewal and differentiation capacity, similar to adult stem cells (Batlle and
Clevers 2017). These cells are posited to account for recurrence or relapse due to their
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resistance to chemotherapeutic agents or radiation therapy. Over the past few years,
CD44 has emerged as a prominent CSC marker in various types of cancers including
breast, prostate, pancreatic, and colorectal tumors (Yan, Zuo, and Wei 2015). Studies
have shown the persistence of CD44high cells upon treatment with chemotherapeutic
agents, such as doxorubicin or gemcitabine (Sung et al. 2009; S. Zhao et al. 2016).
However, in vivo studies have not been able to consistently demonstrate the functional
impact of CD44high cells. One study reported that treatment with an anti-CD44
monoclonal antibody (mAb) did not impact tumor growth compared to IgG control.
However, anti-CD44 mAb treatment was effective in inhibiting growth of tumors that
relapsed after having undergone gemcitabine treatment, thus suggesting that CD44 is
specifically an attractive target for relapsed tumors (Molejon et al. 2015). The mAb used
in this study was not specified; therefore, it is difficult to postulate the mechanism by
which CD44-mediated this response. In another study, treatment of MIAPaCa2 cells with
the anti-CD44 antibody, H4C4, reduced flank tumor burden compared to IgG control, but
these findings could not be replicated in Panc-1 cells (L. Li et al. 2014). Thus, despite
CD44 being accepted as a CSC marker, its functional impact or the mechanisms
governing its upregulation in CSCs remain unknown.
A recent study demonstrated that FOXO3 induction and cGMP suppression are
potential candidates regulating CD44 expression in Panc-1 cells. Gemcitabine treated
Panc-1 cells had increased CD44 and reduced cGMP expression. cGMP inducer,
Bay41-2272, decreased expression of CD44 and clonogenic potential of Panc-1 cells.
Additionally, microarray analysis revealed suppression of FOXO-3 related gene set,
which was also confirmed using western blot analysis for FOXO-3. Knockdown of
FOXO-3 in Panc-1 cells, using siRNA, increased CD44 ubiquitination resulting in
decreased CD44 expression and clonogenic potential. These data reveal a novel
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regulator of CD44 expression in PDA cells; however, further research needs to be
conducted to validate these findings in additional murine or human PDA samples.
Postulated role of CD44 in regulating EMT
Few studies have also implicated CD44 in mediating epithelial to mesenchymal
transition (EMT). EMT is a process by which epithelial cells lose their polarity and
instead acquire a more mesenchymal-like phenotype, characterized by increased
migratory, invasive, and ECM producing properties. EMT has been implicated in
mediating tumor invasiveness and metastasis. Transcription factors snail1, zeb1, twist,
and slug, amongst others, have been implicated in mediating EMT.
In a xenograft model, one study demonstrated a feedback loop regulating
expression of Zeb1 and CD44s. They found that zeb1 repressed epithelial splicing
regulatory protein 1 (ESRP-1), which has been implicated in mediating CD44 alternative
splicing, thus resulting in increased levels of CD44s. Knockdown of CD44s, using
siRNA, in Panc-1 cells reduced levels of zeb1, while overexpression of CD44s in BxPC3 PDA cells increased levels of zeb1 (Preca et al. 2015). Using an inducible KrasG12D/+;
p53R172H/+ model, another study showed that mesenchymal like tumor cells upregulated
CD44s. Knockdown of CD44s, using siRNA, (but not CD44v) reduced snail1 and MMP2,
and increased E-cadherin expression. Inhibiting CD44s also reduced MT1-MMP
expression and correlated with reduced metastasis (W. Jiang et al. 2015). Thus
suggesting a role for CD44s in mediating EMT and supporting metastasis.
In summary, numerous studies have demonstrated aberrant CD44 expression
and accumulation of its primary ligand, HA, in PDA. Past studies suggest that CD44 on
epithelial cells correlates with increased chemoresistance. However, additional
functional roles of CD44 on epithelial cells have not been investigated. Furthermore, the
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concept that CD44 is expressed in both the epithelial and non-epithelial compartments of
tumors has been completely overlooked in PDA.

Materials and Methods
Animals
WT C57BL/6J mice were purchased from Jax Laboratory Inc. CD44-null mice (Schmits
et al. 1997) were backcrossed 12 generations onto a C57BL/6J background. CD44flox/flox
mice were generated by inserting loxP sites surrounding exon 2. LysM-Cre and
VECadherin-Cre mice were crossed with CD44flox/flox mice to obtain myeloid and
endothelial cells specific CD44 deletion. LSL KrasG12D/+ and Pdx-1-Cre C57BL/6 mice
were provided by Drs. Sandra Ryeom and Robert Vonderheide, respectively, at
University of Pennsylvania (Philadelphia, PA). Trp53R172H/+ mice on a mixed
129/SvJae/C57BL/6 background were acquired from the mouse repository at the
National
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Institute.
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12

generations

onto

a

C57BL/6J background. All mice were housed in University of Pennsylvania facilities, and
all research was overseen by University Laboratory Animal Resources (ULAR).
Experimental protocols were approved by the Institutional Animal Care and Use
Committee and were in compliance with the Guideline for the Care and Use of Animals.
Isolation of primary tumor cells
Primary tumor cells were isolated from KPC CD44flox/wt mice at 20 weeks of age. Tumor
was finely minced and digested in a 1 mg/ml Collagenase IV (Worthington) in
DMEM/F12 (Gibco) for 20 minutes on a rotator at 37°C. The digestion was quenched
using equal volume of 10% FCS DMEM, and the tissue was consecutively strained
through a 100 µm and 70 µm cell strainer (Corning Inc.) and pelleted by centrifugation at
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300 g for 5 minutes at 4°C. Cells were resuspended in 10% FCS DMEM containing 0.02
M HEPES, 1mM L-Glutamine, 10 units penicillin and 10 µg streptomyocin and plated on
a tissue culture treated plastic (polystyrene). Cells were maintained at 37 °C with 5%
CO2 in a humidified incubator and were passaged when they reached 80% confluency.
Orthotopic injection of tumor cells
Mice were used between 10 – 16 weeks of age. Mice were anesthetized using isoflurane
and the abdomen was shaved and disinfected using povidine-iodine. Buprenorphine and
bupivacaine were used as analgesics five minutes prior to incision. A 2 cm incision was
made in the upper left quadrant of the abdomen using a sterile scalpel. The peritoneal
cavity was exposed using spreaders and the intestines were moved, to expose the tail of
the pancreas, using cotton swabs. 2.5x105 tumor cells in a 30 µl volume of serum free
media were injected into the tail of the pancreas. After injection, the peritoneum and
abdominal incisions were closed using 4-0 chromic gut absorbable sutures in a simple
continuous suture pattern. Buprenorphine was administered subcutaneously every 4 – 6
hours for 2 days as a post-surgical analgesic. Mice were monitored daily for signs of
distress such as sustained drop in body weight, difficulty breathing or moving. Tumors
were harvested four weeks after injections.
Subcutaneous injection of tumor cells
Mice were used between 10 – 16 weeks of age. The dorsal side of the mice were
shaved and sterilized using 70% alcohol. 2.5x105, 1.0x105, 1.0x104, or 1.0x103 tumor
cells in 100 µl serum free media were injected subcutaneously. Tumor growth was
monitored using electronic caliper measurements every other day. Mice were monitored
daily for signs of distress such as sustained drop in body weight, difficulty breathing or
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moving. Tumors were harvested when the tumor diameter exceeded 2 cm or when the
tumors became ulcerated.
Intraperitoneal injection of caerulein
Mice were used between 10 – 16 weeks of age. 75 µg/kg of caerulein in 0.1% BSA/PBS
or vehicle control (0.1% BSA/PBS) were administered using intraperitoneal injections
every hour for 8 hours over 2 consecutive days. Mice were sacrificed 24 hours, 48
hours, 1 week, 2 weeks, or 3 weeks after last injection. Pancreata were harvested,
weighed, and separated into two halves. Pancreata were either prefer fixed and paraffin
embedded or flash frozen for subsequent analysis.
Serum Collection and Clinical Pathology Analysis
Mice were sacrificed at the endpoint of the experiment using 5% CO2. Blood was
collected from the inferior vena cava and transferred into tubes pre-coated with clot
activator gel (BD Pharmigen). Serum was obtained upon centrifugation and submitted to
Penn Vet Clinical Pathology Core for measurement of amylase and lipase levels.
Calcium Concentration Assay
Pancreata were resuspended in PBS + 0.1% NP-40 and homogenized on ice using a
sonicator. Samples were collected by centrifugation at 15,000 g for 5 minutes at 4°C.
Colorimetric calcium detection kit (Abcam) was used to quantify calcium concentration.
HA Purification and ELISA
HA purification was conducted by digesting tumors in 10 mg/ml proteinase K in
ammonium acetate at 60°C for 4 hours. 4 volumes of pre-chilled 200 proof ethanol was
added and samples were incubated at -20°C overnight. Samples were then pelleted by
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centrifugation at 14,000 g for 10 minutes at room temperature followed by 4 volumes of
pre-chilled 75% ethanol and re-pelleted by centrifugation at 14,000 g for 10 minutes.
Pellets were air-dried and resuspended in 100 µl 100 mM ammonium acetate. A second
ethanol precipitation was conducted by repeating aforementioned protocol and samples
were resuspended in 20 µl of 100 mM ammonium acetate. Total amount of HA was
quantified using Hyaluronan DuoSet ELISA Kit (R&D) as per manufacturer’s instructions
and normalized to tissue dry weight.
Immunohistochemistry (IHC)
Tumor samples were collected, fixed in prefer (Anatech Ltd.), and paraffin-embedded. 5µm sections were mounted onto positively charged glass slides. IHC staining was
conducted as described in chapter 2. List of all antibodies used for IHC are listed in
Table 4.
2P-Second Harmonic Generation
Fibrillar collagen images of 5-µm paraffin embedded sections were obtained using a
Leica SP5 confocal/multiphoton microscope. Images were obtained and analyzed as
described in chapter 2.
Flow Cytometry
Tumors were extracted from mice 4 weeks post-orthotopic tumor injection and digested
in 10 ml of 250 µg/ml of collagenase type I, II and IV in DMEM for 1 hour at 37°C. Tissue
lysates were then filtered through 70- and 40-µm cell strainer (Corning Inc.). Red blood
cells were excluded using a 1X RBC lysis buffer (Thermo Fisher) followed by thorough
wash steps. The single-cell suspension obtained was stained for viability using aqua
live/dead fixable cell stain kit (Molecular Probes). Cell surface staining for stromal and
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immune cell populations was conducted using antibodies listed in Table 5. Prior to
intracellular staining with anti-αSMA FITC 1:540 (Sigma Aldrich), cell suspensions were
fixed and permeabilized using cytofix/cytoperm fixation permeabilization kit (BD
Bioscience). Unstained, LIVE/DEAD only, and single stains were used as controls.
Single cells were gated on using forward and side scatter width and height event
characteristics. The specificity of the FAP antibody was verified using FAP-null
fibroblasts. Flow cytometric analyses were performed on an LSR-Fortessa using
FACSDiva software (BD Bioscience), and data were analyzed using FlowJo (Tree Star).
Histopathological Analysis for PDA Tumors and PanIN lesion scoring
Board-certified veterinary pathologists (Elizabeth Buza and Enrico Radaelli) performed
the microscopic assessment of the different sets of samples included in this study. The
analysis has been completed in a blinded fashion and details concerning study design
and experimental groups have never been disclosed. Classification of the proliferative
and non-proliferative lesions observed in the KPC and KC mouse models of multistep
pancreatic carcinogenesis lesions was performed according to consensus criteria
established at the Penn Workshop (Hruban et al. 2006). The procedure for
histopathological evaluation and the grading scheme utilized are listed in Appendix 1
and 2.
Histopathological Analysis for pancreatitis
Board-certified veterinary pathologists (Elizabeth Buza and Enrico Radaelli) performed
the microscopic assessment of the caerulein-induced pancreatitis samples. Samples
were evaluated based on the following hallmarks: duct ectasia, periductal fibrosis,
degree of inflammation, nature of the inflammatory cell infiltrate, interstitial fibrosis,
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interstitial edema, acinar-ductal metaplasia, zymogen granule depletion, and acinar loss.
The severities of these changes were semiquantitatively graded on a scale of 0 to 5 (i.e.
0: no significant lesion 1: minimal 2: mild 3: moderate 4: severe and 5:marked).
Cell Sorting
Dr. Robert Vonderheide (UPenn) provided primary murine 4662 tumor cells, which were
isolated from a KPC mouse. Primary murine 770 tumor cells were derived from KPC
CD44flox/wt mice at 20 weeks of age. Before sorting, 770 and 4662 tumor cells were
cultured in vitro using standard tissue culture procedures. Cells were washed with PBS,
trypsinized and collected to obtain single cell suspension. Cell surface staining for CD44
and viability using PI was conducted and samples were ran on a BD FACS Aria Cell
Sorting System with BD FACSDiva Software (BD Biosciences). Samples were sorted
based on levels of CD44 expression.
Proliferation Assay
770 and 4662 tumor cells (2x104) were plated in triplicates in 6 well plates. Cells were
washed with PBS, trypsinized, and counted 48 hours, 72 hours and 96 hours after initial
seeding.
Statistical Analysis
All results are expressed as mean ± SEM. Statistical analysis on data sets with two
groups was performed using 2-tailed student’s t test (GraphPad Prism 7.0). Data sets
with multiple groups were analyzed using ANOVA followed by Tukey’s multiple
comparison post test. Kaplan-Meier survival data were analyzed using a log rank test.
Tumor contingency tables were analyzed using chi-squared test. Asterisks denote
statistical significance: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05.
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Results
Malignant

epithelial

tumor

cell-specific

CD44

deletion

accelerates

tumor

progression and reduces survival compared to CD44 wild-type KPC mice and
global CD44-null KPC mice
To elucidate the role of CD44 in pancreatic tumorigenesis, we utilized 3
autochthonous tumor models. LSL KrasG12D/+; p53R172H/+; pdx-1-cre mice bred with WT
mice (KPC.CD44-WT), expressed CD44 in epithelial and non-epithelial cells. We
conditionally deleted CD44 in epithelial tumor cell by breeding LSL KrasG12D/+; p53R172H/+;
pdx-1-cre mice with CD44flox/flox mice (KPC.CD44flox/flox). In adult mice, pdx1-cre is
selectively expressed in the pancreatic epithelium, therefore, resulting in constitutive
activation of Kras, inactive mutation of p53, and CD44 deletion in epithelial cells. LSL
KrasG12D/+; p53R172H/+; pdx-1-cre mice were also bred with CD44-null mice (KPC.CD44KO), resulting in global CD44 deletion in epithelial and non-epithelial cells (Fig. 16A). All
three genotypes were born at expected mendelian ratios and appeared phenotypically
normal at birth.
Given the enhanced tumor-initiating capacity associated with epithelial CD44
expression, we hypothesized that epithelial tumor cell-specific CD44 deletion would be
tumor protective. Surprisingly, we found that KPC.CD44flox/flox mice exhibited significantly
reduced survival compared to KPC.CD44-WT mice (Fig. 16B). The median survival of
KPC.CD44flox/flox and KPC mice were 23 weeks and 32 weeks respectively. It is
interesting to note that this phenotype did not require complete abrogation of CD44
expression on epithelial cells. The reduction of CD44 expression by ~40% on epithelial
cells from CD44 haploinsufficient mice (KPC.CD44flox/wt) had a comparable impact on
survival to that observed in KPC CD44flox/flox mice. With a median survival of 24 weeks,
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KPC CD44flox/wt mice demonstrated reduced survival compared to KPC.CD44-WT mice
(Fig. 16B).
To determine if the CD44 expression in both epithelial and non-epithelial
compartments is tumor suppressive, we compared the survival of KPC.CD44-KO mice to
KPC.CD44-WT and KPC.CD44flox/flox mice. We found that KPC.CD44-KO mice, with a
median survival of 31 weeks, had increased survival compared to KPC.CD44flox/flox mice,
thus suggesting that CD44 expression on non-epithelial cells is tumor promoting. No
significant differences in survival were observed between KPC.CD44-WT and
KPC.CD44-KO mice (Fig. 16B). These data suggest, that CD44 in the neoplastic
epithelial cells curbs the aggression of PDA, while non-epithelial cells, either acting
alone or in conjunction with neoplastic cells, are on balance tumor promoting and able to
counteract the aggression associated with loss of CD44 in epithelial cells.
To further determine the role of CD44 in regulating pancreatic tumor initiation,
progression, and metastasis, primary tumors, liver, and lung samples were harvested at
the median survival age for each genotype. A board-certified pathologist, blinded to the
experimental conditions, evaluated and classified the lesions. We found that
synonymous to the reduced survival found in epithelial CD44 deletion, KPC.CD44flox/flox
mice had a greater incidence of glandular PDA, at 20 weeks of age, compared to
KPC.CD44-WT and KPC.CD44-KO mice, which were analyzed at 30 weeks of age (Fig.
16C). These findings support the notion that epithelial CD44 deletion accelerates PDA,
while combined deletion of CD44 in epithelial and non-epithelial cells is protective
against this phenotype. No significant differences were observed in the differentiation
state of the glandular structures, the number of tumors per mouse, and % tumor area
per mouse (Fig. 16 D – F). We also found an absence of liver and lung metastasis
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across all three genotypes. These data indicate the opposing roles of CD44 in epithelial
and non-epithelial cells in PDA, and prompted us to investigate if cell-specific CD44
expression altered the desmoplastic response characteristic of PDA.
Malignant epithelial cell-specific CD44 deletion attenuated the accumulation of
FAP+ area in PDA
The crosstalk between neoplastic and non-neoplastic cells, including CASCs,
endothelial cells, and inflammatory/immune cells, plays an essential role in driving
stromagenesis. For instance, malignant epithelial cell-derived secreted factors, such as
TGF-β, PDGF, VEGF, or Shh, can stimulate proliferation or activation of surrounding
non-malignant cells, thus further fueling the desmoplastic response. As previously stated
robust desmoplasia is a fundamental hallmark of PDA, and CASCs are the primary cell
type responsible for depositing and remodeling the ECM. Furthermore, the central
dogma that desmoplasia is necessarily pro-tumorigenic has been challenged by recent
studies that have highlighted the functional heterogeneity of CASCs and the paradoxical
results upon depletion of specific subsets of CASCs (Rhim et al. 2014; Özdemir et al.
2014; Wang et al. 2013; Lo et al. 2015). Therefore, we next tested the hypothesis that
deletion of epithelial cell-specific CD44 expression accelerates PDA by regulating the
desmoplastic response, by comparing the stromagenic response between KPC.CD44WT, KPC.CD44-KO and KPC.CD44flox/flox PDA tumors.
Mesenchymal stromal cell content, phenotype, and distribution were defined, by
conducting IHC on serial sections, using vimentin, a pan-mesenchymal cell marker,
PDGFRβ and FAP, markers of a subset of inflammatory/reactive stellate cells, and
αSMA, the canonical myofibroblast marker. The three genotypes had a comparable
accumulation of vimentin+, PDGFRβ+ or αSMA+ area (Fig. 17 A – C). However, KPC
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CD44flox/flox mice had reduced FAP+ area compared to KPC.CD44-WT (Fig. 17D). These
data indicate that CD44 on epithelial cells either regulates FAP expression itself or the
accumulation of FAP+ cells.
FAP, as alluded to above, is a marker for a subset of activated mesenchymal
stromal cells and is a cell surface protease with both dipeptidyl peptidase and
endopeptidase activity. Given the pronounced desmoplasia in PDA, and the role of FAP
in ordered collagen proteolysis, we examined the accumulation of major matrix
components including total collagen, using masson’s trichrome, fibrillar collagen, using
picrosirius red visualized under circular polarized light, and hyaluronic acid, using IHC.
We found that the reduced FAP+ area in KPC.CD44flox/flox mice did not correlate to any
significant differences in accumulation of aforementioned matrix components compared
to KPC.CD44-WT and KPC.CD44-KO mice (Fig. 18 A – C). These data indicate that
CD44 expression on epithelial cells alone or in combination with non-epithelial cells is
dispensable for the accumulation of major ECM components in PDA.
In PDA, depletion of FAP+ cells resulted in attenuated accumulation of matrix
components, reduced primary tumor burden and metastasis (Roberts et al. 2013; Lo et
al. 2015). Additionally, genetic deletion of FAP augmented survival of and reduced
metastasis in KPC mice (Lo et al. 2017). Thus, our findings that epithelial cell-specific
CD44 deletion accelerated PDA but reduced FAP accumulation were surprising.
Additionally, we also did not observe an impact of reduced FAP accumulation on matrix
deposition. As stated above, it is currently unclear if CD44 on epithelial cells regulate the
expression of FAP or the accumulation of FAP+ cells. We hypothesize that deletion of
CD44 on epithelial cells impacts tumor cell-intrinsic signaling resulting in reduced
accumulation of a specific subset of FAP+ cells.
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Reduced levels of CD44 expression augments the tumorigenic potential and
proliferative capacity of malignant epithelial cells
To investigate the mechanism by which haploinsufficiency of CD44 on epithelial
cells reduced survival of KPC mice, we generated a tumor cell line, 770, which was
derived from a KPC.CD44flox/wt mouse and compared it to a KPC.CD44-WT tumor cell
line, 4662, was previously generated by Dr. Robert Vonderheide’s laborartory (Lo et al.
2015). Flow cytometric analysis was conducted to compare the levels of CD44
expression. As expected, 770 tumor cells showed reduced CD44 expression compared
to 4662 tumor cells (Fig. 19A).
To test the impact of reduced CD44 expression on the tumorigenic potential of
malignant epithelial cells, syngeneic CD44 WT (C57Bl/6) mice were subcutaneously
injected with 1.0x103, 1.0x104 or 1.0x105 770 tumor cells (low CD44 expression) or 4662
tumor cells (high CD44 expression). We found that three weeks post tumor cell injection
100% of mice injected with 1.0x105 cells, 770 or 4662, had measurable tumors.
Remarkably, however, 100% and 50% of mice injected with 1.0x104, and 1.0x103 770
tumor cells respectively had tumors while none of the mice injected with 1.0x104 and
1.0x103 4662 tumor cells had detectable tumors (Fig. 19B). External caliper
measurements were conducted to compare the growth of 770 and 4662 tumors. Akin to
the autochthonous tumor model, we found that reduction in CD44 expression on tumor
cells significantly accelerated tumor growth and increased tumor burden (Fig. 19C).
These data suggest that high CD44 expression, as found in 4662 tumor cells, reduces
the tumorigenic potential and growth of tumor cells. Future experiments will be
conducted to test the reproducibility of these data using additional tumor cell lines
derived from KPC.CD44-WT and KPC.CD44flox/wt tumors. To determine if 770 tumor cells
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exhibited accelerated tumor growth due to cell-intrinsic effects of CD44 on malignant
epithelial cells, we compared the proliferative capacity of 770 and 4662 cells in vitro. 770
tumor cells had an enhanced rate of proliferation compared to 4662 tumor cells.
Comparison of the distribution of CD44 expression in 770 and 4662 tumor cells revealed
a heterogeneous spread. 3.36% of 4662 cells and 25% of 770 cells were CD44low.
29.1% of 4662 cells and 73.8% of 770 cells expressed intermediate levels of CD44.
While 71.6% of 4662 tumor cells expressed high levels of CD44, only 1.97% of the 770
tumor cells were CD44high expressers (Fig. 19D).
In view of the heterogeneous CD44 expression in both cell lines, and to further
test the relationship between the levels of CD44 expression and growth capacity, 770
and 4662 tumor cell lines were sorted into low, medium or high CD44 expressing
subpopulations. However, upon culturing in vitro, we found that the phenotypes of the
sorted populations were not stable and that levels of CD44 expression, for some of
these sorted populations, rapidly drifted back to heterogeneous profiles. Therefore, using
this method, we were unable to establish stable for low, medium, and high CD44
expressing tumor cells. However, we were successful in enriching for certain mixed
populations. Upon culturing in vitro, 770 tumor cells sorted based on medium CD44
expression (referred to as 770 CD44med), resembled unsorted 4662 tumor cells, with
2.12% CD44low, 35.6% CD44med, and 63.9% CD44high cells (Fig. 19E). On the other
hand, 4662 tumor cells sorted based on low CD44 expression (referred to as 4662
CD44low), resembled unsorted 770 tumor cells, with 20.2% CD44low, 65% CD44med, and
15% CD44high cells (Fig. 19F).
To test if alterations in levels of CD44 expression can change the proliferative
capacity of epithelial cells, we compared the rate of proliferation between unsorted 770
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tumor cells, unsorted 4662 tumor cells, 770 CD44med cells, and 4662 CD44low tumor
cells. We found that unsorted 770 tumor cells had significantly greater proliferation than
unsorted 4662 tumor cells 72 and 96 hours post-seeding. Interestingly, 770 CD44med
tumor cells had a comparable rate of proliferation as unsorted 4662 tumor cells and
significantly reduced proliferation compared to unsorted 770 tumor cells. On the other
hand, 4662 CD44low tumor cells had a comparable rate of proliferation as unsorted 770
tumor cells and significantly enhanced proliferation compared to unsorted 4662 tumor
cells (Fig. 19G). Thus these data indicate that levels of CD44 expression on epithelial
cells inversely correlate with their proliferative capacity.
Epithelial cell-specific CD44 deletion does not impact PanIN lesion development
or caerulein induced pancreatitis compared to WT or global CD44 deletion
Having determined that epithelial cell-specific CD44 expression accelerates PDA
tumor progression, we next sought to determine if it impacts the development of
pancreatic precursor lesions. PDA evolves from precursor lesions, characterized by
cellular, molecular and histopathological events such as acinar to ductal metaplasia,
inflammation, desmoplasia and nuclear atypia. These phenotypic and morphological
changes increase the propensity for development of PDA; therefore, understanding
mechanisms that govern or contribute to these factors can help in delineating tumorinitiating events. To determine if the expression of CD44 on epithelial and non-epithelial
cells impacts the development of precursor lesions LSL-KrasG12D/+; Pdx-1-Cre (KC) mice
were bred with WT, CD44 KO or CD44flox/flox mice. Mice were harvested at 24 and 40
weeks of age to capture early and late precursor lesions. A board-certified pathologist,
blinded to the experimental conditions, scored the precursor lesions as described in
Appendix 2. We found that epithelial or global CD44 deletion did not impact the total
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number or the grade of precursor lesions at 24 or 40 weeks of age (Fig. 20A). These
data suggest that epithelial cell-specific CD44 deletion exacerbates PDA without
affecting the incidence of precursor lesions.
Chronic pancreatitis, characterized by sustained inflammation, fibrosis, and
acinar cell activation, is a known risk factor for PDA. To determine the role of cellspecific CD44 expression in regulating pancreatitis, we experimentally induced an acute
pancreatitis response in WT, CD44-null, and CD44flox/flox under the control of a Pdx-1-Cre
promoter. Caerulein is a cholecystokinin analogue, a cholinergic agonist, which plays a
vital role in regulating the exocrine pancreas function in response to food intake.
Supramaximal doses of caerulein administration increase pancreatic protein secretion
and interfere with zymogen granule packaging, thus resulting in acinar cell activation and
acute pancreatitis. Mice were treated with 8 hourly intraperitoneal injections of caerulein
or vehicle control over the course of two days (Fig. 20B). Pancreata were harvested 24
hours after final injection and analyzed by a board-certified pathologist. Various
hallmarks for pancreatitis including fibrosis, inflammation, ADM, zymogen granule
depletion and duct ectasia were scored from 0 (no significant lesion) to 5 (marked
presence). The sum of the score for all the hallmarks was calculated and represented as
the total histopathological score. We found that, consistent with previous reports
demonstrating the role of CD44 in mediating early inflammatory response in various
injury models, CD44-null mice had reduced pancreatitis compared to WT or Pdx-1Cre.CD44flox/flox (Fig. 20C). The comparable incidence of precursor lesions in
KC.CD44flox/flox mice compared to KC.CD44-WT mice and equivalent acute pancreatitis
in Pdx-1-Cre.CD44flox/flox mice compared to WT mice, suggest that CD44 expression on
epithelial cells is dispensable for precursor lesion formation.
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Global CD44 deletion reduces early pancreatitis and accelerates tissue restoration
post-caerulein injection compared to WT
To further explore the mechanism by which global CD44 deletion was protective
against early pancreatitis, WT and CD44-null mice were treated with caerulein or vehicle
control, as previously described. Pancreata were harvested 24 hours, 48 hours, 1 week,
2 weeks, or 3 weeks post-final injection (Fig. 21A). This time course allowed us to
investigate the role of CD44 in mediating the early and late inflammatory response, as
well as pancreatic recovery. A board-certified pathologist scored the pancreata based on
the presence of various pancreatitis hallmarks, as described above. We found that
CD44-null mice had reduced pancreatitis 24 and 48 hours post-caerulein treatment
compared to WT mice, indicating that CD44 deletion suppressed the acute phase
response to pancreatitis. The suppression of early response to caerulein was overcome
by 1 week when CD44-null mice exhibited compared pancreatitis to WT mice. Moreover,
we found that CD44 deletion accelerated pancreatic recovery, as evidenced by the
attenuated pancreatitis present in CD44-null mice compared to WT mice 2 weeks postfinal-injection. By 3 weeks, we found that WT and CD44-null mice had recovered and
exhibited no significant changes in total histopathological score compared to vehicletreated mice (Fig. 21B).
Serum amylase and lipase levels are clinical diagnostic tests for pancreatitis, as
auto-activation of acinar cells and release of digestive enzymes result in elevated
enzyme levels in the serum. We found that CD44-null mice had reduced serum amylase
and lipase levels compared to WT mice, thus mirroring the reduced histopathological
score for pancreatitis (Fig. 21 C – D). Ca2+ influx plays a dominant role in the
pathological responses of acinar cells. Testing of Ca2+ concentration 24 hours post last
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injection revealed that CD44-null mice treated with caerulein had reduced Ca2+
compared to WT mice (Fig. 21E). These data suggest that CD44 deficiency reduces
early pancreatitis by suppressing by the auto-activation and depletion of zymogen
granules from acinar cells. Given the protective role of CD44 deletion on non-neoplastic
cells in response to acute pancreatitis and the net pro-tumorigenic effect observed in
KPC.CD44-KO mice, we next investigated the role of non-malignant epithelial cellspecific CD44 expression on pancreatic tumorigenesis.
Non-transformed host cell-specific CD44 expression promotes tumor growth and
inhibits fibrillar collagen accumulation in orthotopic and flank injection models of
PDA
To determine the contribution of non-malignant epithelial cell-specific CD44
expression to pancreatic tumorigenesis, we conducted orthotopic injections of neoplastic
cells expressing CD44, 4662 tumor cells, derived from KPC.CD44-WT mice, into WT
and global CD44-null syngeneic C57Bl/6 mice (Fig. 19A). We found that CD44-null mice
had reduced orthotopic tumor burden compared to WT mice (Fig. 22A). These data were
in alignment with our earlier observation that global CD44 deletion in KPC mice counterbalanced the exacerbation of PDA found in epithelial cell-specific CD44 deletion. Thus,
we now demonstrated that CD44 expression on non-neoplastic cells is pro-tumorigenic.
Nearly all cell types present in the tumor microenvironment express CD44. To
identify the cell type responsible for the pro-tumorigenic effects of host CD44, flank
injections of 4662 tumor cells were conducted in tissue-specific CD44 knockouts. We
generated myeloid and endothelial cell-specific CD44 knockouts by crossing CD44flox/flox
mice to LysM-Cre and VE-Cadherin-Cre mice respectively. Flank injections 2.5x105 4662
tumor cells were conducted in WT, CD44-null and LysM-Cre.CD44flox/flox, and
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VECadherin-Cre.CD44flox/flox mice. Similar to the orthotopic injection model, CD44-null
mice had reduced tumor burden compared to WT mice in the flank injection model as
well. In contrast to global CD44 deletion, neither the myeloid- nor the endothelial-specific
CD44 deletion had an impact on tumor burden compared to WT mice (Fig. 22B). These
data demonstrated that either CD44 expression on a different cell type, such as
mesenchymal cells or lymphocytes, govern the pro-tumorigenic effects of host CD44.
Alternatively, CD44 expression on multiple cell types act in concert to promote tumor
growth and therefore deletion on any individual cell type is not sufficient.
To further delineate the pro-tumorigenic effects of host CD44, orthotopic tumors
were analyzed for predominant matrix and cellular components implicated in
tumorigenesis.
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demonstrated increased accumulation of total and fibrillar collagen in tumors from CD44null mice compared to WT mice (Fig. 22 C,D). These data suggest that the increased
collagen accumulation present in CD44-null tumors potentially restrains tumor growth
(Fig. 22A). We next sought to determine if host cell-specific CD44 expression contributes
to other predominant matrix and cellular components characteristic of the desmoplastic
response in PDA. We found that WT and CD44-null orthotopic tumors had comparable
amounts of HA and fibronectin accumulation (Fig. 23 A – D). To assess the impact of
collagen accumulation on the vasculature, we compared the number of CD31+ vessels
and found no significant differences in vessel number between WT and CD44-null
tumors (Fig. 23 E,F). Additionally, host CD44 expression did not impact the
accumulation of leukocytes, myeloid cells, granulocytes, monocytes, and T cells (Fig. 24
A – D). In contrast to the compromised accumulation of FAP+ area in epithelial cellspecific CD44 deletion, we found that CD44 deletion on non-transformed host cells did
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not alter the accumulation of CASCs including FAP+ or α-SMA+ cells (Figure 24 E –G).
Taken together, these data demonstrate the dual role of CD44 in PDA. Epithelial cellspecific CD44 expression inhibits tumor growth by regulating tumor cell-intrinsic
properties, while non-epithelial cell specific CD44 promotes tumor growth by regulating
extracellular matrix collagen accumulation.

Discussion
In summary, our studies reveal a paradoxical role of CD44 expression on
malignant epithelial cells vs. non-transformed cells on PDA initiation and progression
(Fig. 25). Using the LSL-KrasG12D//+ p53R172H/+ Pdx-1-Cre autochthonous tumor model,
which recapitulates human PDA pathogenesis, we determined that global CD44 deletion
did not impact survival, tumor progression, or tumor architecture compared to WT mice.
However, we found that epithelial cell-specific CD44 deletion or even haploinsufficiency
significantly diminishes survival and accelerates tumor progression compared to WT
mice. Using in vitro and in vivo studies, we’ve shown that modulating levels of CD44
expression had cell intrinsic effects on malignant epithelial cell proliferation and tumor
growth. On the contrary, while epithelial cell-specific CD44 expression played an antitumorigenic role, we found that non-transformed host cells played a pro-tumorigenic role.
Using an orthotopic and flank injection model along with murine tumor cell lines derived
from KPC mice, we demonstrated CD44 expression on host cells promotes tumor
growth and attenuates collagen accumulation. These data highlight the functional duality
of epithelial cell vs. non-transformed host cell CD44 expression in the context of PDA.
The role of CD44 has been studied in numerous tumor types including breast,
lung, pancreas, colon, and leukemia. Despite the wealth of literature pertaining to CD44
expression in malignant tissue, most of the results have been correlative and often
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conflicting with regard to whether CD44 promotes or inhibits tumorigenesis. The
complexity associated with studying CD44 can be attributed to its expression on a wide
distribution of cells and tissues, the potential for expression of multiple isoforms with
diverse functionalities, its function as a signal transducer as well as an extracellular glue,
and differential signaling based on the extracellular milieu. Majority of past research
conducted on CD44 in human pancreatic cancer has focused on examining the
expression of CD44s versus CD44v isoforms in PDA samples compared to normal
pancreata using IHC or PCR. Although complex, these studies overall suggest an upregulation of CD44v isoforms in PDA compared to normal pancreas. A couple studies
have reported attenuated metastasis in global CD44-null mice in autochthonous models
of sarcoma and breast cancer (Weber et al. 2002; Lopez et al. 2005). Although a few
studies have reported a possible role for CD44 in mediating EMT, overall in cancers,
CD44 has been minimized to simply being used a CSC marker and has been conceived
as an attractive target for CSC targeted therapy. (Sung et al. 2009; Preca et al. 2015; W.
Jiang et al. 2015; S. Zhao et al. 2016; W. Li et al. 2017). Thus, the functional role of
CD44 in tumorigenesis remains unknown.
In this study we discovered that malignant epithelial cell-specific CD44 deletion
obtained using KPC.CD44flox/flox mice resulted in reduced survival and increased
incidence of glandular PDA. Interestingly, we found that complete CD44 deletion on
malignant epithelial cells was not required as haploinsufficient KPC.CD44flox/wt mice also
demonstrated reduced survival and increased tumor burden compared to WT mice.
These findings are potentially paradigm shifting as most past studies have associated
high levels of CD44 expression with exacerbated tumor progression and EMT (Poruk et
al. 2017; Preca et al. 2015). These apparently discrepant results can be attributed to
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differences in model systems that provide insight into different stages of tumor
progression. Most previous studies have used cell lines derived from human PDA
samples and either sorted based on CD44 expression or used shRNA to modulate CD44
expression, following which subcutaneous injections of a bolus of large numbers of
tumor cells were conducted into immunodeficient mice. In comparison, our model
system recapitulates spontaneous disease and allowed assessment of the contribution
of CD44 from tumor initiation through progression and did not require the use of immune
deficient mice (therefore leaving intact the immune system that can regulate
tumorigenesis). Thus we were able to analyze the role of CD44 in regulating primary
tumor initiation and growth, and found that reduction or deletion of CD44 expression on
tumor cells increases their proliferative index, accelerates tumor growth, and reduces
survival.
Our data demonstrate that low expression of CD44 on epithelial cells increases
their tumorigenic potential and proliferative capacity. Past research has implicated CD44
in both pro- and anti-proliferative signaling based on extracellular cues. Furthermore,
variations in the ratio of different molecular weight forms of HA can either antagonize or
stimulate cell cycle progression by mediating changes in CD44 intracellular binding from
ERM to merlin, which are involved in regulating cyclin D1 expression (Kothapalli et al.
2007, 2008). Additionally, HA oligomers, <10 kDa, inhibited PI3K activation and Akt
phosphorylation, and promotes caspase 3 activation in HCT16 colon cancer cell line in a
CD44-dependent manner (Ghatak, Misra, and Toole 2002). CD44 overexpression in
E6.1 Jurkat cells inhibited Akt activation, suppressed EGR-1 (early growth response-1)
expression and inhibited cell proliferation (Zhang et al. 2010). These studies provide
evidence to guide potential future directions to explore to better understand the role of
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CD44 in regulating malignant epithelial cell proliferation. Robust HA accumulation is
characteristic of PDA, but HA molecular weight analysis has not yet been conducted in
this context. HA size analysis will aide in better understanding the potential CD44mediated signaling on tumor cells in PDA. Analyzing downstream targets including
PI3K/Akt and ERK/MAPK will provide mechanistic insight in the role of CD44 in
mediating PDA tumor cell proliferation and tumorigenesis.
Depletion of FAP+ cells or genetic deletion of FAP has shown reduction in
primary tumor growth and/or metastasis in pancreatic cancer (Lo et al. 2015, 2017; Feig
et al. 2013; Fearon 2014). An unexpected finding from our study was the reduction in
FAP+ area in KPC.CD44flox/flox mice, a cohort exhibiting increased incidence and
accelerated tumor progression. These apparent paradoxical findings raise an interesting
question: does CD44 deletion in epithelial cells alter malignant cell-intrinsic pathways
driving the desmoplastic response? Evidence in the field supports the notion that
exposure to CAFs can cause genetic and epigenetic mutations in non-transformed
epithelial cells (Y. Wang et al. 2001; Phillips et al. 2001; Hayward et al. 2001).
Additionally, co-transplantation of immortalized human prostate cells with CAFs resulted
in the formation of a large malignant tumor. Remarkably, transplantation of epithelial
cells isolated from these tumors were able to form new tumor without the support of
CAFs (Tlsty and Hein 2001). These data suggest that exposure to CAFs stimulated
transformation of epithelial cells. In the context of our data, it would be interesting to test
if epithelial cell-specific CD44 deletion causes genetic changes that override the
symbiotic relationship between malignant epithelial cells and CASCs in PDA hence
resulting in reduced FAP expression or accumulation.
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Although FAP is primarily expressed on activated fibroblasts, it is also expressed
on a small subset of mesenchymal-like tumor cells and macrophages in PDA (Lo et al.
2017). Further analyses would help unravel the distinct subset of FAP+ cells absent upon
malignant epithelial cell-specific CD44 deletion. Based on our results demonstrating
comparable levels of total fibroblasts, activated fibroblasts, myofibroblasts, and ECM
components including collagen and HA, it is also likely that the reduced FAP expression
represents a distinct subset of FAP+ cells apart from CASCs. One interesting possibility
is that CD44 deletion on malignant epithelial cells inhibits EMT, thus, leading to reduced
expression of markers of mesenchymal-like tumor cells, such as FAP. An interesting
corollary that emerges from this data is the potential biphasic role of CD44 in PDA. Over
the course of tumor progression, changes in the ECM can trigger differential posttranslational modification, glycosylation, sulfation, or splicing of CD44. Therefore
depending on the structural status of CD44 it can potentially play altering roles at various
stages of tumorigenesis. There is some evidence in the literature supporting the
hypothesis that alternative splicing of CD44 evolves over tumor progression in PDA.
Inhibition or knockdown of CD44s correlated with reduced expression of EMT inducers,
such as zeb1 and snail1, and increased expression of epithelial marker, E-cadherin
(Preca et al. 2015; W. Jiang et al. 2015). Using two different human PDA cell lines, a
study demonstrated a positive correlation between expression of epithelial markers and
CD44v isoforms, and a negative correlation of epithelial markers with expression of
CD44s (Preca et al. 2015). Thus, a potential upregulation of CD44, specifically CD44s,
possibly occurs as tumor cells undergo EMT and begin to metastasize. It would be
interesting to determine if CD44 deletion in epithelial cells inhibits metastasis in KPC
mice. Focusing future studies on understanding if CD44 plays an inhibitory role in
epithelial-like tumor cells prior to metastasis, but a supportive role in mesenchymal-like
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tumor cells after metastasis will help explain the possible role of CD44 in mediating FAP
expression on tumor cells undergoing EMT.
Surprisingly, we found that global CD44 deletion rescued the phenotype
observed by epithelial cell-specific CD44 deletion suggesting a diverging role of CD44
on transformed versus non-transformed cells. Few studies have explored the role of
non-transformed cell-specific CD44 expression in xenograft models of breast and lung
cancer. Using CD44-null mice, one study reported reduced 4T1 tumor burden partly due
to impaired differentiation of mesenchymal stem cells into FAP+ CAFs (Spaeth et al.
2013). Another study reported increased CD44 expression in hypovascular areas of the
tumor microenvironment and inability of CD44 knockout CAFs in maintaining stemness
of cancer cells (Kinugasa, Matsui, and Takakura 2014). CD44 expression on CAFs has
also been shown to regulate tumor cell proliferation and drug resistance by activating the
hedgehog signaling pathway in breast cancer (Yonglei Liu et al. 2017). These data
suggest a possible role of CD44 expression on mesenchymal stromal cells in
maintaining the tumorigenicity of malignant cells. In congruence with these findings, we
found that deletion of CD44 in non-transformed host cells decreased tumor burden
compared to WT mice. Using tissue specific CD44 knockouts, we were definitively able
to demonstrate that myeloid- or endothelial-cell-specific CD44 expression, at least
singularly, does not inhibit tumorigenesis.
In addition to the in vivo data presenting paradoxical outcomes based on
depletion of specific stromal compartments, analyses of human PDA samples have also
produced some discrepant results (Provenzano et al. 2012; Rhim et al. 2014; Özdemir et
al. 2014; Sherman et al. 2014; Lo et al. 2015; Feig et al. 2013; Kraman et al. 2010). One
study demonstrated increased collagen accumulation correlating with longer disease
111

free survival in resected PDA samples (Bever et al. 2015). On the contrary, a few studies
have implicated increased collagen fiber diameter and levels of collagen crosslinking
enzyme with reduced patient survival (Miller et al. 2015; Laklai et al. 2016). In our study,
we found that reduced orthotopic tumor burden in CD44-null mice was accompanied
with increased total and fibrillar collagen accumulation. This is in accordance with our
findings depicting increased collagen accumulation, due to attenuated collagenase
activity, in CD44-null cutaneous wounds and fibroblasts derived matrices compared to
WT. It is likely that CD44-null CASCs also exhibit reduced collagenase activity resulting
in increased collagen accumulation. Meticulous analysis of collagen structure,
crosslinking, and spatial relationship to tumor cells can better explain tumor-restraining
properties of collagen in PDA. A plausible mechanism to explain our findings is that
attenuated collagenase activity, by CD44-null CASCs, hinders the release of cryptic
collagen sites, which possess the ability to modulate cell proliferation, migration, and
apoptosis. Thus, hypothesizing that CD44-mediated MMP-cleaved collagen contains
altered bioactive properties and can promote tumorigenesis.
In summary, the data presented herein provide evidence for the divergent roles
of malignant epithelial versus non-transformed cell-specific CD44 expression in PDA.
We demonstrate that, contrary to the existing paradigm, malignant epithelial cell-specific
CD44 expression is tumor restraining, while non-transformed cell-specific CD44
expression is tumor promoting. In light of our findings, we propose that developing a
scoring system encompassing CD44 expression in the epithelial vs. non-epithelial
compartment is a potentially better prognostic marker than analysis of total CD44
expression. Our data provides compelling evidence for reassessing the functional role of
CD44 in PDA.
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Primary Antibody

Company

Antigen Retrieval

Working Concentration

Incubation

Biotinylated - HABP

EMD Milipore (385911)

N/A

2 µg/ml

Overnight at 4°C

Rabbit-anti-vimentin

Cell Signaling (5741)

10 mM boiling
sodium citrate

1 µg/ml

Overnight at 4°C

Rabbit-anti-FAP

abcam (ab207178)

10 mM boiling
sodium citrate

2.5 µg/ml

Overnight at 4°C

Rabbit-anti-SMA

abcam (ab5694)

10 mM boiling
sodium citrate

3 µg/ml

Overnight at 4°C

Rabbit-anti-PDGRFβ

abcam (ab32570)

10 mM boiling
sodium citrate

0.15 µg/ml

Overnight at 4°C

Rabbit-anti-Ki67

abcam (ab10558)

10 mM boiling
sodium citrate

4 µg/ml

Overnight at 4°C

Rabbit-anti-CC3

abcam (ab5690)

10 mM boiling
sodium citrate

1 µg/ml

Overnight at 4°C

Rabbit-anti-CD31

abcam (ab28364)

10 mM boiling
sodium citrate

5 µg/ml

Overnight at 4°C

Chrompure Rabbit IgG

Jackson ImmunoResearch
(011-000-003)

N/A

N/A

Overnight at 4°C

Secondary Antibody

Company

Antigen Retrieval

Working Concentration

Incubation

Biotinylated goat-antirabbit

Vector Laboratory (BA1000)

N/A

1 µg/ml

1 hour at room
temperature

Streptavidin-HRP

Jackson ImmunoResearch
(016-030-084)

N/A

1 µg/ml

1 hour at room
temperature

Table 4. List of antibodies used for IHC staining on PDA samples
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Primary Antibody

Company

Working Concentration

Incubation

Fc block

eBiosciences (14-0161-85)

2 µg/ml

15 minutes on ice

Live Dead Aqua

Molecular Probes

N/A

20 minutes on ice

anti-CD45-PeCy7

eBiosciences (25-0451-82)

0.4 µg/ml

30 minutes on ice

anti-CD90-PE

Biolegend (140308)

0.5 µg/ml

30 minutes on ice

anti-CD44 APC

eBiosciences (17-0441-81)

2 µg/ml

30 minutes on ice

Biotinylated-anti-FAP
(clone 73.3)

Homemade

5 - 10 µg/ml

30 minutes on ice

anti-αSMA FITC

Sigma Aldrich (F3777)

5 µg/ml

30 minutes on ice

anti-CD3 FITC

BD Pharmigen (555274)

5 µg/ml

30 minutes on ice

anti-Ly6G PE

BD Pharmigen (551461)

1 µg/ml

30 minutes on ice

anti-CD11b Pacific Blue

Biolegend (101224)

5 µg/ml

30 minutes on ice

anti-Ly6C APC

eBiosciences (17-5932-82)

0.5 µg/ml

30 minutes on ice

Rat IgG2bκ PeCy7

Biolegend (400618)

0.4 µg/ml

30 minutes on ice

Rat IgG2bκ PE

BD Biosciences (553989)

0.5 µg/ml

30 minutes on ice

Rat IgGbκ APC

eBiosciences (17-4031-81)

2 µg/ml

30 minutes on ice

Biotinylated IgG1κ

BD Biosciences (550615)

5 - 10 µg/ml

30 minutes on ice

IgG 2a FITC

BD Biosciences (554647)

5 µg/ml

30 minutes on ice

Rat IgG2bκ FITC

eBiosciences (11-4031-81)

5 µg/ml

30 minutes on ice

Rat IgG2aκ PE

Biolegend (400508 )

5 µg/ml

30 minutes on ice

Rat IgG2bκ Pacific Blue

Biolegend (400627)

5 µg/ml

30 minutes on ice

Rat IgG2cκ APC

Biolegend (400713)

0.5 µg/ml

30 minutes on ice

Table 5. List of antibodies used for flow cytometry analysis on PDA samples
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Figure 16. Malignant epithelial tumor cell-specific CD44 deletion accelerates tumor
progression and reduces survival compared to CD44 wild-type KPC mice and
global CD44-null KPC mice
A) Schematic representation of KPC mouse models used in this study. B) Kaplan-Meier survival curve of
KPC mice. Mice that developed severe ulcerated facial or vaginal papillomas or large thymic lymphomas
flox/flox
flox//wt
were not included in the survival study. KPC.CD44-WT, CD44 KO, CD44
, CD44
N = 9, 12, 13, 10
respectively. Quantification of % mice with C) predominant PanIN lesions or Glandular PDA D) poor,
moderate, or well differentiated glandular PDA. Quantification of E) number of tumor nodules per mouse F)
% tumor to pancreas area measured using H&E images. Graphs depict mean ± SEM. *p <.05
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and proliferative capacity of malignant epithelial cells
A) Representative histogram plot of flow cytometric analysis of CD44 expression on 770 and
4662 tumor cells. B) Quantification of percent tumor bearing versus non-tumor bearing mice three
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4
3
weeks post-injection of 1.0x10 , 1.0x10 , or 1.0x10 4662 tumor cells into WT mice. C)
Quantitative measurement of tumor volume calculated using external caliper measurements and
2
the formula V = (length x width ) x π/6. N = 4 D) Histogram plot quantifying distribution of CD44
low, medium and high expression in 4662 tumor cells (left) and 770 tumor cells (right). E)
Representative histogram plot of flow cytometric analysis of CD44 expression on 770 tumor cells
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+

A) Quantification of % CD45 live cells in WT and CD44 KO orthotopic tumors (left).
Representative histogram plot of flow cytometric analysis of WT and CD44 KO orthotopic tumor
+
+
+
+
+
for CD45 cells (right). B) Quantification of % live CD11b, CD11b Ly6C , CD11b Ly6G , and
+
CD3 cells in WT and CD44 KO orthotopic tumors. C) Representative histogram and dot plot of
flow cytometric analysis of WT orthotopic tumor for CD11b, CD11b Ly6G, CD11b Ly6C, and
+
CD3 cells. D) Representative histogram and dot plot of flow cytometric analysis of CD44 KO
+
orthotopic tumor for CD11b, CD11b Ly6G, CD11b Ly6C, and CD3 cells. E) Representative
+
histogram plot of flow cytometric analysis of WT orthotopic tumors for CD90 cells (left).
+
+
Representative dot plot of flow cytometric analysis of WT orthotopic tumors for FAP and α-SMA
cells (right). F) Representative histogram plot of flow cytometric analysis of CD44 KO orthotopic
+
tumors for CD90 cells (left). Representative dot plot of flow cytometric analysis of CD44 KO
+
+
+
+
orthotopic tumors for FAP and α-SMA cells (right). G) Quantification of % live CD90 FAP and
+
+
CD90 αSMA cells in WT and CD44 KO orthotopic tumors.
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Figure 25. Schematic representation of paradoxical roles of CD44 on neoplastic
and mesenchymal cells in pancreatic tumorigenesis
CD44 plays diverging and opposing roles on neoplastic versus non-neoplastic cells in the context
of pancreatic ductal adenocarcinoma. CD44 on neoplastic cells restrain tumor growth by altering
neoplastic cell signaling resulting in attenuated proliferative capacity. Non-neoplastic cell-specific
CD44 expression is tumor promoting by altering neoplastic cell extrinsic properties and is
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accumulation resulting in accelerated tumor progression.
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CHAPTER 4 – CONCLUSIONS AND FUTURE DIRECTIONS
Multifaceted roles of CD44: Where do we go from here?
The work presented in this dissertation investigated the role of CD44 in three
distinct fibroinflammatory contexts: cutaneous wound healing, pancreatitis, and
pancreatic ductal adenocarcinoma. By evaluating CD44 in distinct pathological states,
which share underlying hallmarks that drive disease progression, we were able to unveil
new roles of CD44 in mediating injury response and tumorigenesis. We determined that
CD44 mediates the fibrotic response during wound healing and PDA with ultimate
implications in wound resolution and tumor growth. We also uncovered a previously
unknown role of CD44 in regulating the accumulation of FAP+ area in remodeling tissue.
Furthermore, within the context of PDA, we have presented a novel tumor-suppressive
role of CD44 on epithelial cells and demonstrated the distinct functions of epithelial
versus non-epithelial cell-specific CD44 expression in PDA.

CD44-mediated fibrogenic response in remodeling tissue
Clinical Relevance of Aberrant Collagen Accumulation
Fibrosis,

characterized

by

aberrant

collagen

accumulation

and

chronic

inflammation, is the outcome of improper termination of injury responses, or persistent
insult. In mammals, the reparative process is initiated upon exposure to stimuli including,
chemical insult, tissue injury, radiation, or infection to name a few. Regenerative repair,
which is a remarkable feature of fetal tissue but lost in adulthood, results in the
replacement of the original tissue with new tissue that possesses similar biomechanical
properties as the original injured tissue. Hence at the end of regenerative repair, all
fibrotic and inflammatory processes are terminated in a timely manner, and normal
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physiological function is resumed. However, in most mammalian tissues, healing occurs
by fibrosis, rather than regeneration, resulting in a non-functional patch of tissue known
as a scar. The effects of a scar can range from a discolored area of the skin remaining
after an injury to idiopathic pulmonary fibrosis, which can eventually lead to organ failure.
Thus, it is of prime interest to identify common underlying cellular and molecular
processes that govern fibrotic healing compared to regenerative healing.
Insights into CD44-mediated collagen proteolysis in remodeling tissue
One of the most intriguing findings from our studies was the previously unknown
role of CD44 in regulating collagen proteolysis and accumulation. In a cutaneous wound
healing model, we found that CD44 deficiency increased fibrillar collagen accumulation
due to impaired collagen proteolysis. Akin to these findings, in PDA, non-neoplastic cellspecific CD44 knockout resulted in increased fibrillar collagen accumulation. These
novel findings support the concept that emerges from this dissertation that CD44
expression on non-epithelial cells regulates fibrillar collagen biosynthesis and
accumulation, potentially highlighting its role as a key mediator in fibrosis.
Our data indicate that CD44 regulates collagen turnover. We found attenuated
collagenase, but not gelatinase, activity in CD44-null wounds and FDMs derived from
CD44-null fibroblasts. These data are fitting with past studies that have demonstrated
the role of CD44 as a docking platform for MMP2, MMP7, MMP9 and MT1-MMP on the
cell surface, thus, mediating tumor cell migration, invasion, TGF-β activation, and CD44
cleavage from the cell surface (Q. Yu and Stamenkovic 2000; W. Yu et al. 2002;
Acharya et al. 2006; W. Jiang et al. 2015; Kazuhisa Takahashi, Eto, and Tanabe 1999).
There is also some evidence that CD44-ICD nuclear translocation can promote gene
transcription of MMP 9 (Miletti-González et al. 2012). Using genetic CD44 deletion, we
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have now demonstrated the importance of CD44-dependent MMP activity in collagen
accumulation. We propose further examining the mechanism by which CD44 regulates
MMP activity and fibrillar collagen deposition. Generation of FDMs, using dermal adult
fibroblasts and PSCs treated with anti-CD44 monoclonal antibodies that inhibit or
enhance HA binding will help determine the possible HA-dependent and HAindependent mechanism by which CD44 regulates MMP activity and collagen
accumulation. A similar approach can be adopted using a γ-secretase inhibitor to
determine if CD44-ICD cleavage is required for mediating MMP activity. More unbiased
approaches such as MMP arrays can also be utilized to determine the specific MMPs or
TIMPs that are upregulated in WT compared to CD44-null dermal fibroblasts or PSCs.
Future Directions: Disentangling CD44 from HA in remodeling tissues
More broadly speaking, the paradigm that CD44-MMP interactions potentially
modulate injury resolution and tumorigenesis is quite intriguing. In addition to degrading
matrix components, MMPs have also been identified as modulators of inflammatory
processes. MMP-mediated cleavage of chemokines, cytokines and growth factors can
result in enhancement or inactivation of soluble factors. For instance, using a yeast-twohybrid system one study revealed that monocyte chemoattractant proteins 1- 4 (MCPs),
belonging to the CC chemokine subfamily, can be cleaved at the N-terminal by multiple
MMPs, resulting in compromised agonist activity (Mcquibban et al. 2002). Use of
isotype-coded affinity tag combined with tandem mass-spectrometry revealed previously
unknown substrates of MT1-MMP including, IL-8, pro-TNFα, and connective tissue
growth factor (CTGF) amongst others. MMP-mediated proteolysis of soluble factors has
been implicated in modulating leukocyte infiltration to sites of tissue injury (Hall et al.
2014; Song et al. 2015). Analogously, CD44-HA interactions have been implicated in
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mediating leukocyte recruitment, adhesion, and clearance. Given our hypothesis that
CD44-MMP interaction mediates collagen turnover in remodeling tissue, it is interesting
to speculate if CD44-MMP interactions extend to influence other fibroinflammatory
processes as well. CD44-deficient mice have exhibited reduced leukocyte recruitment in
specific injury models (Heather C. DeGrendele, Estess, and Siegelman 1997; Huebener
et al. 2008; Van Der Windt et al. 2010; Mikecz et al. 1999; Vistejnova et al. 2014). It is
interesting to now question if this is due to decreased docking of MMPs on the cell
surface? Is CD44-MMP interaction HA-independent? Extending our analysis of CD44
beyond HA can help elucidate novel mechanisms regulating fibroinflammatory process
vital to injury response and fibrosis, including collagen accumulation, as we’ve
demonstrated in the studies highlighted in this dissertation.

CD44: Potential Regulator of FAP expression
In epithelial tumors, pulmonary fibrosis, liver cirrhosis and myocardial infarction,
FAP and α-SMA identify distinct, yet to varying degrees, overlapping subsets of
activated fibroblasts (Acharya et al. 2006; Levy et al. 1999; Tillmanns et al. 2015; Lo et
al. 2015; Öhlund et al. 2017; Tchou et al. 2013). Recent studies have demonstrated that
FAP+ and α-SMA+ fibroblasts exhibit distinct gene expression patterns and divergent
functions in vitro (Avery et al. 2017; Öhlund et al. 2017). Data from our lab demonstrated
that ECM composition and stiffness governs the generation of activated fibroblasts.
Specifically, culturing primary lung MAFs on a soft FN-coated hydrogel enriched for
FAPHi fibroblasts compared to a stiff FN-coated hydrogel, which selected for α-SMAHi
fibroblasts. In light of new data depicting diverging functions of FAP+ and α-SMA+
fibroblasts in tumorigenesis, elucidating mechanisms that govern the selection of specific
subpopulations of activated fibroblasts is of great interest.
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Intriguingly, in our models of cutaneous wound healing and PDA, we found an
interesting correlation between CD44 and FAP. We discovered that in a cutaneous
wound healing model, CD44-null mice had delayed accumulation of FAP+ area, which
was overcome by wound closure. We also found that epithelial cell-specific CD44
deletion resulted in reduced accumulation of FAP+ area in PDA tumors. It is plausible
that the mechanisms governing the attenuated accumulation of FAP+ area in these
pathological conditions are unrelated, as discussed in Chapter 2 and Chapter 3.
However, it is also conceivable to hypothesize that CD44 expression on epithelial cells
regulates FAP expression on mesenchymal cells.
In our model of PDA, we found that neoplastic epithelial-cell specific CD44
deletion (KPC.CD44flox/flox) reduced the accumulation of FAP+ area in PDA. Interestingly,
this deficiency was overcome when CD44 was deleted in both epithelial and nonepithelial cells (KPC.CD44-KO). Similarly, deletion of CD44 in non-transformed host
cells also did not impact the accumulation of FAP+ cells in PDA (injection of 4662 tumor
cells in CD44-null mice). Therefore, hinting towards a possible regulation of FAP
expression based on epithelial-cell specific CD44 expression. In our model of cutaneous
wound healing, we observed a reduction of FAP+ area, at day 5 and day 7 when wounds
were actively undergoing re-epithelialization and contraction. The deficiency in FAP+
area was overcome by day 11 when wounds had completely re-epithelialized and were
undergoing more active remodeling of the granulation tissue. During the reepithelialization phase of wound healing, chemokines, cytokines, and growth factors
promote the migration, proliferation, and activation of keratinocytes. As activated
keratinocytes begin to restore the epithelium, they secrete signaling factors that work in
a paracrine fashion to activate endothelial cells and fibroblasts. Similarly, malignant
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epithelial cell-derived secreted factors, such as TGF-β, PDGF, VEGF, or Shh, can
stimulate proliferation or activation of surrounding mesenchymal cells leading to
activation of fibroblasts. CD44 is known to function as a co-receptor for various growth
factors using HGF/cMet, FGF and VEGF (Bennett et al. 1995; Sherm et al. 1998; Orianrousseau et al. 2002; Tremmel et al. 2009; Volz et al. 2015). Thus, future studies should
delineate if epithelial cell-specific CD44 deletion impacts the secretory profile of epithelial
cells resulting in attenuated accumulation of FAP+ cells. These studies could potentially
help unveil mechanisms governing the activation of distinct subsets of fibroblasts in
remodeling tissues.

CD44: Tumor Suppressor or Tumor Promoter?
The poorly understood role of CD44 in tumorigenesis stems from a few reasons,
including the sparse number of studies that have evaluated the role of CD44 through
various stages of tumorigenesis and the largely forgotten role of CD44 in non-neoplastic
cells. GEMMs grant us the opportunity to push past these shortcomings.
Select studies have investigated the role of CD44 in tumorigenesis using
GEMMs. The role of CD44 in lung adenocarcinoma was examined using an LSLKrasG12D/+ mouse model. Upon intranasal administration of adenoviral cre, LSL-KrasG12D/+
mice develop multifocal hyperplasia followed by adenoma and adenocarcinoma
(Jackson et al. 2001). Crossing CD44-KO mice with LSL-KrasG12D/+resulted in increased
survival and reduced lung tumor burden compared to LSL-KrasG12D/+CD44 heterozygous
mice (P. Zhao et al. 2013). Similar results were also obtained using autochthonous
tumor models of gastric cancer and leukemia (Ishimoto et al. 2011; Du et al. 2013).
Contrarily, in models of breast cancer, CD44 exhibited anti-metastatic properties. Mice
expressing the transgene Polyoma Virus middle T antigen under the direction of the
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mouse mammary tumor virus promoter/enhancer (MMTV-PyVT) develop multi-focal
adenocarcinomas in the mammary fat pad and exhibit pulmonary metastasis. Studies
using MMTV-PyVT mice crossed with CD44-KO mice showed no significant changes in
primary tumor growth, but significantly higher pulmonary metastasis compared to
MMTV-PyVT CD44 heterozygous mice (Lopez et al. 2005). These studies highlight the
paradoxical roles of CD44 in various malignancies. It is reasonable to assume that the
net effect of CD44 is pro-tumorigenic in certain types of cancers, such as lung or gastric,
but anti-tumorigenic in others, including breast. However, our data demonstrate that
CD44 plays opposing roles on neoplastic vs. non-neoplastic cells, a concept that the
aforementioned studies did not investigate. Evaluating the role of CD44 in malignant
epithelial cells versus non-malignant host cells across various types of tumors will foster
our understanding of the complex role of CD44 in cancer going forward.
These future studies will help answer specific critical questions. For instance, is
epithelial cell-specific CD44 expression tumor suppressive across all carcinomas? Does
CD44 play opposing roles based on cellular compartments in other tumor types? What
mediates the net effect of CD44 expression in tumorigenesis? These future studies will
help disentangle the conflicting data in the field and establish a more accurate role of
CD44 in carcinomas.

Summary
In summary, the data presented in this dissertation evaluated the role of CD44 in
regulating cutaneous wound healing and pancreatic ductal adenocarcinoma. Previous
research in these fields involving CD44 has largely either been absent or misunderstood.
Our data demonstrates previously unknown roles of CD44 in matrix remodeling and
tumorigenesis (Fig. 26). Future mechanistic investigations building on our data will help
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elucidate novel regulators of scarring post injury, stromagenesis, and pancreatic tumor
aggressiveness.
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Figure 26. CD44-mediated collagen remodeling promotes wound resolution and
tumor progression
CD44 expressed on mesenchymal stromal cells promotes MMP-mediated fibrillar
collagen proteolysis. Degraded fibrillar collagen alters tissue biophysical and
biochemical properties. Presence of degraded fibrillar collagen promotes wound
resolution and increases tensile strength of scar tissue compared to scars predominantly
consisting of intact fibrillar collagen. In the context of pancreatic ductal adenocarcinoma,
MMP-cleaved fibrillar collagen accelerates tumor progression by altering extrinsic cues
and regulating neoplastic cell signaling.
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APPENDIX 1 – Grading Scheme for Pancreatic Ductal Adenocarcinoma

•

Glandular PDA:
o Neoplasm is:
§ (++) present as predominant tumor phenotype
§ (+) present as non-predominant tumor phenotype
§ (-) not present
o Neoplasm shows:
§ (p) poor, (m) moderate, (w) well-differentiated glandular
morphology

•

Undifferentiated PDA:
o Neoplasm is:
§ (++) present as predominant tumor phenotype
§ (+) present as non-predominant tumor phenotype
§ (-) not present.
o Neoplasm shows (a) anaplastic, (s) sarcomatoid, (m) mixed
anaplastic/sarcomatoid morphology

•

Non-invasive cystic papillary PDA:
o Neoplasm is:
§ (++) present as predominant tumor phenotype
§ (+) present as non-predominant tumor phenotype
§ (-) not present

•

Invasive adenosquamous PDA:
o Neoplasm is:
§ (++) present as predominant tumor phenotype
§ (+) present as non-predominant tumor phenotype
§ (-) not present

•

PanIN:
o Changes are reported as (++) diffuse, (+) focal/multifocal, (-) absent

•

Tumor necrosis:
o Extent of tumor necrosis is expressed as an estimate (%) of the total
tumor area

•

Lymphoid follicle:
o Formation of lymphoid follicle is reported as present (+) or absent (-)

•

Lymph node metastasis
o Evidence of lymph node metastasis is reported as present (+) or absent
(-)
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APPENDIX 2 – Grading Scheme for Pancreatic Intraepithelial Neoplasia
•

Tissues were scanned under low magnification (2x) to evaluate the size of tissue
and heterogeneity of lesions.

•

Tissues were evaluated at high magnification (40x) starting at the lower left or
right hand corner (depending on orientation of tissue).

•

PanIN lesions were counted in a total of 10 random 40x fields (with the goal of
sweeping across the entire tissue).

•

If field of view (FOV) did not contain >75% pancreatic tissue (e.g. consists of
fibroadipose, lymph node, acellular) then FOV was moved one consecutive field
over

•

If FOV had no ducts and only 1 partial rim of ductal structure (normal or PanINs
or ADMs, or pADMS) then the FOV was adjusted to include entire ductal
structure.

•

Incomplete (partial rims) were not counted if ductal structures were on the
periphery of the FOV and only counted ducts with a lumen

•

Ductal structures were not counted if the grading of metaplasia or PanIN was
unclear

•

If FOV contained a majority of ductal structures in which metaplasia or PanIN
was unclear then FOV was moved one consecutive field over

•

Ductal structures must have a lumen and identifiable zymogen granules in at
least one cell to be counted as metaplasia.

•

Only count duct if entire duct with lumen is a PanIN – can have different portions
within a given duct that have differentiated into a PanIN.

•

All lesions were totaled.
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